subsequent entry biologic review report€¦ · inflectra (ct-p13; infliximab) is a subsequent...
TRANSCRIPT
November2017
Drug Inflectra(infliximab)
Indication• AdultswithmoderatelytoseverelyactiveCrohn’sdisease• AdultswithfistulizingCrohn’sdisease• Adultswithmoderatelytoseverelyactiveulcerativecolitis
ListingrequestForeachindication,listinasimilarmannertothepublicplanlistingcriteriaforRemicade
Dosageform(s) Intravenousinfusion(powderforsolution,100mg/vial)
NOCdate June10,2016
Manufacturer Hospira,aPfizerCompany
CommonDrugReviewSubsequentEntryBiologicReviewReport
ThisreviewreportwaspreparedbytheCanadianAgencyforDrugsandTechnologiesinHealth(CADTH).ThroughtheCADTHCommonDrugReview(CDR)process,CADTHundertakesreviewsofdrugsubmissions,resubmissions,andrequestsforadvice,andprovidesformularylistingrecommendationstoallCanadianpubliclyfundedfederal,provincial,andterritorialdrugplans,withtheexceptionofQuebec.Thereportcontainsanevidence-basedclinicaland/orpharmacoeconomicdrugreview,basedonpublishedandunpublishedmaterial,includingmanufacturersubmissions;studiesidentifiedthroughindependent,systematicliteraturesearches;andpatient-groupsubmissions.InaccordancewithCDRUpdate—Issue87,manufacturersmayrequestthatconfidentialinformationberedactedfromtheCDRClinicalandPharmacoeconomicReviewReports.TheinformationinthisreportisintendedtohelpCanadianhealthcaredecision-makers,healthcareprofessionals,healthsystemsleaders,andpolicy-makersmakewell-informeddecisionsandtherebyimprovethequalityofhealthcareservices.Theinformationinthisreportshouldnotbeusedasasubstitutefortheapplicationofclinicaljudgmentwithrespecttothecareofaparticularpatientorotherprofessionaljudgmentinanydecision-makingprocess,norisitintendedtoreplaceprofessionalmedicaladvice.WhileCADTHhastakencareinthepreparationofthisdocumenttoensurethatitscontentsareaccurate,complete,andup-to-dateasofthedateofpublication,CADTHdoesnotmakeanyguaranteetothateffect.CADTHisnotresponsibleforthequality,currency,propriety,accuracy,orreasonablenessofanystatements,information,orconclusionscontainedinthesourcedocumentation.CADTHisnotresponsibleforanyerrorsoromissionsorinjury,loss,ordamagearisingfromorrelatingtotheuse(ormisuse)ofanyinformation,statements,orconclusionscontainedinorimpliedbytheinformationinthisdocumentorinanyofthesourcedocumentation.ThisdocumentisintendedforuseinthecontextoftheCanadianhealthcaresystem.Otherhealthcaresystemsaredifferent;theissuesandinformationrelatedtothesubjectmatterofthisdocumentmaybedifferentinotherjurisdictionsand,ifusedoutsideofCanada,itisattheuser’srisk.Thisdisclaimerandanyquestionsormattersofanynaturearisingfromorrelatingtothecontentoruse(ormisuse)ofthisdocumentwillbegovernedbyandinterpretedinaccordancewiththelawsoftheProvinceofOntarioandthelawsofCanadaapplicabletherein,andallproceedingsshallbesubjecttotheexclusivejurisdictionofthecourtsoftheProvinceofOntario,Canada.CADTHtakessoleresponsibilityforthefinalformandcontentofthisdocument,subjecttothelimitationsnotedabove.ThestatementsandconclusionsinthisdocumentarethoseofCADTHandnotofitsadvisorycommitteesandreviewers.Thestatements,conclusions,andviewsexpressedhereindonotnecessarilyrepresenttheviewsofHealthCanadaoranyCanadianprovincialorterritorialgovernment.ProductionofthisdocumentismadepossiblebyfinancialcontributionsfromHealthCanadaandthegovernmentsofAlberta,BritishColumbia,Manitoba,NewBrunswick,NewfoundlandandLabrador,NorthwestTerritories,NovaScotia,Nunavut,Ontario,PrinceEdwardIsland,Saskatchewan,andYukon.Youarepermittedtomakecopiesofthisdocumentfornon-commercialpurposes,provideditisnotmodifiedwhenreproducedandappropriatecreditisgiventoCADTH.Youmaynototherwisecopy,modify,translate,postonawebsite,storeelectronically,republish,orredistributeanymaterialfromthisdocumentinanyformorbyanymeanswithoutthepriorwrittenpermissionofCADTH.PleasecontactCADTH’sVice-PresidentofCorporateServicesatcorporateservices@cadth.cawithanyinquiriesaboutthisnoticeorotherlegalmattersrelatingtoCADTH’sservices.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
iCommonDrugReview November2017
TABLEOFCONTENTSABBREVIATIONS............................................................................................................................................iiEXECUTIVESUMMARY.................................................................................................................................iv1. PRODUCTINFORMATION....................................................................................................................1
1.1 OverviewoftheSEBProduct.....................................................................................................1 1.2 OverviewoftheReferenceProduct..........................................................................................4
2. INDICATIONS.......................................................................................................................................6
2.1 HealthCanada-ApprovedIndications........................................................................................63. MANUFACTURER’SREQUESTEDLISTINGCRITERIA.............................................................................7
3.1 RequestedListingCriteria..........................................................................................................7 3.2 RationaleforRequestedListingCriteria....................................................................................7
4. BIOSIMILARITY....................................................................................................................................8
4.1 QualityInformation...................................................................................................................8 4.2 KeyClinicalStudies....................................................................................................................9 4.3 Pharmacokinetics.....................................................................................................................24 4.4 Immunogenicity.......................................................................................................................25
5. CRITICALAPPRAISALOFCLINICALSTUDIES......................................................................................27
5.1 InternalValidity.......................................................................................................................27 5.2ExternalValidity..........................................................................................................................28
6. EXTRAPOLATIONOFINDICATIONS....................................................................................................30
6.1 Manufacturer’sRationaleforExtrapolation............................................................................30 6.2 HealthCanada’sConclusiononExtrapolation.........................................................................34 6.3 InternationalRegulatoryConclusionsonExtrapolation..........................................................35 6.4 CDRCommentsonExtrapolation............................................................................................36
7. COSTCOMPARISON..........................................................................................................................398. DISCUSSION.......................................................................................................................................429. CONCLUSION.....................................................................................................................................44APPENDIX1:ADDITIONALDATA................................................................................................................45APPENDIX2:DRUGPLANLISTINGSTATUSFORREFERENCEPRODUCT....................................................51APPENDIX3:SUMMARYOFPATIENTINPUT.............................................................................................67REFERENCES...............................................................................................................................................70
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
iiCommonDrugReview November2017
ABBREVIATIONS5-ASA 5-aminosalicylicacidACPM AdvisoryCommitteeonPrescriptionMedicinesADA anti-drugantibodiesADCC antibody-dependentcell-mediatedcytotoxicityAE adverseeventAS ankylosingspondylitisATI anti-infliximabantibodiesCCC Crohn’sandColitisCanadaCD Crohn'sdiseaseCDAI Clinical/Crohn’sDiseaseActivityIndexCDC complement-dependentcytotoxicityCDEC CanadianDrugExpertCommitteeCDR CommonDrugReviewCSR ClinicalStudyReportCTD CommonTechnicalDocumentsDMARD disease-modifyingantirheumaticdrugEAP ExceptionalAccessProgramELISA enzyme-linkedimmunosorbentassayEMA EuropeanMedicineAgencyEU EuropeanUnionFCD FistulizingCrohn'sdiseaseFDA FoodandDrugAdministrationGI gastrointestinalHCP residualhostcellproteinHMW highmolecularweightIBD inflammatoryboweldiseaseIGF-1 recombinantinsulin-likegrowthfactor1IgG1 chimerichuman-murineimmunoglobulinG1IL interleukinIRR infusion-relatedreactionLD50 lethaldose50LOCF lastobservationcarriedforwardLPS lipopolysaccharideLRV log10reductionvalueMAH MarketingAuthorizationHolderMLR mixedlymphocytereactionMMP matrixmetalloproteinaseMSS MayoscoringsystemMTX methotrexateNDS NewDrugSubmissionNK naturalkillerNOC NoticeofCompliancePBMC peripheralbloodmononuclearcell
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
iiiCommonDrugReview November2017
PBRER periodicbenefit-riskevaluationreportPK pharmacokineticPsA psoriaticarthritisPsO plaquepsoriasisPSUR PeriodicSafetyUpdateReportRA rheumatoidarthritisRCT randomizedcontrolledtrialSAE seriousadverseeventSCCAI SimpleClinicalColitisActivityScoreSD standarddeviationSEB subsequententrybiologicSOC systemorganclassSNDS SupplementalNewDrugSubmissionsTNFalpha solubletumournecrosisfactoralphaTEAE treatment-emergentadverseeventTESAE treatment-emergentseriousadverseeventTGA TherapeuticGoodAdministrationtmTNFalpha transmembranetumournecrosisfactoralphaTNFalpha tumournecrosisfactoralphaTNFR TNFreceptorUC ulcerativecolitisUS UnitedStates
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
ivCommonDrugReview November2017
EXECUTIVESUMMARY
ApproachtotheReviewTheCADTHCommonDrugReview(CDR)approachtoreviewingInflectrafollowedtheCDRProcedureandSubmissionGuidelinesforSubsequentEntryBiologics(March,2014).TheCDRteamreviewedtheinformationprovidedbythemanufacturerregardingproductinformation,indicationsunderreview,themanufacturer’srequestedlistingcriteria,biosimilarity,extrapolation,andcost.ClinicalStudyReportsandpublishedarticleswerealsoappraised.Reviewersprovidedacriticalappraisaloftheclinicalevidence,adiscussionofextrapolationfromtheindicationsofrheumatoidarthritis(RA)andankylosingspondylitis(AS)toinflammatoryboweldisease(IBD),andanevaluationofcost.ProductInformationInflectra(CT-P13;infliximab)isasubsequententrybiologic(SEB)basedonthereferenceinfliximabproduct(Remicade).InflectrahasbeenapprovedinCanadaforthefollowingindications:• Useincombinationwithmethotrexate(MTX)forthereductioninsignsandsymptoms,inhibitionof
theprogressionofstructuraldamage,andimprovementinphysicalfunctioninadultpatientswithmoderatelytoseverelyactiveRA.
• ReductionofsignsandsymptomsandimprovementinphysicalfunctioninpatientswithactiveASwhohaverespondedinadequatelyto,orareintolerantto,conventionaltherapies.
• Reductionofsignsandsymptoms,inductionofmajorclinicalresponse,andinhibitionoftheprogressionofstructuraldamageofactivearthritis,andimprovementinphysicalfunctioninpatientswithpsoriaticarthritis(PsA).
• Treatmentofadultpatientswithchronic,moderatetosevereplaquepsoriasis(PsO)whoarecandidatesforsystemictherapy.Forpatientswithchronic,moderatePsO,Inflectrashouldbeusedafterphototherapyhasbeenshowntobeineffectiveorinappropriate.
• Reductionofsignsandsymptoms,inductionandmaintenanceofclinicalremissionandmucosalhealingandreductionofcorticosteroiduseinadultpatientswithmoderatelytoseverelyactiveCrohn'sdisease(CD)whohavehadaninadequateresponsetoacorticosteroidand/oraminosalicylate.Inflectracanbeusedaloneorincombinationwithconventionaltherapy.
• TreatmentoffistulizingCD(FCD),inadultpatientswhohavenotrespondeddespiteafullandadequatecourseoftherapywithconventionaltreatment.
• Reductionofsignsandsymptoms,inductionandmaintenanceofclinicalremissionandmucosalhealing,andreductionoreliminationofcorticosteroiduseinadultpatientswithmoderatelytoseverelyactiveulcerativecolitis(UC)whohavehadaninadequateresponsetoconventionaltherapy(i.e.,aminosalicylateand/orcorticosteroidand/oranimmunosuppressant).
ThemanufacturerisrequestingthatInflectrabereimbursedforadultswithCD,FCD,andUC.TheindicationsforRA,AS,PsO,andPsAwerepreviouslyreviewedbyCDRin2015.ClinicalEvidenceCT-P13PMS(post-marketingsurveillance)isanongoing(fouryear)phaseIV,open-label,singlearmstudyofCT-P13forallapprovedindicationsinSouthKorea.AninterimanalysiswasconductedinadultswithmoderatelytoseverelyactiveCD(N=83),FCD(N=12),andmoderatelytoseverelyactiveUC(N=78)across15studycentresinSouthKoreawithfollow-upof30weeks.CT-P13wasadministeredevery8weeks(±5days)afterinductiontherapyofthree5mg/kgdosesatweeks0,2,and6.Mostpatients(59.0%)receiveddosesof5mg/kg.Higherdosesof5mg/kgto10mg/kgwereadministeredto
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
vCommonDrugReview November2017
41%ofpatients.TheefficacyanalysissetconsistedofpatientswhoreceivedatleastonedoseofCT-P13andhadatleastoneassessmentfollowingbaseline(N=145,83.8%).Allpatientswereincludedinthesafetyanalyses.Outcomesofclinicalresponse,remission,diseasecontrol,needforrescuemedication,andsafetywerereportedforpatientswithCD,FCD,andUCaswellasmucosalhealingforpatientswithUC.Basedonlastobservationcarriedforward(LOCF)imputation,amongCDinfliximab-naivepatients,31/39(79.5%)achievedclinicalresponseand23/39(59.0%)achievedclinicalremissionatweek30.AmongCDpatientswhowereswitchedfromRemicadetoCT-P13,25/31(80.6%)achievedremissionthroughoutvisitstwotosixand27/31(87.1%)patientsdidnotexperiencediseaseworsening.InFCDinfliximab-naivepatients,2/6(33.3%)achievedclinicalresponseand1/6(16.7%)achievedclinicalremission.InFCDpatientsswitchedfromRemicadetoCT-P13,clinicalremissionanddiseasecontrolwasachievedinonlyonepatientatvisitsix.InUCinfliximab-naivepatients,39/54(72.2%)achievedclinicalresponseand20/54(37.0%)achievedclinicalremissionatweek30.AmongUCpatientswhowereswitchedfromRemicadetoCT-P13,5/11(45.5%)achievedremissionthroughoutvisitstwotofiveandnopatientsexperienceddiseaseworsening.BasedoncompletecaseanalysisofUCinfliximab-naivepatients,9/13(69.2%)experiencedmucosalhealingatweek30while6/9(66.7%)patientswhowereswitchedfromRemicadetoCT-P13experiencedmucosalhealingthroughoutvisitstwotofive.ThemanufactureralsosubmitteddatatoHealthCanadasuggestingsimilarincidencesofclinicalresponseandremissionatweeks14and30forCDandUC,andmucosalhealingforUC,amongtreatment-naivepatientsintheCT-P13PMSstudyandpatientsfrompreviouslyconductedRemicadestudies.Atotalof51treatment-emergentadverseevents(TEAEs)in38patientsoccurredinCT-P13PMS.TherewerenonotabledifferencesinTEAEsbetweenpatientswhowereinfliximab-naive(23.9%)andthosewhoswitchedfromRemicade(18.3%).Nomalignancies,pneumonia,deaths,oranyothereventsofspecialinterestwereobservedduringthe30-weekinterimperiod.TheCT-P13PMSstudyislimitedbyitsuncontrolledobservationaldesign,smallsamplesize,absenceofimportantefficacyoutcomes,suchasextra-intestinalmanifestations,diseasebiomarkers,qualityoflife,andimmunogenicity,andshortdurationoffollow-up(30-weekinterimanalysis).ThegeneralizabilityoftheobservedoutcomesinpatientsfromSouthKoreatoCanadianpatientswithIBDisuncertain.OtherStudies:CT-P134.1isasmall(N=20)phaseIV,ongoing(fouryear),open-label,singlearmstudyconductedinadultpatientswithCDorUCinSouthKorea.Aninterimanalysisofefficacyandsafetyin10patients(vvvvvvvvvvvvvvv)fromvvvstudycentreswasavailableforreview.OtherobservationalstudiesofCT-P13inIBD,notsponsoredbythemanufacturer,havebeenconductedincohortsfromNorway,Hungary,theCzechRepublic,andKorea.Themanufacturerconductedasystematicliteraturesearchofrandomizedcontrolledtrials(RCTs)andobservationalstudiesofthereferenceproductRemicade,inpatientswithCDandUC.Ratesofinfusion-relatedreactions(IRRs),infections,pneumonia,tuberculosis,malignancies,andneedforsurgeryorhospitalizationwerecomparedwithratesfromobservationalstudiesofCT-P13(PMS+non-Celltrionsponsoredstudies).SafetydataweregenerallysimilarbetweenCT-P13andthereferenceproduct,Remicade,intreatment-naiveandswitchedpatientscombinedforIRRs,pneumonia,tuberculosis,andmalignancies.ThereweresomedifferencesbetweenRemicadeandCT-P13fortheratesofinfection,ratesofsurgery,anddisease-relatedhospitalization;however,theinterpretationofthedataislimitedduetothedifferencesinstudydesign,studypopulations,andoutcomedefinitions.Overall,datafromcumulativepost-marketingpatientexposuretoCT-P13fromOctober2013toDecember2015suggestthatnonewsafetysignalshaveemerged.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
viCommonDrugReview November2017
ExtrapolationCT-P13(Inflectra)receivedmarketauthorizationinCanadainJanuary2014fortheindicationsofPsOandPsAbasedontheextrapolationofevidencefromstudiesconductedinpatientswithRAandAS.ExtrapolationwassupportedbysimilaritiesinthepathologyofRA,AS,PsA,andPsOandthemechanismofactionofalltumournecrosisfactoralpha(TNFalpha)blockersintheseindications.InJune2016,HealthCanadaapprovedCT-P13foradultCD,FCD,andUC.TheEuropeanMedicinesAgency(EMA),theFoodandDrugAdministration(FDA),andtheAustralianTherapeuticGoodsAdministrationhavealsoapprovedCT-P13forCDandUC.InHealthCanada’sinitialreviewofCT-P13forallindications,someconcernsaboutextrapolatingdatafromstudiesconductedinpatientswithRAandAStoIBDwerementioned.TheseincludeddifferencesindiseasemechanismsbetweenrheumaticandboweldiseasesandhigherriskofhepatosplenicT-celllymphomainpatientswithIBDtreatedwithinfliximab.ThepredominantformofTNFinRAandASissolubleTNFalpha(sTNFalpha);whereas,inCDandUC,transmembraneTNFalpha(tmTNFalpha)playsanadditionalandcentralrole.Also,unlikeRAandAS,inboweldiseasesantibody-dependentcell-mediatedcytotoxicity(ADCC)isanimportantmechanismofactionandismediatedbyafucosylationandFcγIIIareceptorbinding.MinordifferenceshavebeenobservedbetweenCT-P13andthereferenceproductinFcγIIIabindingandADCCactivityusinginvitroassayswithnaturalkiller(NK)cellsfrompatientswithCDandV/VorV/FFcγIIIagenotype(nodifferenceobservedwithF/Fgenotype).Inotherassaysusingperipheralbloodmononuclearcells(PBMCs)frompatientswithCDandV/ForF/FFcγIIIagenotype,nodifferenceinADCCactivitywasobserved.InJune2016,HealthCanadaauthorizedtheuseofCT-P13fortheIBDindicationsbasedonextrapolationfrompreviouslysubmittedclinicalstudiesinpatientswithRAandAS,comparablepharmacokinetics,andnewlysubmittedphysiochemicalandbiologicaldata.1OtherconsiderationsfortheextrapolationofdatabetweenRAandAS,andIBD,includedifferencesintreatmentstrategiesbetweentheindications,suchastheuseofconcomitantmedication,andthehigherdoses(>5mg/kg)ofCT-P13thatmaybeused.InCT-P13PMS,41%ofpatientsreceiveddoseshigherthan5mg/kgofCT-P13andnonotabledose-dependentdifferencesinthedistributionofTEAEswereobservedbetweenpatientswhoreceived5mg/kgorpatientswhoreceived>5mg/kg.However,theimmunogenicsimilarityofthehigherdosecomparedwitharegularorhigherdoseofRemicadeisuncertain.CostComparisonThemanufacturer’ssubmittedpriceforInflectra($525.00per100mgvial)is47%lowerthanthepriceofinfliximab($987.56per100mgvial),whenusingtheOntarioExceptionalAccessProgram(EAP)priceforinfliximab.ClinicalExpertComments1Theclinicalexpertconsultedforthisreviewnotedthatbothprivateandpublicdrugplanshaveguidelinesinplacethatstipulatewhichpatientsareeligiblefortreatmentwithanti-TNFdrugs,andCT-P13willfitwithinthatframework.Theexpertindicatedthatanimportantquestion,whichwillneedtobeaddressedifthedrugisintroduced,iswhetherpatientswhoarestableonthereferenceproduct,
1 ThisinformationisbasedoninformationprovidedindraftformbytheclinicalexpertconsultedbyCDRreviewersforthepurposeofthisreview.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
viiCommonDrugReview November2017
Remicade,willhavetheirtreatmentsubstitutedwithCT-P13orwhetheritwillonlybeusedintreatment-naivepatients.Endoscopicevaluationofdiseaseactivitymayberequiredinpatientswhoexperienceadiseaseflareafterswitching,andtherearesignificantbarrierstothatintermsofaccesstoendoscopy.Currently,limitedevidenceisavailabletoassessandpredictpatientresponsetoswitchingfromRemicadetoCT-P13.ConclusionCT-P13providescliniciansandpatientswithanotherpotentiallycost-effectivechoiceofabiologicaldrugforIBD.ThefocusofthisCDRreviewofCT-P13(Inflectra)isfortherecentlyapprovedindicationsofCD,FCD,andUCinadultpatients.TheNoticeofCompliance(NOC)fortheCD,FCD,andUCindicationswasgrantedsubsequenttoanearlierNOCforCT-P13fortheindicationsofRA,AS,PsO,andPsA.Ofnote,HealthCanadaapprovedtheindicationsofPsOandPsAbasedontheextrapolationofdatafromstudiesconductedwithpatientswithRAandAS.AllclinicalevidencecurrentlyavailableforCT-P13inpatientswithIBDisbasedonobservational,open-labelstudiesfromKoreaorEuropeinsmallnumbersofpatients.Thepivotalstudy,CT-P13PMS,isanobservational,open-labelstudyconductedinSouthKoreainpatientswithIBD,witha30-weekinterimanalysis.NaiveindirectcomparisonsofCT-P13withstudiesofRemicade(infliximab)suggestsimilarefficacyandsimilarsafetyforsomesafetyendpointsinpatientswithCDorUC.Nonetheless,intheabsenceofdatafromRCTs,theclinicalsimilarityofCT-P13andRemicadeforIBDintheCanadianpopulationremainsuncertain.GiventhattheresultsofCT-P13PMSarebasedonaninterimanalysis,theongoingmonitoringofCT-P13inpatientswithIBDwillbeimportantforevaluatinglong-termefficacyandsafety.Note:Referencesinsquarebrackets[]indicatethereferencescitedbythemanufacturer,whilethereferencescitedbyCDRareindicatedbysuperscripts.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
1CommonDrugReview November2017
1. PRODUCTINFORMATION1.1 OverviewoftheSEBProductHospirahasaco-exclusivedistributionagreementinplacewithCelltrionHealthcareCorporationwherebyCelltrionHealthcareCorporationisthemanufactureroftheinfliximabbiosimilarCT-P13,whichismarketedundertheTradenameINFLECTRA®orREMSIMA®.CelltrionHealthcareCorporationistheMarketingAuthorizationHolder(MAH)forREMSIMA®(infliximab;CT-P13)inanumberofterritoriesandHospiraistheMAHforINFLECTRA®(infliximab;CT-P13)inanumberofterritories,someofwhichoverlapwithCelltrionHealthcareCorporation.Inthefollowingsectionsofthistemplate,CT-P13,INFLECTRA®andREMSIMA®allrefertothesamemolecule,theinfliximabbiosimilarmanufacturedbyCelltrion.InCanada,HospirahasacquiredtherighttomarketanddistributeINFLECTRA®(infliximab;CT-P13)fromCelltrionHealthcareCorporation.Characteristics Manufacturer-ProvidedDetails
INFLECTRA® REMICADE®Brandname: INFLECTRA® REMICADE®Non-proprietaryname: Infliximab InfliximabManufacturer: HospiraHealthcareCo. JanssenInc.Strength(s): 100mg/vial 100mg/vialDosageform: PowderforSolution,Sterile,
LyophilizedPowderforSolution,Sterile,Lyophilized
Routeofadministration: IntravenousInfusion IntravenousInfusionDrugIdentificationNumber(s): 02419475 02244016Therapeuticclassification: BiologicalResponseModifier BiologicalResponseModifierExcipients Sucrose,sodiumdihydrogen
phosphatemonohydrate,di-sodiumhydrogenphosphatedihydrate,polysorbate80.Nopreservativesarepresent.
Dibasicsodiumphosphatedihydrate,monobasicsodiumphosphatemonohydrate,polysorbateandsucrose.Nopreservativesarepresent.
Impuritiesa Product-relatedHighmolecularweightspecies:vvvvvvvvvvvOthers:seeTablebelowProcess-relatedResidualhostcellprotein:vvvvvvResidualhostcellDNA:vvvvv(max)ResidualProteinA:vvvvvvvvvvvvvvvOthers:seesectionbelow
Product-relatedHighmolecularweightspecies:vvvvvvvvvvvOthers:seeTablebelowProcess-relatedNotavailable,seeexplanationattheendofthissection
Source:INFLECTRA®andREMICADE®productmonographsaIncludebothproductandprocess-relatedimpurities.PleasenotethattherehavebeennochangestothemanufacturingofINFLECTRA®sincetheNewDrugSubmission(NDS)wasfiledtoHealthCanadain2012,andsubsequentNOCgrantedin2014fortheRA,AS,PsAandPsOindications.Thismeansthat,fortheconsiderationofthecurrentCDRsubmissionfortheindicationsofCDandUC,thepharmaceuticalform,composition,dosageform,strength,routeofadministration,purityandimpuritiesforINFLECTRA®remainthesameasdescribedinthefirstCDRINFLECTRA®submissionandpositiverecommendationin2014fortheRA,AS,PsAandPsOindications.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
2CommonDrugReview November2017
Therefore,fortheremainderofSection1.1ofthetemplate,thesameinformationthatwassubmittedintheoriginalINFLECTRA®CDRsubmissionisbeingincluded.Asfortheproduct-relatedimpurities,itwastestedinthe3-waysimilaritystudiesandtheresultsareinlinewithwhatwassubmittedintheoriginalCDRsubmission(CTDModule3.2.R).Ifmoredetailsarerequiredonthissection,theINFLECTRA®submissionfrom2014shouldbeconsulted.Pharmaceuticalform:chimerichuman-murineimmunoglobulinG1(IgG1)monoclonalantibody
Pharmaceuticalcomposition:astheformulationofINFLECTRA®wassetidenticaltothatofREMICADE®,thedosageformforbothproductscontain100mginfliximab,500mgsucrose,0.5mgpolysorbate80,2.2mgsodiumdihydrogenphosphatemonohydrateand6.1mgdi-sodiumhydrogenphosphatedihydrate.Nopreservativesarepresent.
Dosageform:bothINFLECTRA®andREMICADE®arethesamedosageform,namelyformulatedaswhitelyophilizedpowder.
Strength:bothINFLECTRA®andREMICADE®aresuppliedin100mgvialstobereconstitutedwith10mLsterilewaterresultinginafinalconcentrationof10mg/mL.Forbothproducts,thetotaldoseofthereconstitutedproductmustbefurtherdilutedto250mLwith0.9%SodiumChlorideInjectionUSP.
Routeofadministration:bothINFLECTRA®andREMICADE®areadministratedviaintravenousinfusion.(PleasebeadvisedthatintheREMICADE®productmonograph(p.3),routeofadministrationislistedasi.v.injection,however,infusioniscitedintheremainingofthedocument).
Purityandimpurities:Product-relatedimpuritiesProduct-relatedimpuritiesinclude:oxidizedvariants,deamidatedvariants,C-terminallysinevariants,glyco-variants,highmolecularweight(HMW)speciesaswellasmolecularfragments.Asummaryoftheresultsforproduct-relatedimpuritycomparisonbetweenINFLECTRA®drugproductandREMICADE®arepresentedinthetablebelow.Impurity TestMethod ResultsOxidizedvariants
PeptideMapping(liquidchromatography-mass-spectrometry;LC-MS)
• Basedontheavailabledata,itcanbeconcludedthatonlyverylowandcomparableamountsofoxidizedmolecularvariantsarepresentinIFTdrugproductandREMICADE®.
Deamidatedvariants
Ion-exchangechromatography-highperformanceliquidchromatography(IEC-HPLC)
• vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv
C-lysineterminalvariants
IEC-HPLC • ItwasdemonstratedthatthedifferenceobservedbetweenINFLECTRA®andREMICADE®withrespecttotherelativeproportion(peakratio)ofthe6IEC-HPLCpeaksisattributabletoC-terminallysinevariability.
• However,ithasbeenshownthatC-terminallysinevariabilityholdsnobearingonbiologicalactivityinvitro,andthatC-terminallysineclippingoccursrapidlybothinvitroandinvivo,suggestingthatnearlyallinfliximabmoleculesarefullyclippedwithinseveralhoursfollowingdosing.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
3CommonDrugReview November2017
Impurity TestMethod ResultsGlyco-variants
SiteSpecificandN-LinkedGlycanAnalysisbyMeansofLC-MSPeptideMapping;OligosaccharideProfiling;MonosaccharideAnalysis;SialicAcidAnalysis
• Asparagine300wasshowntobetheonlysiteofN-glycosylationforbothINFLECTRA®andREMICADE®.NoO-linkedglycansweredetected,asonemightexpectforanIgG1monoclonalantibody,forINFLECTRA®ortheREMICADE®.
• BothINFLECTRA®drugproductandREMICADE®wereshowntocontainmostlyG0FandG1Fstructures.MinorspeciesincludingMan5,G2F,G0FminusN-acetylglucosamine,andG0weredetected.
• HPAEC-PADdatarevealthatthetypeandproportionoftheunchargedglycansisconservedbetweenINFLECTRA®andtheREMICADE®.
• Theidentifiedsugarswerevvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv;bothINFLECTRA®andREMICADE®hadsimilarmolarratiosforthe4sugars.
• ThemolarratioofneutralandaminosugarswasobservedtobehighlysimilarforINFLECTRA®drugproductandREMICADE®.
• INFLECTRA®samplescontainthesametypeaswellashighlysimilarlevelsofsialicacid(expressedasmolarratios)whencomparedtoREMICADE®.
Highmolecularweightspecies
Sizeexclusionchromatography(SEC)-HPLC
• INFLECTRA®drugproductandREMICADE®samplescontainprominentlymonomerdrugsubstancewithinacomparablerange(vvvvvvvvvvvvvvvvvvvvvvvvvvvvv,respectively).Theimpuritiesarehighmolecularweightspecies,whichareallvvvvacrossbothINFLECTRA®andREMICADE®products.
Molecularfragments
Capillaryelectrophoresissodiumdodecylsulfate(CE-SDS)(Reduced/Non-Reduced)
• INFLECTRA®andREMICADE®displaythesametypesofIgGfragments.
• INFLECTRA®drugproductandREMICADE®havesimilaramountofintactIgG(vvvvvvvvvvvvvvvvvvvvvvvvv,respectively)
Process-relatedimpuritiesProcess-relatedimpuritiesinclude:residualhostcellprotein(HCP),hostcellDNA,residualProteinA,recombinantInsulin-LikeGrowthFactor1(IGF-1),recombinanthumaninsulinandPluronicF-68.Abriefsummaryoftheseresultscanbefoundbelow.i. IntermsofHCP,thelevelthatwasdetectedacrossvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv
vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvisgenerallyconsideredasanacceptablelevelfortherapeuticproteins.
ii. ThelevelofresidualhostcellDNA,vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv,belowtheacceptancecriterionof≤4ppb(pg/mg)atrelease.
iii. TherangeofresidualProteinAvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv,belowthelimitof≤4ppm(ng/mg).
iv. TheabilityoftheINFLECTRA®purificationprocesstoclearIGF-1andrecombinantinsulinwasevaluatedaspartofaspikingstudy.Thestudydemonstratedthatthecapabilityofclearancebyspecificachromatographyvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv(Log10reductionvalue)forIGF-1andvvvvvvvvvvvvvvvvv.
v. vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
4CommonDrugReview November2017
vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv.
ForREMICADE®,theprocess-relatedimpuritiesandtheirclearanceisspecifictoeachmanufacturingprocess,therefore,Celltrion(manufacturerofINFLECTRA®)doesnothaveinformationonthemanufacturingprocessofREMICADE®andthetestsusedtodemonstrateclearanceoftheimpuritiesinthatprocess.ItisalsotechnicallyinappropriatetoapplyaCelltrionimpuritiestesttoREMICADE®togeneratethisdata.Theapproachisthereforeforthebiosimilarcompanytodevelopthemanufacturingprocessandcontrolstrategytoremoveprocess-relatedimpuritiesandtomaintaintheimpuritiesatthelowestpossibleleveltomeettheregulatoryrequirement.Process-relatedimpuritiessuchasresidualhostcellprotein,residualDNA,andendotoxinallfitthisapproach.Duetothesereasons,therearenoregulatoryagenciesrequestingthiscomparativeanalysis.1.2 OverviewoftheReferenceProductThereferenceproductdescribedinthissubmissionisREMICADE®(Infliximab;PowderforSolution,Sterile,Lyophilized,100mg/vial).REMICADE®iscurrentlyauthorizedforsaleandmarketinginCanada(DIN:02244016).TheinfliximabdrugsubstanceisachimericIgG1κantibody1328aminoacidsinlengththatiscomposedofhumanconstantandmurinevariableregions.InfliximabneutralizesthebiologicalactivityofhumanTNFαbybindingwithhighaffinitytothesolubleandtransmembraneformsofTNFα(sTNFα,andtmTNFα)andinhibitstheirbindingtoTNFreceptors(TNFRs).InCanada,REMICADE®(infliximab)isindicatedfor:1. useincombinationwithMTXforthereductioninsignsandsymptoms,inhibitionoftheprogression
ofstructuraldamageandimprovementinphysicalfunctioninadultpatientswithmoderatelytoseverelyactiveRA.
2. thereductionofsignsandsymptomsandimprovementinphysicalfunctioninpatientswithactiveASwhohaverespondedinadequately,orareintolerantto,conventionaltherapies.
3. reductionofsignsandsymptoms,inductionandmaintenanceofclinicalremissionandmucosalhealingandreductionofcorticosteroiduseinadultpatientswithmoderatelytoseverelyactiveCDwhohavehadaninadequateresponsetoacorticosteroidand/oraminosalicylate.REMICADE®canbeusedaloneorincombinationwithconventionaltherapy.
4. reductionofsignsandsymptomsandinductionandmaintenanceofclinicalremissioninpediatricpatientswithmoderatelytoseverelyactiveCDwhohavehadaninadequateresponsetoconventionaltherapy(corticosteroidand/oraminosalicylateand/oranimmunosuppressant).ThesafetyandefficacyofREMICADE®isnotestablishedinpatientslessthan9yearsofage.
5. treatmentofFCD,inadultpatientswhohavenotrespondeddespiteafullandadequatecourseoftherapywithconventionaltreatment.
6. reductionofsignsandsymptoms,inductionandmaintenanceofclinicalremissionandmucosalhealing,andreductionoreliminationofcorticosteroiduseinadultpatientswithmoderatelytoseverelyactiveUCwhohavehadaninadequateresponsetoconventionaltherapy(i.e.,aminosalicylateand/orcorticosteroidand/oranimmunosuppressant).
7. reductionofsignsandsymptoms,inductionandmaintenanceofclinicalremission,andinductionofmucosalhealinginpediatricpatientswithmoderatelytoseverelyactiveUCwhohavehadaninadequateresponsetoconventionaltherapy(i.e.,aminosalicylateand/orcorticosteroidand/oranimmunosuppressant).ThesafetyandefficacyofREMICADE®havenotbeenestablishedinpatientslessthan6yearsofage.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
5CommonDrugReview November2017
8. reductionofsignsandsymptoms,inductionofmajorclinicalresponse,andinhibitionoftheprogressionofstructuraldamageofactivearthritis,andimprovementinphysicalfunctioninpatientswithPsA.
9. treatmentofadultpatientswithchronicmoderatetoseverePsOwhoarecandidatesforsystemictherapy.ForpatientswithchronicmoderatePsO,REMICADE®shouldbeusedafterphototherapyhasbeenshowntobeineffectiveorinappropriate.Whenassessingtheseverityofpsoriasis,thephysicianshouldconsidertheextentofinvolvement,locationoflesions,responsetoprevioustreatments,andimpactofdiseaseonthepatient’squalityoflife.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
6CommonDrugReview November2017
2. INDICATIONS
2.1 HealthCanada-ApprovedIndicationsIndication(s) Extrapolation• useincombinationwithmethotrexateforthereductioninsignsand
symptoms,inhibitionoftheprogressionofstructuraldamageandimprovementinphysicalfunctioninadultpatientswithmoderatelytoseverelyactiverheumatoidarthritis.
No
• thereductionofsignsandsymptomsandimprovementinphysicalfunctioninpatientswithactiveankylosingspondylitiswhohaverespondedinadequately,orareintolerantto,conventionaltherapies.
No
• reductionofsignsandsymptoms,inductionofmajorclinicalresponse,andinhibitionoftheprogressionofstructuraldamageofactivearthritis,andimprovementinphysicalfunctioninpatientswithpsoriaticarthritis.
Yes
• treatmentofadultpatientswithchronicmoderatetosevereplaquepsoriasiswhoarecandidatesforsystemictherapy.Forpatientswithchronicmoderateplaquepsoriasis,INFLECTRA®shouldbeusedafterphototherapyhasbeenshowntobeineffectiveorinappropriate.Whenassessingtheseverityofpsoriasis,thephysicianshouldconsidertheextentofinvolvement,locationoflesions,responsetoprevioustreatments,andimpactofdiseaseonthepatient’squalityoflife.
Yes
• reductionofsignsandsymptoms,inductionandmaintenanceofclinicalremissionandmucosalhealingandreductionofcorticosteroiduseinadultpatientswithmoderatelytoseverelyactiveCrohn’sdiseasewhohavehadaninadequateresponsetoacorticosteroidand/oraminosalicylate.INFLECTRA®canbeusedaloneorincombinationwithconventionaltherapy
Yes
• treatmentoffistulizingCrohn’sdisease,inadultpatientswhohavenotrespondeddespiteafullandadequatecourseoftherapywithconventionaltreatment.
Yes
• reductionofsignsandsymptoms,inductionandmaintenanceofclinicalremissionandmucosalhealing,andreductionoreliminationofcorticosteroiduseinadultpatientswithmoderatelytoseverelyactiveulcerativecolitiswhohavehadaninadequateresponsetoconventionaltherapy(i.e.,aminosalicylateand/orcorticosteroidand/oranimmunosuppressant).
Yes
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
7CommonDrugReview November2017
3. MANUFACTURER’SREQUESTEDLISTINGCRITERIA
3.1 RequestedListingCriteriaRequestedListingCriteria• ListinasimilarmannertothepublicplanlistingcriteriaforREMICADE®.• Alternatively:reductionofsignsandsymptoms,inductionandmaintenanceofclinicalremission
andmucosalhealingandreductionofcorticosteroiduseinadultpatientswithmoderatelytoseverelyactiveCrohn’sdiseasewhohavehadaninadequateresponsetoacorticosteroidand/oraminosalicylate.INFLECTRA®canbeusedaloneorincombinationwithconventionaltherapy.
• ListinasimilarmannertothepublicplanlistingcriteriaforREMICADE®.• Alternatively:treatmentoffistulisingCrohn’sdisease,inadultpatientswhohavenotresponded
despiteafullandadequatecourseoftherapywithconventionaltreatment.• ListinasimilarmannertothepublicplanlistingscriteriaforREMICADE®.• Alternatively:reductionofsignsandsymptoms,inductionandmaintenanceofclinicalremission
andmucosalhealing,andreductionoreliminationofcorticosteroiduseinadultpatientswithmoderatelytoseverelyactiveulcerativecolitiswhohavehadaninadequateresponsetoconventionaltherapy(i.e.,aminosalicylateand/orcorticosteroidand/oranimmunosuppressant).
3.2 RationaleforRequestedListingCriteriaTheover-archingrationalefortherequestedlistingcriteriaforallindicationslistedbelowisbasedontheprincipleofdemonstratedbiosimilaritybetweenINFLECTRA®andthecurrentlyreimbursedreferencemedicinalproduct,REMICADE®.First,theformulationofINFLECTRA®hasbeendesignedtoreplicatethatofREMICADE®andbothdrugproductsareidenticalwithrespecttostrength,pharmaceuticalform,routeofadministration,andcompositioninexcipients(seeSection1.1above).Second,theactivesubstanceofINFLECTRA®,infliximab,hasbeendevelopedasasimilarbiologicalmedicinalproducttothatoftheactivesubstanceofREMICADE®(infliximab).Specifically,anextensiveseriesoforthogonalmethodsweredesignedtocomparethephysiochemicalpropertiesaswellasthebiologicalactivitiesofINFLECTRA®andREMICADE®,andresultsclearlydemonstratedthattheactivesubstanceishighlysimilarbetweenthesetwoproducts(seeSection4.1fordetailedinformation).In2014,theCanadianDrugExpertCommittee(CDEC)issuedapositiverecommendationforINFLECTRA®forthePsAandPsOindicationsviaextrapolation.Similarly,thedatatosupporttheCDandUCindicationsforINFLECTRA®viaextrapolationisbasedonthetotalityoftheevidencecollectedfromthequality,non-clinical,andclinicalcomparabilityexercise.PleaseseebelowinSection6forManufacturer’srationale,aswellasInternationalRegulatoryConclusionstosupporttheCDandUCindicationsviaextrapolation.Currently,infliximab(REMICADE®)isreimbursedbyallCDR-participatingdrugplansacrossthecountryforthetreatmentofCD(seeAppendix2).Consequently,weanticipatethatINFLECTRA®willalsobereimbursedunderthesameclinicalcriteriaasREMICADE®fromtheseCDR-participatingdrugplans,assumingthattheCDECissuesapositiverecommendationforINFLECTRA®forCD.Currently,5oftheCDRparticipatingdrugplansreimburseinfliximab(REMICADE®)fortheUCindication.Inthese5provinces,weanticipateINFLECTRA®willalsobereimbursedunderthesameclinicalcriteriaasREMICADE®,assumingthattheCDECissuesapositiverecommendationforINFLECTRA®forUC.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
8CommonDrugReview November2017
TheCDR-participatingdrugplansthatdonotcurrentlyreimburseREMICADE®forUCmayfindthatsignificantcostsavingsassociatedwithusingINFLECTRA®maytakethisopportunitytoexpandtreatmentoptionstothepatientswhorequiretreatmentforthisindication.AssumingapositiveHealthCanadaandCDECrecommendationfortheseindications,therequestedlistingcriteriaarereasonableandjustified.
4. BIOSIMILARITY4.1 QualityInformationAproductcharacterizationexercisewasconductedpreviouslyusingarangeofstate-of-the-artmethodologiestodemonstratecomparabilitybetweenCT-P13andEuropeanUnion(EU)approvedREMICADE®.Theresultsofthese2-waysimilaritystudiescomparingCT-P13withEU-approvedREMICADE®werepresentedinthepreviousCDRsubmissionin(CTDModule3.2.R.5)oftheinitialSubmission.Subsequently,awiderangeoforthogonaltestmethodswereperformedtodeterminecomparabilityofCT-P13andREMICADE®ina3-waystudy(CTDModule3.2.R-reg-infodocument)usingEUandUnitedStates(US)approvedREMICADE®.Thesestudiesincludedanextensivecomparativeanalysisofprimary,secondaryandtertiarystructure,glycanprofilesandofpost-translationalmodificationsaswellascomparativestabilitystudies.Inaddition,manybiologicalassayshavebeenincludedtoevaluatesimilarityinallbiologicalactivitiesassociatedwithknownandputativefunctionsandtherapeuticeffects.Theanalyticalmethodsandbiologicalassaysusedinsimilaritystudieshavebeensuitablyvalidatedorqualifiedtoprovideahighlevelofassurancethatthemethodscoulddetectanyslightdifferencesandarescientificallysound,fitforpurpose,reliableandreproducible.Similaritywaspreviouslydemonstratedintermsofprimarystructure,secondaryandhigherorderstructureaswellassimilardisulfidebonding.ThisinformationwasincludedintheoriginalCDRSubmissionforINFLECTRA®aspartoftheCommonTechnicalDocuments(CTD).Foreaseofreference,thesameCTDdocumentsareincludedinthissection,andtheinformationcanbefoundintheCTD3.2.R-regdocument(Modules3.2.R.2.2,3.2.R.2.3.1,3.2.R.2.3.2,3.2.R.2.3.3,3.2.R.2.3.4,3.2.R.2.3.5and3.2.R.2.3.6).BelowisasummaryofkeyfindingsrelatedtoqualityattributesaswellasbiologicalactivitiesinrelationtoCDandUC:Qualityattributes:Asimilarglycosylationprofilewithminordifferencesinafucosylatedglycans(G0+Man5),whichresultsinalowerbindingaffinitytoFcγRIIIaandaloweractivityinthemostsensitiveADCCassayusingNKcellsaseffectorcellsandtmTNFαJurkattargetcellswasobservedforCT-P13.TheimpactofthelowerlevelofafucosylatedglycansinCT-P13hasbeencomprehensivelyinvestigated:1. The3-waystudyconfirmedthattherewasnodifferenceinbindingtoFcγRI,FcγRIIa,FcγRIIband
FcRn,C1qbinding(enzyme-linkedimmunosorbentassay-ELISA)andcomplement-dependentcytotoxicity(CDC)activityduetodifferencesincoreafucosylationlevels.
2. TheimpactonFcfunctionalityislimitedtoaslightreductioninrelativebindingaffinityofCT-P13torecombinantFcγRIIIa(VandFhemizygote).
3. TheslightdifferenceinafucosylatedglycansCT-P13doesnothavediscernibleimpactonimmunogenicityfollowingrepeatedadministrationusingthesensitiveassayappliedintheclinicalstudyprogram.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
9CommonDrugReview November2017
Biologicactivity:Inaddition,approximately20differentorthogonalbiologicaltestsdirectlyrelatedtothemechanismsofactionordownstreamtherapeuticeffectswereperformedwhichcomparedCT-P13tobothEUandUSapprovedREMICADE®anddemonstrated:• HighlysimilarbindingaffinitytosTNFα,neutralizationofsTNFα,suppressionofcytokineinduction
bysTNFαandsuppressionofapoptosisbysTNFα• SimilarbindingaffinitytotmTNFα,andresultingcytokinesuppressionthroughreversesignaling
followingbindingtotmTNFαhavebeenobservedforCT-P13versusEUandUSapprovedREMICADE®.Theinductionofapoptosisthroughreversesignalinghasbeenshowntobesimilar.
• Highlysimilarininductionofregulatorymacrophages,suppressionofT-cellproliferationandinmediatingwoundhealing
• HighlysimilarFcγRIa,FcγRIIa,FcγRnandC1qbindingaffinityandCDCactivity• SlightdifferencesinbindingaffinitytotheFcγRIIIaandFcγRIIIbreceptorobservedforCT-P13in
comparisonwithREMICADE®wereobserved.Therelevanceofthisfindingwaspreviouslyinvestigatedusingfurthermodelsanditwasdemonstratedthatthedifferencewasnotclinicallymeaningful.Thefindingsarealsosupportedbydatafromtheliterature.
• MarginaldifferencesinADCCactivityusingoneartificialcellsystemwereshowntohavenoclinicallymeaningfuleffect,sinceusingmoreclinicallyrelevantmodelsandasimilarassaysystemwithcellsderivedfromdonors,highsimilaritywasdemonstrated.Incommonwithotheranti-TNFmonoclonals,infliximabdoesnotinducediscernibleADCCactivityagainstnaturallyderivedtargetcells.Thus,ADCCdoesnotappeartoplayaroleinmediatingtherapeuticeffect.
Inconclusion,thesecomprehensiveanalyseshaveshownthatCT-P13issimilartoEUandUSapprovedREMICADE®inprimarystructure,higherorderstructure,aggregateandmonomericpurity,andpost-translationalmodifications.ThedifferencesdetectedbythesehighlysensitivemethodshavebeenshowntobeofnoclinicalrelevanceinASandRAstudiesandhighlyunlikelytohaveaclinicallymeaningfulimpactonefficacyorsafetyinIBDindications.TheextensiverangesofinvitroandexvivobiologicalassayshavedemonstratedcomparablebiologicalactivitiesforCT-P13andEUandUSapprovedREMICADE®inassaysmimickingtheputativemechanismsofactionofinfliximabinCDandUC.AbriefoverviewofthetestsandconclusionsfortheoligosaccharideprofilingandbiologicactivitycomparisonbetweenCT-P13andREMICADE®arepresentedinTable1ofAppendix1.4.2 KeyClinicalStudiesPleasenotethattheapprovalofINFLECTRA®fortheIBDindicationsfrombothHealthCanadaandtheCDRrelyontheconceptofextrapolation(seeSection6forfurtherexplanation).Therefore,basedonthealreadyestablishedhighdegreeofsimilaritybetweenINFLECTRA®andREMICADE®,postmarketingstudies(studyreports)willbeusedtoevaluatetheclinicalsafetyandefficacyofINFLECTRA®inCDandUCpatients.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
10CommonDrugReview November2017
4.2.1 Post-MarketingSurveillanceofCT-P13100mg(Infliximab)(monoclonalantibody,recombinant)toEvaluateitsSafetyandEfficacyinKorea
StudyName Design Objectives PopulationPost-MarketingSurveillanceofCT-P13100mg(Infliximab)(monoclonalantibody,recombinant)toEvaluateitsSafetyandEfficacyinKorea.ReferredtoinremainderofdocumentasstudyCT-P13PMS
Phase4open-labelsafetysurveillancestudy
TheobjectivesofthisPMSwastoevaluatethesafetyandefficacyofCT-P13inKoreaunderroutinecare.
• AdultpatientswithmoderatetosevereactiveCDwhohadnotrespondeddespiteafullandadequatecourseoftherapywithcorticosteroidand/orandimmunosuppressant;orwhowereintoleranttoorhadmedicalcontraindicationsforsuchtherapies.
• AdultpatientswithFCDwhodidnotshowanyresponsetogeneraltreatments(includingantibiotics,drainageandimmunosuppressivetherapy).
• AdultpatientswithmoderatetosevereactiveUCwhohadaninadequateresponsetoconventionaltherapyincludingcorticosteroidsand6-mercaptopurineorazathioprine,orwhowereintoleranttoorhadmedicalcontraindicationsforsuchtherapies.
a) StudyCharacteristicsBriefdescriptionofthestudyThisPMSisanongoing,open-label,single-arm,phase4studythatisdesignedtoevaluatethesafetyandefficacyofCT-P13inallapprovedindicationsinSouthKorea.Thissurveillanceisplannedtobecarriedoutinapproximately60studycentersinSouthKoreawithanapproximatesamplesizeof1,600patients.AninterimanalysiswasperformedtoevaluatesafetyandefficacyofCT-P13inthespecificIBDpatientpopulation.Thisinterimanalysisincluded173patientswithIBDthathavebeentreatedwithCT-P13across15participatingIBDclinicalstudycenters.IBDpatientsenrolledinthisstudywereeithernaïvetoinfliximab(N=113)orwerepreviouslytreatedwithREMICADE®(N=60).Patientdisposition,demographicandbaselinecharacteristicsaredetailedbelow.IBDpatientsenrolledinthisstudycouldhavebeeneithernaïvetoinfliximaborwerepreviouslytreatedwithREMICADE®.Thereisnospecifieddosingwindow,asPMSisanobservationalstudy.Patientswillbetreatedaccordingtotheproductlabelandwillbefollowed-upuptoandincludingWeek30.Efficacyevaluationswereperformedaccordingtoplannedvisitsandcriteriasetforeachindividualindication:FCD,UCandCD.AllAdverseEvents(AEs)andSeriousAdverseEvents(SAEs)whichoccurredduringorafterCT-P13exposurewerecollectedthroughoutthestudy.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
11CommonDrugReview November2017
Characteristics Detailsfor(providestudyname)ST
UDYDESIGN
Objective ToevaluatethesafetyandefficacyofCT-P13inKoreaunderroutinecare.Studyperiod InitiationDate:23January2013
CompletionDate:on-goingCut-offdateforthisreport:14November2014
Studycentres Thisstudywasconductedat15clinicalcentersinKorea.Design ObservationalPhase4study,openlabel,singlearmInclusioncriteria AdultspatientswithmoderatetosevereCD,FCDandUCExclusioncriteria N/A
DRU
GS Intervention N/A
Comparator(s) N/A
DURA
TION
Run-in N/ATreatment N/Aasthisisanon-goingPostMarketingSurveillanceStudyFollow-up ForFCDandmoderatetosevereactiveUC,theefficacyevaluationwas
performedatbaseline,Week14andWeek30.TheevaluationofefficacyincaseswithmoderatetosevereactiveCDwasperformedatbaseline,Week2andWeek30.AllAEsandSAEswhichoccurredduringandafterCT-P13exposurewerecollectedthroughoutthestudy.
OUTC
OMES
PrimaryEndPoint(s) N/A
OtherEndPoints • ClinicalresponseforCDandUC• ClinicalremissionforCDandUC• DiseasecontrolforCDandUC• RescuemedicationforCDandUC• MucosalhealingforUC
NOTES
Publications • ParkSH,KimYH,LeeJHetal.ExpertRevGastroenterolHepatol.2015:9:sup1,35-44[1].
• clinicaltrials.govidentificationcode(e.g.,NCTXXXXXXXX):N/Ab) InterventionandComparatorsDosingandAdministrationDoseandregimenincludingdoseescalationwerecompliedwiththeapprovedposologybyKoreanMinistryofFoodandDrugSafetyandtimeintervalsbetweendoseswerecontrolledflexiblyupontheinvestigator’sdecisionunderroutinecare.PleaserefertotheCT-P13Koreanlabelfordosingandadministration[2].PatientswillbetreatedwithCT-P13every8weeks(±5days)followinginductiontherapy.ForFCDandmoderatetosevereactiveUC,theefficacyevaluationwasperformedatbaseline,Week14andWeek30.TheevaluationofefficacyincaseswithmoderatetosevereactiveCDwasperformedatbaseline,Week2andWeek30.AllAEsandSAEswhichoccurredduringandafterCT-P13exposurewerecollectedthroughoutthestudy.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
12CommonDrugReview November2017
ReferenceProductusedintheTrial:N/APlacebosandControls(ifapplicable):N/AConcomitantMedicationsAnynewtreatments(i.e.,treatmentsnotongoingatstudyentry)anddoseincreaseforexistingmedicationswereconsideredasrescuetreatments.Concomitantmedicationsforothermedicalconditionswerepermittedasclinicallyindicatedsubjecttospecificprotocolrequirementsoutlinedbelow.Permittedmedicationsincludedthefollowing:• Paracetamol• Oral5-AminosalicylicAcid(5-ASA)treatment• Inhaledortopicaldermatological(notperrectum)corticosteroids• Systemiccorticosteroids(e.g.,prednisone,budesonide,cortisoneacetate)• Oral5-ASAtreatmentinpatientsnotreceivingthismedicationatstudyentry.Forpatientsreceiving
5-ASAatstudyentry,noincreaseindosagewasallowed.• Corticosteroidsor5-ASAsperrectum• OthertreatmentsforUC,eithersystemicortopical,initiatedduringthetreatmentorobservation
period• AntibioticsusedfortreatmentofIBD.Theseincluded,butwerenotexclusiveto,agentsinthe
quinoloneclassandmetronidazole.c) Outcomes(KeyEfficacyandSafetyOutcomes)Efficacyevaluationsaretobeperformedaccordingtoplannedvisitsandcriteriasetforeachindividualindication.Allefficacyevaluationsaredescribedbelowbyindication:PatientswithFCD:• Proportionofpatientsachievingclinicalresponsedefinedasareductionofatleast50%from
baselineinthenumberofdrainingfistulas[3].• Proportionofpatientsachievingclinicalremissiondefinedastheabsenceofdrainingfistulas[3].• Proportionofpatientswithdiseasecontroldefinedbytheexclusionoflossofresponsecasesfrom
diseasecontrol.Lossofresponseisdefinedbytherecrudescenceofdrainingfistulas,theneedforachangeinmedicationforCDortheneedforadditionaltherapyforpersistentorworseningluminaldiseaseactivity,theneedforasurgicalprocedureforCD,orthediscontinuationofthestudymedicationowingtoaperceivedlackofefficacy[3].
PatientswithModeratetoSevereActiveCD:• Proportionofpatientsachievingclinicalresponsedefinedbya≥25%and≥70pointsdecreasein
ClinicalDiseaseActivityIndex(CDAI)scorefrombaselinescores[4].• ProportionofpatentsachievingclinicalremissiondefinedbyCDAIscoreof<150[4].• Proportionofpatientswithdiseasecontroldefinedbytheexclusionofdiseaseworseningcases
fromdiseasecontrol.DiseaseworseningisdefinedbyanincreaseinCDAIofatleast70pointsfromthequalifyingscorewithatotalscoreofatleast175andanincreaseinCDAIof35%ormorefromthebaselinevalue,ortheintroductionofanewtreatmentforactiveCD[4].
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
13CommonDrugReview November2017
PatientswithModeratetoSevereActiveUC:• ProportionofpatientsachievingclinicalresponsedefinedbyadecreaseinpartialMayoscoresfrom
baselineofatleast2pointsandatleast30%,withanaccompanyingdecreaseinthesubscoreforrectalbleedingofatleast1point,oranabsolutesubscoreforrectalbleedingof0or1[5].
• Proportionofpatientsachievingclinicalremission,whichisdefinedasatotalpartialMayoscoreof2pointsorlower,withnoindividualsubscoreexceeding1point[6].
• ProportionofpatientsachievingmucosalhealingdefinedbyMayoendoscopicsubscoreof≤1point.
• Proportionofpatientswithdiseasecontroldefinedthatdiseaseworseningcaseisexcludedfromdiseasecontrol.DiseaseworseningisdefinedbyanincreaseinpartialMayoscoreof≥3pointsfrombaseline(=beforeswitching)valueandapartialMayoscore≥5points.
PatientswithModeratetoSevereActiveCDandUC:• ForallIBDpatients,proportionofpatientsreceivingrescuemedicationwasassessed.Rescue
medicationisdefinedasanyconcomitantmedicationthatwerecommencedafterthefirstinfusiondatetotreatneworunresolvedsymptomsofCDorUC[7][8].
Thesafetyendpointswere:• Seriousadverseevents(SAEs).SAEwasconsideredassuchifit:
o resultedindeathorlife-threatening;o requiredinpatienthospitalizationorprolongationofexistinghospitalization;o causedapersistentorsignificantdisability/incapacity;o resultedinacongenitalanomaly/birthdefect;oro associatedwithanyothermedicallyimportantcondition.
• Adverseevents(AEs)• OtherinformationaboutsafetyAdverseeventswerecodedusingtheMedicalDictionaryforRegulatoryActivitiesVersion16.0.d) StatisticalAnalyses• AllstatisticalanalyseswereconductedusingSASVersion9.3(SASInstitute,Inc.).Continuousdata
weresummarizedusingdescriptivestatistics:n,mean,standarddeviation,median,minimumandmaximum,unlessotherwiseindicated.Categoricaldataweresummarizedusingcountsandpercentages.Datapresentedinlistingsweresortedbyindicationandthenbypatientnumberandvisit,whereapplicable.Allanalyseswereperformedbysubgroup(Naïve,Switch):NaïvegroupconsistsofpatientswhohadnotreceivedatleastonedoseofREMICADE®beforefirstinfusionofCT-P13.
• SwitchgroupconsistsofpatientswhohadeverreceivedatleastonedoseofREMICADE®beforefirstinfusionofCT-P13.
PremedicationThepremedicationwassummarizedbyindication,drugclassandpreferredtermforthesafetypopulation.Thepremedicationwasqualifiedwhencorticosteroids,antihistaminesoranalgesicswerecommencedatCT-P13infusiondateforthepurposeofprophylaxis.Afrequencytableforthemaximumamountofdosereceived(mg/kg)ispresentedbyindicationforpatientsinthesafetyanalysisset.PleaserefertoPMSstudyreport,Table9-4[9,Table9-4]showingthenumberandpercentageofpatientswithineachcategoryofamountofdosereceivedateachvisit
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
14CommonDrugReview November2017
EfficacyanalysisTheefficacyanalysissetconsistedofallpatientswhoreceivedatleastonedoseofCT-P13andhadatleastoneassessmentfollowingbaseline.Efficacyanalyseswereperformedontheefficacyanalysissetbyapplyingdifferentcriteriaforeachindication.Theproportionofpatientsachievingclinicalresponse,remissionanddiseasecontrolwereanalyzedbyindication.DescriptivestatisticsforactualvalueandchangefromBaselinewerepresentedbyindicationandvisitfornumberoffistulas,CDAIandMayoscore.LOCFmethodwasconsideredformissingdataimputationforclinicalresponseandremissionfornaïveCDandUCpatients.TheproportionofpatientsachievingmucosalhealingwasanalyzedinUCpatients.Therescuetherapywillbesummarizedbyindication,drugclassandpreferredtermforthesafetypopulation.TherescuetherapywasqualifiedwhenanyconcomitantmedicationwerecommencedafterthefirstinfusiondatetotreatneworunresolvedsymptomsofCDorUC.Discontinuedpatientswerenotincludedinthesummarytablesforefficacyanalysisateachvisit.SafetyanalysisThesafetyanalysissetconsistedofallpatientswhoreceiveatleastonedose(fullorpartial)ofthestudytreatmentduringanydosingperiod.Allanalysesofsafetywereconductedusingthesafetyanalysisset.SafetyanalyseswereperformedbypresentingdataonTreatment-EmergentAdverseEvents(TEAEs),anddurationofREMICADE®andCT-P13administration.TEAEsweresummarizedbyrelationship,intensity,systemorganclass,andpreferredtermdisplayingthenumberandpercentageofpatientswithatleastoneAEusingonlytheworstintensityrecordedateachlevelofsummarization.ThetotalnumberofeventsandnumberofpatientswithatleastoneAEoverallsystemorganclasseswasalsodisplayed.AdverseeventswerecodedusingtheMedicalDictionaryforRegulatoryActivitiesVersion16.0.RescuetherapyandpremedicationwerecodedusingtheWHODrugDictionaryVersion01September2013.AnalysisSetsTABLE1:NUMBEROFIBDPATIENTSINEACHPOPULATION-CT-P13PMSSTUDY
Analysisset ModeratetosevereactiveCD
FistulisingactiveCD ModeratetosevereactiveUC
Total Total
Naïve Switched Naïve Switched Naïve Switched Naïve Switched
Safetyanalysisset1 43 40 8 4 62 16 113 60 173
Efficacyanalysisset2 39 31 6 4 54 11 99 46 145
Source:[10,Table1]1Patientsadministeredatleast1doseofCT-P132Patientsadministeredatleast1doseofCT-P13andhadatleastoneofassessmentaftertreatmentForthedescriptionofthestatisticsprotocol,pleaserefertotheClinicalTrialStudyReport[9,page8].
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
15CommonDrugReview November2017
e) ResultsBaselineCharacteristicsTABLE2:SUMMARYOFDEMOGRAPHICANDBASELINECHARACTERISTICSFOR(CT-P13PMSSTUDYSAFETYANALYSISSETINTREATMENT-NAÏVEPATIENTS)Parameter Moderatetosevere
activeCD(N=43)FistulisingactiveCD(N=8)
ModeratetosevereactiveUC(N=62)
Total(N=113)
Age(years) 31.8(10.88) 27.9(10.13) 45.2(14.57) 38.9(14.71)
Mean(SD)
Median(range) 30.0(18-67) 25.5(18-48) 46.5(19-74) 39.0(18-74)
Sex,no(%) 34(79.1) 6(75.0) 40(64.5) 80(70.8)
Male
Female 9(20.9) 2(25.0) 22(35.5) 33(29.2)
Bodyweight(kg) 57.1(12.13) 71.2(11.77) 58.5(9.67) 58.8(11.26)
Mean(SD)
Median(range) 54.8(35-80) 67.9(57-93) 58.2(40-81) 58.0(35-93)
Baselinediseaseactivity1
340.0(90.35) 1.6(0.92) 6.8(1.13) n/a
Mean(SD)Median(range) 340.6(181-564) 1.0(1-3) 7.0(3-9)
Source:[10,Table2]1CDAIformoderatetosevereactiveCD,No.offistulaforfistulisingactiveCDandpartialMayoscoringsystem(MSS)inmoderatetosevereactiveUCpatientswereusedtoassessdiseaseactivity.
TABLE3:SUMMARYOFDEMOGRAPHICANDBASELINECHARACTERISTICSFOR(CT-P13PMSSTUDYSAFETYANALYSISSETINSWITCHEDPATIENTS)Parameter Moderatetosevere
activeCD(N=40)FistulisingactiveCD(N=4)
ModeratetosevereactiveUC(N=16)
Total(N=60)
Age(years) 31.1(10.41) 33.0(13.34) 42.9(13.54) 34.3(12.43)
Mean(SD)
Median(range) 28.5(19-60) 33.5(20-45) 41.0(21-64) 30.0(19-64)
Sex,no(%) 24(60.0) 3(75.0) 9(56.3) 36(60.0)
Male
Female 16(40.0) 1(25.0) 7(43.8) 24(40.0)
Bodyweight(kg) 58.9(13.45) 64.4(12.36) 58.0(9.46) 59.0(12.34)
Mean(SD)
Median(range) 60.0(37-97) 64.3(50-79) 56.9(40-73) 59.0(37-97)
Baselinediseaseactivity1
168.9(112.65) 0.5(0.58) 4.8(2.81) n/a
Mean(SD)
Median(range) 134.0(24-412) 0.5(0-1) 4.5(0-9)
Source:[10,Table3]1DAIformoderatetosevereactiveCD,No.offistularforfistulisingactiveCDandpartialMSSinmoderatetosevereactiveUCpatientsusedtoassessdiseaseactivity.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
16CommonDrugReview November2017
ThedemographicandbaselinecharacteristicsofpatientswereinlinewithtargetpatientpopulationinCT-P13andREMICADE®label.Overall,therewerenoimportantdifferencesbetweenCDandUCpatientsexceptthatUCpatientswereslightlyolderthanCDpatients.TherewasgreaterproportionofmalescomparedtofemalesinCDandUCsubgroups.Baselinediseasecharacteristicsinallsubgroupswereinlinewithmoderate-to-severeactivestatusofthedisease.Themajorityofinfliximab-naïvepatientswereexposedtoatleast3dosesoftreatmentwhichspanned6weekinductionperiodwith52.2%ofpatientsreachingdose6(30weeks).Likewise,themajorityofswitchedpatientswereexposedtoatleast3dosesoftreatmentand65.0%ofpatientsreacheddose5.ConcomitantConditionsandMedicationsAtotalof48of173(27.7%)patientsrequiredrescuemedicationtocontrolIBDsymptoms.However,lessthan15%ofCDandUCpatientsrequiredrescueanti-inflammatory,corticosteroidsorimmunosuppressionagents.Overall,theproportionofuseofrescuemedicationwashigherininfliximab-naïvegroupscomparedtoswitchedgroups[9,page10].EfficacyResultsThestudywasnotpoweredforefficacybuthadapositiveoutcomefortheefficacyendpointofinductionandmaintenanceofresponseinCD,FCDandUCpatientsregardlessoftreatment-naïveorswitchstatus.Pleaseseebelowkeyefficacyresults.2,3(A)Thefollowingresultsarebasedoncompletecaseanalysis:(i)AmongCDinfliximab-naïvepatients,vvvvvvvvvvvvandvvvvvvvvvvvvachievedclinicalresponseandvvvvvvvvvvvvandvvvvvvvvvvvvachievedclinicalremissionatweek14and30,respectively.(ii)AmongFCDinfliximab-naïvepatients,vvvvvvvvvandvvvvvvvvvachievedclinicalresponseatweek14and30,respectively.vvvvvvvvvvandvvvvvvvvvvachievedclinicalremissionatweek14and30,respectively.vvvvvvvvvvvvvvvvvvvvvvvvvvv.(iii)AmongFCDpatientsswitchedfromREMICADE®toCT-P13,clinicalremissionanddiseasecontrolwasvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv(iv)AmongUCinfliximab-naïvepatients,vvvvvvvvvvvvandvvvvvvvvvvvvachievedclinicalresponseandvvvvvvvvvvvvandvvvvvvvvvvvachievedclinicalremissionatweek14and30,respectively.(v)vvvvvvvvvvvvandvvvvvvvvvvvUCinfliximab-naïvepatientsexperiencedmucosalhealingatweek14and30whilevvvvvvvvvvpatientswhowereswitchedfromREMICADE®toCT-P13experiencedmucosalhealingthroughoutvisits2-5.(B)ThefollowingresultsarebasedonimputationofmissingdatawithLOCFandincludeallpatientsintheefficacyanalysisset.Theneedforrescuemedicationincludesallpatientsinsafetyanalysisset:(i)AmongCDinfliximab-naïvepatients,34/39(87.2%)and31/39(79.5%)achievedclinicalresponseatweek14and30,respectively.27/39(69.2%)and23/39(59.0%)achievedclinicalremissionatweek14and30,respectively.Rescuemedicationwasneededby7/43(16.3).
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
17CommonDrugReview November2017
(ii)AmongCDpatientswhowereswitchedfromREMICADE®toCT-P13,25/31(80.6%)achievedremissionthroughoutvisits2-6and27/31(87.1%)patientsdidnotexperiencediseaseworsening.Rescuemedicationwasneededby9/40(22.5%).(iii)AmongUCinfliximab-naïvepatients,40/53(75.5%)and39/54(72.2%)achievedclinicalresponseatweek14and30,respectively.26/53(49.1%)and20/54(37.0%)achievedclinicalremissionatweek14and30,respectively.Rescuemedicationwasneededby30/62(48.4%).(iv)AmongUCpatientswhowereswitchedfromREMICADE®toCT-P13,5/11(45.5%)achievedremissionthroughoutvisits2-5andnopatientsexperienceddiseaseworsening.Rescuemedicationwasneededby2/16(12.5%).SafetyResultsSafetyassessmentswerecarriedoutduringandafterCT-P13exposureandeventswererecordediftheyoccurredatanytimeduringthestudyperiod.2,3
Overall,CT-P13waswell-toleratedinalltreatedpatients.51TEAEwerereportedin38patients(22.0%).InpatientswithCD,19eventsoccurredin15/83patients(18.1%),inFCD2eventsoccurredin2/12patients(16.7%),andinUC30eventsoccurredin21/78patients(26.9%).22eventswereconsideredtoberelatedtotreatmentin18patients.Mosteventswereofmildseverityin25patients.FiveTESAEswerereportedin5(2.9%)patients:moderatetreatment-relatedtuberculosis(improved),moderatetreatment-relatedlungabscess(resolved),moderatetreatment-relatedanaphylacticreaction(resolved),severetreatment-relatedIRR(resolved),andseveretreatment-unrelatedabdominalpain(resolved).Amongthese5TESAEs,atotalof4caseswereconsideredtoberelatedtotreatmentand3casesledtodiscontinuationfromthestudy(IRR,lungabscess,andanaphylacticreaction).Infectionandseriousinfectionwerereportedin9patients(5.2%,vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv)and2patients(1.2%),respectively.Onlyonepatient(0.6%)hadactivetuberculosisafterCT-P13exposure.Infusion-relatedreactionincludinghypersensitivityandanaphylaxiswasreportedin9patients(5.2%).Therewerenopatientswithmalignancy,pneumonia,deathoranyothereventsofspecialinterestreportedinthestudy.Doseescalationresults• Themajorityofpatients(59.0%)receiveddosesof5mg/kgofCT-P13.41.0%patientsweretreated
withdoses>5-≤10mg/kg.Therewerenonotabledifferencesindose-escalationbetweeninfliximab-naïveandswitchedpatients.
TherewerenonotabledifferencesinincidenceofTEAEsbetweeninfliximab-naïveandswitchedpatientswith23.9%and18.3%ofpatients,respectively,reportedTEAEs.Furthermore,therewerenonotabledose-dependentdifferencesindistributionofTEAEsbetweenpatientswhoreceived5mg/kgor>5mg/kgdosesofCT-P13[9,page10].4.2.2 OtherLinesofEvidenceforUseofCT-P13inIBDa) OtherOngoingStudiesSponsoredbyCelltrion
(i)CT-P133.4:ThisisaphaseIIIefficacyandsafetystudytodemonstratenon-inferiorityofCT-P13withRemicadeinadultswithactiveCDover54weeks.Thedesignisrandomized,double-blind,parallelgroup.Anenrollmentof214patientsisplanned.Inaninterimanalysis(week14),formationofADAwas
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
18CommonDrugReview November2017
foundtobesimilarbetweenCT-P13andUS-licensedRemicadeinpatientsreceiving5mg/kg[75,page65].(ii)CT-P134.3:ThisisaphaseIV,observationalregistrystudyintheEuropeanUnionandSouthKoreatoevaluatetheefficacyandsafetyofCT-P13inpatientswithCDorUCovera5yearperiod.Anenrollmentof500patientsisplanned.Noresultsareavailabletodate.b) Non-CelltrionSponsoredStudiesThemanufacturerconductedasystematicsearchtoidentifynon-CelltrionsponsoredstudiesthatevaluatedtheuseofCT-P13inIBD.Sixobservationalstudiesinadultpatientswereidentified.ThesestudieswereconductedinNorway4,Hungary5,6,theCzechRepublic7,andKorea.8,9Eachstudyissummarizedbrieflyandselectedresultsprovided.Norway4:Aprospective,observationalstudywasconductedinasinglecenterin46patientswithCDand32patientswithUC.PatientsreceivedthreeinductiondosesofCT-P13atweeks0,2,and6,withthemajorityreceiving5mg/kg.Efficacyandsafetywereassesseduptoweek14.OfthepatientswithCD,79%achievedremission(Harvey-BradshawIndexscore≤4)andofthepatientswithUC,56%achievedremission(partialMayoscore≤2).StatisticallysignificantreductionsinC-reactiveproteinandcalprotectinfrombaselinetoweek14wereobserved.AdverseeffectsincludedIRRs(1patientwithCDand1withUC),colectomy(1patientwithUC),muscleandjointpainduetoantibodyformation(1patientwithCD),andinfections(patientswithCD:infectiousenterocolitis,herpeszoster,herpessimplex,recurrentupperairwayinfection;patientswithUC:pneumoniaanderysipelas).Hungary5,6:Gecseetal.conductedanationwide,multicentreprospectiveobservationalstudytoassesstheefficacy,safety,andimmunogenicityofCT-P13inpatientswithCD(N=126)orUC(N=84).PatientsreceivedCT-P135mg/kginductionatweeks0,2,and6andthenevery8weeksthereafter.Clinicalresponsewasachievedby81.4%ofpatientswithCD(decreaseinCDAI>70oratleast50%reductioninthenumberofdrainingfistulas)and77.6%ofpatientswithUC(decreaseinpartialMayoscore>3)atweek14.Clinicalremissionwasachievedby53.6%ofpatientswithCD(CDAI<150ornofistuladrainage)and58.6%ofpatientswithUC(partialMayoscore<3).Significantlymorepatientswhowereinfliximab-naïveachievedclinicalremissionatweek14comparedwithpatientswhohadpreviouslyreceivedtheinnovatorproduct.Infusion-relatedreactionswereexperiencedin14(6.6%)patientsandinfectionsin12(5.7%).Infusion-relatedreactionsoccurredatahigherincidenceinpatientswhowereswitchedfrominnovatorproduct(27%vs.2.5%).Molnaretal.examinedmucosalhealingsubsequenttoCT-P13administrationin12patientswithUC.Atweek6,clinicalresponsewasobtainedby2patients,clinicalremissionby5patients,andmucosalhealingwasobservedin7patients.TheCzechRepublic7:Apost-marketsurveillancestudyof140patientswithIBD(107CDand33UC)wasconductedwithaninterimanalysisofefficacyandsafetyatweek10(completefollow-upwillbetoweek30).Ofthe140patients,36weretreatment-naïveand104wereswitchedtoCT-P13fromotherbiologicalagents.Efficacydatawereavailablefortreatment-naïvepatientsonly(23CDand13UC).StatisticallysignificantreductionsinHarvey-BradshawIndexforCDandSimpleClinicalColitisActivityScore(SCCAI)forUCfrombaselinetoweek10wereobserved.Clinicalresponsewasobtainedby5patients(21.7%)withCD(decreaseinHarvey-BradshawIndex≥3)and6(46.2%)patientswithUC(decreaseinSCCAI≤2).Clinicalremissionwasobtainedby17(73.9%)patientswithCD(Harvey-BradshawIndex≤4)and2(15.4%)patientswithUC(SCCAI≤2).Comparedwithbaseline,therewerestatisticallysignificantreductionsinC-reactiveproteinandfecalcalprotectininbothCDandUC.Six
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
19CommonDrugReview November2017
TEAEs(IRRs,pneumonia,C.difficileinfection,tonsillitis,anddermatitispsoriasiform)wereexperiencedby6(4.3%)patients(3CDand3UC).Korea8,9:Kangetal.evaluated17patientswithIBD(8CDand9UC)whoreceivedCT-P13atasinglestudycenter.Amongtreatment-naïvepatients(N=8),clinicalresponse(CD:decreaseCDAI>60;UC:decrease>30%intheactivityindex+decreaseinrectalbleedingandendoscopysubscores)andremission(CD:CDAI<150;UC:Mayoscore≤2andnosubscores>1)wereachievedin7(2CDand5UC)atweek8.AmongpatientswhoswitchedtoCT-P13frominnovatorproduct(N=9),8hadsimilarclinicaloutcomes.OnepatientwithCDhadlossofresponse.Jungetal.conductedaretrospectivemulticenterstudyinpatientswithCD(N=59)andUC(N=51)withfollow-upto54weeks.Atweek8,clinicalresponseandremissionintreatment-naïvepatientswithCD(N=32)were90.6%and84.4%respectively.Atweek54,clinicalresponseoccurredin7/8(87.5%)andremissionin6/8(75.0%).Intreatment-naïvepatientswithUC(N=42),clinicalresponseandremissionatweek8were81.0%and38.1%respectively.Atweek54,clinicalresponseoccurredin12/12(100%)andremissionin6/12(50%).MucosalhealinginUCwasachievedin14/24(58.3%)atweek8andin2/3(66.7%)atweek54.Amongpatientswhoswitchedfromthereferenceproduct(27CDand9UC),efficacywasmaintainedin25(92.6%)withCDand6(66.7%)withUC.TherewerestatisticallysignificantdeclinesinC-reactiveproteinanderythrocytesedimentationrateinCDandUC.Six(11.8%)patientswithUCexperiencedanAE.4.2.3 SummaryofSafetySectiona) SafetyEvaluationPlanTheobjectiveoftheclinicaldevelopmentprogramforCT-P13wastodemonstratethatCT-P13iscomparabletothereferencemedicinalproduct,REMICADE®,intermsofitsclinicalpharmacology,efficacyandsafety.DatafromclinicaltrialsinRAandASpatientsshowedthatthesafetyprofilesofCT-P13andREMICADE®weresimilar.Inviewofthesedataandthestructural,biological,toxicologicalandpharmacokinetic(PK)comparabilitytothereferencedrugproductREMICADE®(CTDModules3.2Rand2.4),CT-P13isalsoexpectedtodisplayacomparablesafetyprofileinCDandUCpatients.Therefore,thesafetyevaluationinCDandUCpatientswasbasedonthesafetyprofileofREMICADE®aspresentedintheproductinformationfromREMICADE®productmonograph[11]andtheSummaryofProductcharacteristics[12].TocomparethesafetydataofCT-P13andthatofREMICADE®,literaturesearcheshavebeenperformedtoidentifyarticlesreportingREMICADE®studies.Thedatafromthesehistoricalstudieswereincludedinthemeta-analyseswithregardtotheincidenceofAdverseEventofSpecialInterest(AESI),inparticulartotheincidenceof(seeCTDModule2.7.4.2.1.5):• Infectionsincludingseriousinfections,pneumonia,activetuberculosis• Infusion-relatedreactionsincludinganaphylacticreactions• MalignanciesincludinglymphomaTheliteraturesearchesfocusedonRCTsandalsoconsideredobservationalstudies.PublicationswereselectedwhentheyreportedthemethodologyofcollectingsafetydataandspecificallyAEsandwhentheincidenceofAEswasclearlycapturedandreportedusingreliabledenominators.Forfurtherdetails,refertoaSystematicLiteratureReviewontheSafetyofinfliximabinthetreatmentofpatientswithCDandUC[13]andaSystematicliteraturereviewreportonREMICADE®observationalstudies[14].Belowarecomparisonsofoverallrates(per100patient-yearswith95%confidenceintervals)fromRCTsofRemicade(ACCENTI,ACCENTII,andSONIC,+others),observationalstudiesofRemicade,andobservationalstudiesofCT-P13.10
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
20CommonDrugReview November2017
1.Infusion-relatedreactions:CD:Remicade(RCTs)–vvvvvvvvvvvvvvvper100patient-yearsRemicade(observational)-vvvvvvvvvvvvper100patient-yearsCT-P13(PMS+non-Celltrionsponsoredstudies)–vvvvvvvvvvvvvper100patient-yearsUC:Remicade(RCTs)–vvvvvvvvvvvvvvvper100patient-yearsRemicade(observational)–vvvvvvvvvvvvper100patient-yearsCT-P13(PMS+non-Celltrionsponsoredstudies)–vvvvvvvvvvvvvper100patientyears2.Infections:CD:Remicade(RCTs)–vvvvvvvvvvvvvvvper100patient-yearsRemicade(observational)-vvvvvvvvvvvvper100patient-yearsCT-P13(PMS+non-Celltrionsponsoredstudies)–vvvvvvvvvvvvvper100patient-yearsUC:Remicade(RCTs)–vvvvvvvvvvvvvvvper100patient-yearsRemicade(observational)–vvvvvvvvvvvvper100patient-yearsCT-P13(PMS+non-Celltrionsponsoredstudies)–vvvvvvvvvvvvvper100patientyears
3.Pneumonia:CD:Remicade(RCTs)–vvvvvvvvvvvvper100patient-years*Remicade(observational)–vper100patient-yearsCT-P13(PMS+non-Celltrionsponsoredstudies)–vvvvvvvvvvvvvper100patient-yearsUC:Remicade(RCTs)–vvvvvvvvvvvvper100patient-yearsRemicade(observational)–vvvvvvvvvvvvper100patient-yearsCT-P13(PMS+non-Celltrionsponsoredstudies)–vvvvvvvvvvvvper100patient-years*PneumoniawasnotreportedinACCENTI,ACCENTII,orSONIC
4.Tuberculosis:CD:Remicade(RCTs)–vvvvvvvvvvvvvper100patient-yearsRemicade(observational)–vvvvvvvvvvvvvper100patient-yearsCT-P13(PMS+non-Celltrionsponsoredstudies)–vvvvvvvvvvvvvper100patient-yearsUC:Remicade(RCTs)–vvvvvvvvvvvvvper100patient-yearsRemicade(observational)–vvvvvvvvvvvvvper100patientyearsCT-P13(PMS+non-Celltrionsponsoredstudies)–vper100patient-years5.Malignancies:CD:Remicade(RCTs)–vvvvvvvvvvvvper100patient-yearsRemicade(observational)–vvvvvvvvvvvvper100patient-yearsCT-P13(PMS+non-Celltrionsponsoredstudies)–vper100patient-yearsUC:Remicade(RCTs)–vvvvvvvvvvvvper100patient-years
Remicade(observational)–vper100patient-yearsCT-P13(PMS+non-Celltrionsponsoredstudies)–vper100-patient-years
6.Surgery:CD:Remicade(RCTs)–vvvvvvvvvvvvper100patient-years*Remicade(observational)–vvvvvvvvvvvvper100patient-yearsCT-P13(PMS+non-Celltrionsponsoredstudies)–vvvvvvvvvvvvvper100patient-yearsUC:Remicade(RCTs)–vvvvvvvvvvvvvvvper100patient-years*
Remicade(observational)–vvvvvvvvvvvvvper100patient-yearsCT-P13(PMS+non-Celltrionsponsoredstudies)–vvvvvvvvvvvvper100-patient-years*DatafromthemajorRCTsofRemicade+otherRCTs
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
21CommonDrugReview November2017
7.Disease-RelatedHospitalization:CD:Remicade(RCT)–vvvvvvvvvvvvvvvper100patient-yearsRemicade(observational)–vvvvvvvvvvvCT-P13(PMS+non-Celltrionsponsoredstudies)–vvvvvvvvvvvvvper100patient-yearsUC:Remicade(RCT)–vvvvvvvvvvvvvvvper100patient-yearsRemicade(observational)–vvvvvvvvvvv
CT-P13(PMS+non-Celltrionsponsoredstudies)–vvvvvvvvvvvvper100-patient-yearsInaddition,safetydatawascollectedfromseveralpost-marketingobservationalstudies.Thesafetypopulationandoutcomesarefurtherdescribedinthesectionsbelow.ForadditionalinformationonthespecificstudiespleaserefertotheClinicalStudyReports(CSRs)includedinthelistedreferences.b) SafetyPopulationsEvaluatedThesafetydatabaseofCT-P13consistsofdatafromthe2ongoingclinicaltrialsconductedwithCT-P13forCDandUC:thePhase4trialCT-P134.1inIBDpatients[15],andtheobservationalPhase4trialCT-P13PMS[9].ThelatterstudyisdescribedindetailinSection4.2.CT-P134.1isasmall(N=20)phaseIV,ongoing(fouryear),open-label,singlearmstudyconductedinadultpatientswithCDorUCinSouthKorea.11Aninterimanalysisofefficacyandsafetyin10patients(vvvvvvvvv)fromvstudycentershasbeenpresented.vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv.AnalysesofthesafetyofCT-P13atdoses>5mg/kgincludeddatafromStudyCT-P13PMSandStudyB2P13111,whichisanExtensionStudyofthePhaseI/IIClinicalStudyofCT-P13inTreatmentofPatientswithRheumatoidArthritis[16].ForStudyCT-P13PMSvvvvvvvvvvvvvvvvv,thesafetyanalysissetconsistedofallpatientswhoreceivedatleastonedose(fullorpartial)ofthestudytreatmentduringanydosingperiod.Atotalof173IBDpatientshavebeentreatedwithCT-P13inStudyCT-P13PMSand75patientsweretreatedwithdoses>5mg/kg.InStudyB2P13111,vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv.Atotalof71RApatientsweretreatedwithCT-P13.vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv.c) OverviewofSafetyThesafetydatabaseofCT-P13inIBDpatientshasbeenspeciallyevaluatedwithregardtotheidentifiedandpotentialrisksofREMICADE®i.e.,IRRs,infections,inparticularpneumoniaandtuberculosis,andmalignancies.Inaddition,analysesoneventsofsurgeryordisease-relatedhospitalizationhavebeenperformed.Theresultsoftheseanalysesarepresentedinthefollowingsections.Inaddition,thefindingsonIRRs,infections,pneumonia,tuberculosisandmalignanciesfromRCTsconductedwithREMICADE®aswellasfromobservationalstudiesaresummarizedandcomparedwiththesafetydatafromStudyCT-P13PMS,StudyCT-P134.1,andnon-CELLTRIONsponsoredstudies.d) TreatmentEmergentAdverseEvents(TEAS)StudyCT-P13PMS(InterimCSR)Atotalof51TEAEswerereportedin38patients(22.0%).Ofthese,22eventswereconsideredtoberelatedtotreatmentin18patients.TherewasnonotabledifferenceinincidenceofTEAEsbetweeninfliximab-naïveandswitchedpatientswith23.9%and18.3%ofpatientsreportingTEAEs,respectively.MoreTEAEswerereportedbyUCpatientscomparedtoCDpatients;30TEAEsbyUCpatientsand19TEAEsbyCDpatients.PatientswithFCDreported2TEAEs.Themostfrequently(≥5patients)reportedsystemorganclasses(SOCs)includedinfectionsandinfestations(9patients),skinandsubcutaneous
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
22CommonDrugReview November2017
tissuedisorders(8patients),gastrointestinal(GI)disorders(5patients),generaldisordersandadministrationsiteconditions(5patients).MostTEAEswereofmildseverity(10patientsreportedmildTEAEsconsideredrelatedtotreatmentand15patientsreportedmildTEAEsconsideredtobeunrelatedtotreatment);7patientsreportedrelatedmoderateTEAEsandalso7patientsreportedunrelatedmoderateTEAEs.TwoTEAEswereassessedtobeofsevereseverity.InfectionsandGIdisorderswerethemostfrequentlyreportedTEAEs,whichisnotinconsistentwiththesafetyprofileofREMICADE®inIBDpatients.StudyCT-P134.1(InterimCSR)vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvve) DeathsNodeathswerereportedintheinterimCSRsofStudiesCT-P13PMS,vvvvvvvvvvvvvvvvvvv.f) TreatmentEmergentSeriousAdverseEvents(TESAEs)StudyCT-P13PMS(InterimCSR)FiveTESAEswerereportedby5(2.9%)patientsinthestudy(CTDModule2.5-12);ofthese,4wereconsideredtoberelatedand1tobeunrelatedtotreatment.TheTESAEswerereportedby4patientsreceiving5mg/kgasmaximumdoseand1patientinthe>5mg/kg-≤7mg/kggroup.TheTESAEsreportedinthestudyareconsistentwiththesafetyprofileofREMICADE®asdescribedintheREMICADE®ProductMonograph[11].NounexpectedTESAEoccurredduringthestudy.StudyCT-P134.1(InterimCSR)vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvg) ReactionsDuetoInfusionoftheStudyDrugsvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv.InStudyCT-P13PMS,atotalof10IRRswerereportedby9IBD(9of173;5.2%)patients,vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv.IntheCDgroup,2patientsreportedIRRs(bothswitchedtoCT-P13)andintheUCgroup8patients(6infliximab-naïve,2switch).NoneofthepatientswithFCDreportedIRRs.FourIRRsledtopermanentdiscontinuationoftreatment.TheincidenceofIRRswasnothigherinthegroupofpatientsreceivingdosesof>5mg/kg(3of71,4.2%)comparedtopatientsreceiving5mg/kgasmaximumdose(6of102,5.9%).InStudyCT-P134.1,2(20%)patientsexperiencedIRRs;1patientexperiencingvomiting(possiblerelated,moderate)andnausea(possiblerelated,moderate)intheCDgroup,1patientreportingskinexfoliation(possible,mild)andrash(probable/likely,mild)intheUCgroup.NoneoftheseIRRsledtodiscontinuationoftreatment.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
23CommonDrugReview November2017
h) InfectionsInStudyCT-P13PMS,atotalof10TEAEsofinfectionswerereportedby9IBDpatients;ofthese,3wereconsideredtoberelatedand6tobeunrelatedtotreatment.The3TEAEsconsideredtoberelatedincluded:1TEAEoftuberculosis(moderate)experiencedbyaFCDpatient,1TEAEofrhinitis(mild)reportedbyatreatment-naïveUCpatient,and1TEAEoflungabscess(moderate)reportedbyatreatment-switchUCpatient.Theeventofrhinitis,however,wasconfirmedtobeanIRRbythesiteinvestigator.TEAEsunrelatedtotreatmentincludedfolliculitis(mild),upperrespiratoryinfections(3mild,2moderate),andurinarytractinfection(moderate).Theincidenceofinfectionswasnothigherinthegroupofpatientsreceivingdosesof>5mg/kg(2of71,2.8%)comparedtopatientsreceiving5mg/kgasmaximumdose(7of102,6.9%).vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvOverall,1caseoftuberculosis(StudyCT-P13PMS)wasreportedinIBDpatients.Forfurtherdetails,refertoCTDModule2.7.4.i) SurgeryNocasesofsurgerywerereportedintheperiodcoveredbythePMSinterimCSR.j) Hospitalization(disease-related)InStudyCT-P13PMS,1treatment-naïvepatientwithCDwashospitalized.NoothercasesofhospitalizationwerereportedintheperiodcoveredbytheinterimCSR[17,Table24].k) Post-marketingDataAspreviouslymentioned,REMSIMA®andINFLECTRA®arethesamemolecule,theinfliximabbiosimilar(CT-P13)manufacturedbyCelltrionHealthcareCorporation,justmarketedanddistributedunderdifferentcommercialnamesindifferentcountries.Assuch,thepostmarketingdataforCT-P13isbasedonboththeperiodicbenefit-riskevaluationreport(PBRER)[18],dated23Mar2015fortheREMSIMA®brandaswellastheperiodicsafetyupdatereport(PSUR)dated29Mar2016fortheINFLECTRA®brand[19]REMSIMA®(infliximab;CT-P13)Thisreportcontainssafetydatafromindividualcasereportsderivedfrompost-marketingspontaneousreporting,publishedliteratureandclinicaltrials,coveringtheperiodfrom20Jul2014to20Jan2015(forfurtherdetails,seeCTDModule2.7.4).vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv.Duringthereportingperiod,nonew,ongoing,orclosedsignalswereidentifiedforinfliximab.Nonewinformationwasreceivedforthepreviouslyidentifiedorpotentialrisksandtherewasnoupdateonmissinginformationduringthisreportingperiod.Therewerenoactionstakenorriskminimizationactivitiesproposedforanysafetyreason.Overall,nosignificantnewsafetyinformationwasidentifiedfromthereviewofworldwidesafetydataduringthereportingperiodthatwouldwarrantchangestotheReferenceSafetyInformationofinfliximab.Thebenefit-riskratioofinfliximabremainsfavorable.ThisreportsummarizesthesafetyinformationreceivedbytheProductSafetyDepartmentofHospira,forINFLECTRA®(infliximab),duringtheperiod21Jul2015to20Jan2016(forfurtherdetails,seethePSURdocumentincludedinthelistedreferences).SourcesofadversereportingdatawithinthisPSURincludespontaneousreports(medicallyconfirmedandnon-medicallyconfirmed),reportsfromregulatory
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
24CommonDrugReview November2017
authorities,reportsfromnon-Hospirasponsoredstudiesornamedpatient/compassionateuseprograms,andtheliterature.vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv.DuringthereportingperiodcoveredbythisPSUR,therewerenoactionstakenwithINFLECTRA®(infliximab)forsafetyreasons,byeithertheRegulatoryAuthoritiesor,byHospiraastheMAHandnochangesintheefficacyofINFLECTRA®(infliximab)werereportedeither.Followingareviewoftheadverseeventinformationreceivedduringthe6monthperiodcoveredbythisreport,therisk-benefitbalanceofINFLECTRA®(infliximab)isconsideredfavorable4.3 PharmacokineticsThePKsimilarityofREMICADE®andCT-P13wasdemonstratedbyaphaseI(CT-P131.1)studyinASpatientswith5mg/kgandaphaseIII(CT-133.1)studyinRApatientswith3mg/kg.ThesestudieswerepresentedanddescribedwithinthepreviousCDRsubmissionforINFLECTRA®.DoseproportionalityofCT−P13intherangeof3−10mg/kgwasanalyzedinaPKmodelingstudytosupportIBDindicationdosingregimen.TheprimaryobjectiveofthisanalysiswastoevaluatethedoseproportionalityofCT−P13basedonthefollowing:pharmacokineticdatafromthephaseIstudy,externalvalidationwithphaseIIIdataandreviewofpreviouspharmacokineticstudiesonREMICADE®.RefertotheCT-P13PKModellingReportforfurtherdetails[20].ThisstudyhasshownthattherearenodifferencesinpharmacokineticparametersbetweenREMICADE®andCT−P13.BothREMICADE®andCT−P13appeartobedoseproportionalinthedoserangeof3−5mg/kgbasedontheexternalvalidation.ThepharmacokineticparametersofREMICADE®areknowntobeproportionaltothedosesgiven(5and10mg/kginpatientswithCD,5,10,and20mg/kginpatientswithRA)inpreviouspharmacokineticsreportsofREMICADE®andCT-P13werelinear(doseproportionalexposure)inourstudiesasobservedinpreviousreports.ForfurtherdiscussiononREMICADE®PKlinearity,pleaserefertoAppendixI.Inaddition,severalnon-sponsoredstudieshaveinvestigatedCT-P13PKinIBDpopulation.Anoverviewofthedataisprovidedbelow.TheObservationalHungarianNationwideIBDStudy[21,22],thatenrolled90CDpatientsand51UCpatientsasofFebruary,15,2015,showedthatforbothCDandUCpatients,troughlevelsincreasedfrompre-dosestatusatweek0toweek2andsubsequentlystabilizedbetweenweeks6and14.Preliminaryresultsthroughinductiontherapymeasuredbyweek14showedtherapeuticallymeaningfulconcentrationsofdrugpresentinpatients.AsimilarstudywasdonebythesamegroupusingREMICADE®[23].TheresultsinthecurrentstudyforCT-P13arecomparabletothosereportedpreviouslyforREMICADE®[22].AcohortstudythatiscurrentlyunderwayinNorway[24,25]hasenrolled44CDpatientsand30UCpatientsasofJanuary,31,2015,including56patientswhowerenaïvetoinfliximabtherapyand18patientswhowereswitchedfromREMICADE®toCT-P13.Themeantroughlevelsatweek14inCDpatientswas7.0mg/L(range:0.0-21.8mg/L),andforUCpatientsitwas6.1mg/L(range:0.0–16.7mg/L)[25].AnotherobservationalstudyfromPraguein140IBDpatientsshowedamediantroughlevelofCT-P13inalltreatment-naïvepatientsof14.8µg/mL(0.9-45.0µg/mL)and8.7µg/mL(0.2-45.0µg/mL)atWeeks2and6,respectively.ThemediantroughlevelofCT-P13inallswitchedpatientswere2.4(0-22.0µg/mL)atbaselineand3.2(0-19.0µg/mL)atweek8afterthefirstinfusion[26].Inconclusion,CT-P13hasdemonstratedalinearandpredictablepharmacokineticprofilethatwashighlysimilartoREMICADE®inmodeling,sponsoredandnon-sponsoredobservationalstudies.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
25CommonDrugReview November2017
4.4 ImmunogenicityImmunogenicitydatawasthoroughlyassessedinthekeypivotalstudiespresentedinthepreviousCDRsubmission(PLANETASandPLANETRAStudies).ThefollowingsectionsummarizesdatarelevanttoCDandUCandbrieflydiscussesimmunogenicitysimilarity.AseriesofstudieswereundertakentoinvestigateifimmunereactivityagainstREMICADE®iscross-reactivewithCT-P13.SerafromIBDpatientswhodevelopedanti-infliximab(ATI)antibodiesfollowingtreatmentwithREMICADE®wereexaminedforcross-reactivitytoCT-P13bycomparisonofantibodytitersusinganELISAassay[27,28].52seraobtainedfrom46IBDpatientsandhealthyindividualsweretested.NoneofthepatientswaseverexposedtoCT-P13.Testingwasperformedbyasensitiveandvalidatedanti-Lambdachainsemi-quantitativeELISA.ATIdetectionforthisassayis2.7µg/ml.WhentestingREMICADE®-sensitizedIBDsera,therewasstrongcorrelationbetweentitersofATIreactivetoEU-approvedREMICADE®andtitersofATIcross-reactivewithUSapprovedREMICADE®andCT-P13inpatientsneverexposedtoUSapprovedREMICADE®ortoCT-P13.Thesesimilarcross-reactivityresultspointtosharedimmuno-dominantepitopesonREMICADE®andCT-P13.Whilstthesereassuringdataweregeneratedinvitro,theysupportthenotionthattheimmunogenicpotentialofREMICADE®andCT-P13andthecharacteristicsofcross-reactivitywithclinicallyrelevantanti-drugantibodies(ADA)inIBDpatientsaresimilarandwilltranslateintosimilarimmunogenicityfeaturesinclinicalsettings.AnothercohortexperiencefundedbytheNorwegianGovernmentisbeingconductedtoaccumulateexperiencewithCT-P13inNorwayfollowingproductlaunchinJanuary2014.ThisNor-Switchstudyisanongoingrandomized,double-blind,parallelgroupstudywith500patientsacrossallindications[24].vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvInHungary,aprospective,multicenter,observationalcohortwasdesignedtoexaminethesafetyandefficacyofCT-P13inclinicalresponseandtheinductionandmaintenanceofremissioninCDandUC[29],[21].vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv.TABLE4:VVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVV
TheimmunogenicityintermsofADApositivityresultsobtainedbyCELLTRION from Studies CT-P131.1and CT-P133.1(whichpreviouslypresentedanddescribedinthepreviousCDRSubmissionforINFLECTRA®) are in line with those reported in theliteratureindicatingthatthestateofthearttestmethodologyappliedinCT-P13studiesprovidesresultsinlinewiththoseoftheassaysemployedinthemorerecentlyreportedstudies.TheuseofconcomitantMTXandotherimmunomodulatorytherapiesisknowntodifferbetweenapprovedconditions.Nevertheless, it isevidentthattheASandRApatientpopulationsrepresentsensitivepopulationsinwhichtocompareimmunogenicityofCT-P13andREMICADE®.Theimmunogenicityinotherpopulations(PsO,PsA,CDandUC)isnotlikelytodifferfromthelevelsobservedinASandRApatientssincetheuseofMTXiseitherlesscommon(PsO,CDandUC)
vvvvvvvv vvvvv vvvvv vvvvvv
vvv vvvvvvvvvvvv vvvvvvvvvvv vvvvvvvvvvv vvvvvvvvv
vvvvvvvvvvvvvvvvvvvvvvv
vvvvvvvvvv vvvvvvvvv vvvvvvvvvvv vvvvvvvvvvv
vvvvvvvvvvvvvvvvvvvv vvvvvvvvvvv vvvvvvvv vvvvvvvv vvvvvvvvvv
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
26CommonDrugReview November2017
oroptionallyindicated(PsA)andthereforeapproximatetoconditionstestedintheCT-P13clinicalprogram.Overall,theresultsoftheimmunogenicityassessmentofthestudiesconductedwithCT-P13showthattheproportionofpatientsdevelopingADAswhiletreatedwithCT-P13issimilartothatforthosetreatedwithREMICADE®.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
27CommonDrugReview November2017
5. CRITICALAPPRAISALOFCLINICALSTUDIES
5.1 InternalValidityMostclinicalevidencecurrentlyavailabletoevaluatetheefficacyandsafetyofCT-P13forCDorUCcomesfromobservationalstudies(Celltrion-sponsoredstudies,non–Celltrion-sponsoredstudies,andpost-marketingdata).OneRCT(CT-P133.4)comparedCT-P13withthereferenceproduct,Remicade,inadultswithCD.TheobservationalstudiesofCT-P13inCDorUCareallsinglearmwithoutdirectcomparisonswithRemicade.OnlynaiveindirectcomparisonsofsafetyendpointsandsomeefficacyendpointswithRemicadeareavailablefromthemanufacturer’ssystematicreview10andmanufacturer-submitteddatatoHealthCanada.{20}TheabsenceofrandomizedtrialsintheclinicalbodyofevidenceforCT-P13inboweldiseasesmakesitdifficulttoascribeanyobservedimprovementsinefficacy,oranyapparentmaintenanceoftreatmenteffect,totheintervention.Inaddition,thedegreeofsimilarityinefficacy,safety,andimmunogenicitybetweenCT-P13andRemicadehaveyettobeclearlydelineatedwithexperimentaltrials.Inthediscussionbelow,specificcriticalappraisalpointsareprovidedforthestudyCT-P13PMS,asthiswasthekeyclinicalstudypresentedinthemanufacturer’ssubmission.CT-P13PMSisanongoing(fouryear)phaseIV,open-label,singlearmstudyofCT-P13forallapprovedindicationsinSouthKorea.AninterimanalysiswasconductedinadultswithmoderatelytoseverelyactiveCD(N=83),FCD(N=12),andUC(N=78)across15studycentresinSouthKoreawithfollow-upof30weeks.Ofthe173patients,113weretreatment-naivetoinfliximaband60wereswitchedtoCT-P13fromthereferenceproduct,Remicade.CT-P13wasadministeredevery8weeks(±5days)afterinductiontherapyofthree5mg/kgdosesatweeks0,2,and6.Mostpatients(59.0%)receiveddosesof5mg/kg.Higherdosesof5mg/kgto10mg/kgwereadministeredto41%ofpatientswithaflexibletitrationschedule.Themajorityofpatientsreceivedatleastthreedosesoftreatmentduringasixweekinductionperiod(90.3%oftreatment-naiveand86.7%oftreatment-switch).Amongtreatment-naiveandtreatment-switchpatients,52.2%and11.7%respectivelyreacheddose6atweek30.TheefficacyanalysissetconsistedofpatientswhoreceivedatleastonedoseofCT-P13andhadatleastoneassessmentfollowingbaseline(N=145,83.8%).MissingdatawereimputedusingLOCF.Allpatientswereincludedinsafetyanalyses.ThemanufacturersubmitteddatatoHealthCanadasuggestingsimilarefficacyforclinicalresponseandremissioninCDandUCandmucosalhealinginUCatweeks14and30betweenCT-P13PMSandhistoricalRemicadedata.{20}TheinternalvalidityofCT-P13PMSislimitedbecauseofitsnon-comparative,open-labelstudydesign.ThemagnitudeofimprovementinefficacyoutcomesduetoCT-P13administrationincomparisonwithRemicadeisunknownwithoutacomparatorgroup.Also,confounders,suchasvariationsinsymptomsovertimeandtheeffectofconcomitanttreatments,couldnotbeadjustedforwithanon-comparativestudydesign.Theabsenceofblindingmayhaveinfluencedtheassessmentofsubjectivecomponentsofthescoringtools,suchasseverityofabdominalpainandgeneralwell-beingoftheCDAIandphysician’sglobalassessmentoftheMayoscore.Thesamplesizeisrelativelysmall,withatotalof83patientswithCD,12withFCD,and78withUC.Whenanalyseswerestratifiedaccordingtotreatment-naiveorswitchstatus,samplesizesbecameevensmallermakingitdifficulttodrawconclusions(e.g.,inFCD,only8patientsweretreatment-naiveand4patientstreatment-switch).PatientswhoreceivedatleastonedoseofCT-P13butwhodidnothaveatleastonepost-baselineefficacyassessment(n=28,16.2%)wereexcludedfromefficacyanalyses.Ofthe
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
28CommonDrugReview November2017
28patientsexcludedfromefficacyanalyses,8discontinuedtreatmentforthefollowingreasons:lackofefficacyandswitchtoanothertreatment(n=2),experienceofanAE(n=4),losstofollow-up(n=1),andpregnancy(n=1).13Thecompletecaseanalysesshowedthataconsiderablenumberofpatientswerenotevaluatedatfollow-upvisits(e.g.,only14/39and20/39patientswhowereinfliximab-naivewithCDwereevaluatedatweeks14and30respectively;only44/54and23/43patientswhowereinfliximab-naivewithUCwereevaluatedatweeks14and30respectively).Missingdata(excludingthe16.2%ofpatientswhowereexcludedfromtheefficacyset)wereimputedusingLOCFandthemanufacturerpresentedanalysesshowingsimilarresultsforclinicalresponseandremissioninCDandUCusingcompletecaseandLOCFmethods.2ThemethodofimputingdatausingLOCF,however,mayoverestimatetreatmentbenefitifpatientswithdrewfromthestudybecausetheyexperiencedworseningofoutcomes.TheLOCFimputationwillassumethatpatientswhowithdrewremainedconstantinoutcomemeasuresfromthepointofwithdrawalandworseninginoutcomes,ifpresent,wouldnotbecaptured.WhiletheefficacyoutcomesassessedbythestudywereappropriatebasedontypicaloutcomesevaluatedintrialsofCDandUC(i.e.,clinicalresponsedefinedbyCDAI,numberofdrainingfistulas,Mayoscore,clinicalremission,endoscopicmucosalhealingforUC,diseasecontrolforpatientswhoswitchedfromreferenceproduct,andneedforrescuemedication)andthethresholdsusedtodefineclinicalresponseandremissionwereappropriate,14dataareabsentforotherimportantoutcomesofIBD.Theseotheroutcomesincludeextra-intestinalmanifestations,diseasebiomarkers(e.g.,C-reactiveprotein,fecalcalprotectin),qualityoflife,andimmunogenicity.Certainnon-Celltrionsponsoredstudiesprovideddataondiseasebiomarkers,butaresimilarlylimitedbyobservational,singlearmdesigns.Thefollow-upperiodof30weeksisalsotooshorttoadequatelyevaluatesomeoutcomes,suchastheneedforsurgeryandmortality.CT-P13PMSpresentspreliminary,interimresultsand,therefore,longer-termfollow-upisneededtoassessifefficacyandsafetyoutcomesremainstable.Qualityoflife,concernaboutdiseaseflare-ups,anxietyandstress,andcaregiverburdenhavebeenidentifiedbypatientsasimportantconcernsandtheimpactofCT-P13ontheseaspectsofdiseasearecurrentlyunknown(Appendix3).5.2ExternalValidity TheprimarylimitationwithrespecttotheexternalvalidityofCT-P13PMSisthedifficultyindirectlyapplyingtheresultsobservedinpatientswithIBDfromKoreatotheCanadianpopulation,duetodifferencesindietandmicrobiotabetweenthecountries.ThesamplepopulationofCT-P13PMSwerefromstudycentresinSouthKorea.Ofthetreatment-naivepatients,themeanage(standarddeviation[SD])was38.9(14.7)years(CD:31.8years,FCD:27.9years,UC:45.2years).Oftreatment-switchpatients,themeanage(SD)was34.3(12.4)years(CD:31.1years,FCD:33.0years,UC:42.9years).Mostpatientshadmoderatelytoseverelyactivedisease,althoughtherewerealsopatientswithCDAIscores<220orpartialMayoscore<6,whichindicatelowerdiseaseseverity.3Femalesappearedtobeunderrepresentedinthestudy(29.2%amongtreatment-naiveand40%amongtreatment-switchpatients).EstimatesofprevalenceofIBDbysexvaryamongstudiesandbyregion.InEuropeanandNorthAmericanpopulations,female-maledistributionhasbeenfoundtorangefromequalto2.5:1.15TherearespecialdiseaseandmanagementconsiderationsofIBDrelevantparticularlytofemales,suchasahigherincidenceofextra-intestinalmanifestationsobservedinwomen,whichwerenotaddressedbythisstudy.16
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
29CommonDrugReview November2017
TheadministereddoseofCT-P13wasinaccordancewiththedosingrecommendationsofinfliximabforCDandUC.CT-P13wasgivenintravenouslystartingwiththreedosesofinductionof5mg/kgatweeks0,2,and6,andthen5mg/kgevery8weeksthereafter.Forpatientswithincompleteresponse,thedosewasincreasedupto10mg/kg.Themajority(89.0%)completedthe3dosesofinductiontherapy.However,only66(38.2%)completed6dosesoftreatmentbyweek30.Morepatientsinthetreatment-naivegroup(59/113,52.2%)received6dosescomparedwiththetreatment-switchgroup(7/60,11.7%).Themanufacturerexplainedthatthelargediscrepancyinreaching6dosesamongtreatment-naiveandtreatment-switchgroupswasduetodifferencesinintervalsbetweendosesratherthananysafetyconcerns.Treatment-naivepatientsweregiventhreedosesofinductionwithin6weeks;whereas,switchpatientsreceivedeachdoseatapproximately8-weekintervalsand,therefore,theswitchgroupgenerallytookbeyond30weeks(mean:34.5±8.1weeks)toreachdose6.{20}The5mg/kgdosewasreceivedbythemajorityofpatients(59%)and41%receiveddosesof5mg/kgto10mg/kg.Thestudypopulationincludedthosewhoweretreatment-naive(113/173,65.3%)andtreatment-switchfromthereferenceproduct(60/173,34.7%).Patientswereallowedtoreceivepremedicationsofanalgesics(acetaminophen),antihistamines(chlorpheniramine,piprinhydrinate),orcorticosteroids(hydrocortisone,dexamethasone,methylprednisolone)beforeorduringCT-P13infusion.Atleast1premedicationwasadministeredto49/173(28.3%)patients.Thefollowingconcomitantmedicationswerepermitted:acetaminophen,5-ASAwithnoincreaseindoseallowed,corticosteroids,othertopicalorsystemictreatmentsforUC,andantibioticsforIBD.RescuemedicationsweredefinedasinitiationofconcomitantmedicationafterthefirstinfusiondatetotreatneworunresolvedsymptomsofCDorUCandwereadministeredifneeded.Drugsadministeredwereantidiarrheals,intestinalanti-inflammatory/anti-infectives(e.g.,sulfasalazine),systemiccorticosteroids,andimmunosuppressants(azathioprine).Rescuemedicationwasadministeredto48/173(27.7%)ofpatients.Theinclusionoftreatment-naiveandtreatment-switchpatientsandtheadministrationofpremedicationsand/orrescuemedicationsalongwithCT-P13arereflectiveofclinicalpractice.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
30CommonDrugReview November2017
6. EXTRAPOLATIONOFINDICATIONS
6.1 Manufacturer’sRationaleforExtrapolationThedatatosupporttheIBDindicationisbasedonthetotalityofevidencecollectedfromthequality,non-clinical,andclinicalcomparabilityexercise.ApositionpaperpreparedbyCELLTRIONtosupportextrapolationinIBDissummarizedinthefollowingsections.RefertoCT-P13ExtrapolationPositionPaperwhichwassubmittedtoHealthCanada[30]forcompletedetails.a) Pathophysiology–Crohn’sDisease/UlcerativeColitisTNFαisapleiotropiccytokinewithnumerousbiologicalfunctions[31][30]andhasbeenshowntobecriticalinthepathogenesisofIBD[30,page26].BothCDandUCarechronicinflammatorydisordersthatarecharacterizedbyadysregulatedmucosalimmuneresponse.InCD,inflammationistypicallyseenthroughouttheintestinalwall;whereasinUC,inflammationistypicallyrestrictedtosuperficialtissuese.g.thelaminapropria.InIBDpatients,immunecellspresentattheinflammationsitewillleadtoanoverproductionofTNFα[32,33].MucosalinflammationinthesmallandlargeintestineduetoIBDisaccompaniedbybarrierdysfunctionwhichleadstotwomainconsequences.First,smallsolutesandwatercanflowintothelumenandcauseleakfluxdiarrhea.Secondly,largermoleculesandevenmicroflora,whichundernormalconditionseitherdonotorcrosstheepithelialbarriertoonlyasmalldegree,allowingforimmunetoleranceinduction.TNFαsignalingisalsoimplicatedinmucosaldamage,aswellasinthedevelopmentofulcersandfistulasviathestimulationofmyofibroblasts[34].MyofibroblastsareknowntocausedamagetostructuresoftheGItractbysecretingmatrixmetalloproteinases(MMPs).TheexpressionofMMPsisincreasedintheinflamedgutandhighlevelsofMMPshavebeenassociatedwithmucosaldegradation,ulcerationandfistulas[34].AsincreasedlevelsofTNFαarealsopresentintheinflamedgut,andmyofibroblastsareknowntobesensitivetopro-inflammatorycytokines,TNFαhasbeenproposedtobetheinitiatingfactorthatdrivestheincreaseinMMPs.Thissequenceofeventshasrecentlybeenconfirmedby[35]whohaveshownthatTNFαisabletoincreasetheexpressionofMMP-3inhumancolonicmyofibroblasts.TheroleofTNFαisalsorelatedtotheinductionoflocallyandsystemicallyproducedpro-inflammatorycytokines,increasingepithelialapoptosisandalteringT-cellregulationviareversesignalingpathways[36],[37].DamagetoepithelialcellsbydirecteffectofcytokinessuchasTNFαvianecrosisorapoptosiscancontributetothelossofepithelialbarrier.Indeed,therearesignificantchangesinepithelialtightjunctionstructureandfunction,notonlyinCDbutalsoinUC.Inaddition,therateofapoptosiswasalsofoundtobeupregulatedinUC,therebycontributingtothebarrierdefect.Interestingly,innon-IBDformsofcolitis,suchascollagenouscolitis,therateofmucosalapoptosisisnotaltered[38].Additionally,inhibitoryimpactofTNFαandothercytokinesonapoptosisofTlymphocytesresidinginlaminapropriacancontributetoimmunedysregulationandperpetualmucosalinflammation[38-40].Also,researchintogranulomashasprovidedfurtherevidencefortheroleofTNFαinpromotinginflammationinCD.Granulomasconsistofaggregatesofmacrophages,andassuchrepresentaspecializedtypeofinflammation.Theyappeartoformaroundforeignbodiesthattheimmunesystemisunabletoeliminate.GranulomasarecommonlyfoundinbiopsysamplesfrompatientswithCDandtheformationofthesecellularstructureshasbeenshowntoberegulatedbycomplexinteractionsbetweenTlymphocytesandmacrophagesandtobedependentuponTNFαsignaling[41][30,page27][42].Inconclusion,TNFαisimplicatedinthechronicinflammationinCDandUCandisalsoassociatedwithmucosaldegradation,ulcerationandfistulasinCD[30,page27-29][42,page165].TheprolongedexpressionofTNFαobservedinIBDanditspivotalroleinthepro-inflammatorycytokinecascade
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
31CommonDrugReview November2017
indicatethatTNFαisamajordrivingfactorofchronicinflammationinCDandUC[30,page27][42],page164.b) MechanismofactionofinfliximabInfliximabisachimericIgG1mAbcomposedofavariablemurineFabregionlinkedtoahumanIgG1κconstantregion.InfliximabcanbindtoboththemonomerandtrimerformsofsTNFα[43].ThehighaffinitythatinfliximabdisplaystowardssTNFαsupportsitsuseininflammatorydiseasessuchasRA,PsA,ASandPsO,UCandCDinwhichsTNFαsignalingthroughbindingtoTNFR1andTNFRplaysadominantroleinthepathogenesisofthecondition[44][42,page167].InfliximabexertsitseffectintheameliorationofinflammatorydiseasessuchasCDandUCaswellasRA,AS,PsA,PsOthroughanumberofmechanismsofaction.ThesehavebeenevaluatedintheoriginalNDSincomparisonwiththereferenceproduct.TheywerealsoevaluatedinthesupplementalNewDrugSubmission(sNDS)withinthe3waysimilaritystudiesasdescribedinSection4.1.1. BindingandNeutralizationofSolubleTNFαpreventingitsbindingtoTNFRsandresultingin
blockingsTNFαinducedinflammatoryactivitiesincluding:• Inductionofpro-inflammatorycytokinessuchasinterleukins(IL-1andIL-6)[45]• Enhancementofleukocytemigrationbyincreasingendotheliallayerpermeabilityand
expressionofadhesionmoleculesbyendothelialcellsandleukocytes[46,47]• Activationofneutrophilandeosinophilfunctionalactivity[47-50]• InductionofacutephasereactantssuchasC-reactiveproteinandotherliverproteins[44],as
wellastissuedegradingenzymesproducedbysynoviocytesand/orchondrocytes[51]• Inductionofapoptosisoftissuecellssuchasintestinalepithelialcells[52]throughtheactivityof
sTNFαontheTNFR1receptor[30,page34].2. BindingtoTransmembraneTNFαbyInfliximab:InfliximabisabletobindtotmTNFαlocatedonthe
surfaceofvariouscelltypes.Thisresultsinanumberofeffectsthatinclude:• BlockingtheinteractionoftmTNFαwithTNFRs• Stimulationofreversesignalingpathwaysresultinginsuppressionofsecretionofpro-
inflammatorycytokinessuchasIL-1,IL-10andIL-12frommonocytes[53,54]• Inductionofregulatorymacrophages[55,56]• Stimulationofapoptosisinmonocytes[57]andTcells[58]
3. InductionofRegulatoryMacrophagesandWoundHealing:Macrophagesarepresentinallphasesofadultwoundhealing,andcontributetoinflammation,granulationtissueformation,andmatrixdeposition.Bothpro-inflammatory"M1"macrophagesandanti-inflammatoryorregulatory"M2"macrophagesexist.Pro-inflammatory"M1"macrophagesareproducedbyexposuretoIFN-γandTNFα[59]andsotheirproductionisinhibitedbyanti-TNFagentssuchasinfliximab.InIBDpatients,ithasbeenshownthatlaminapropriamacrophagesarepredominantlyoftheinflammatoryorM1phenotype[60,61].Theanti-inflammatoryM2phenotypeincludesM2a,theregulatorymacrophageswhichareactivatedbyIL-4andIL-13;theotherM2phenotypesareM2bandM2c[62].HencetheratioofM1andM2phenotypesarethoughttobeofimportanceintheetiologyofIBD.“Regulatory”macrophageshavealsobeentermed"woundhealing"macrophages[63],“AlternativelyActivatedMacrophages”[62]and“Mφ2”macrophages[56].RegulatorymacrophageshavebeenshowntoinhibitTcellproliferationviacellcontactand/orthereleaseofsolublemediators[56].
4. Complement-DependentCytotoxicity(CDC):FollowingbindingtotmTNFαonthecellsurface,infliximabmayinducecytotoxicityofthetmTNFαexpressingcellviacomplementactivation[58,64].InfliximabisoftheIgG1classandthereforecanbindcomplementC1q.Activationofthe
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
32CommonDrugReview November2017
complementcascadecanprotectagainstinfectionbutininflammatorydiseasescouldcontributetothepathology.ComplementcomponentscaninduceCDCoftargetcellsresultingincelllysis.
5. Antibody-dependentcellularcytotoxicity(ADCC):ADCCistheimmunedefensemechanismswherebyimmuneeffectorcells(e.g.macrophagesorNK)bindtotheFcregiononantibody-antigencomplexesonthesurfaceoftargetcellsandtherebyactivelypromotetargetcelllysis.Antibody-dependentcell-mediatedcytotoxicityismediatedprimarilythroughasetofcloselyrelatedFcreceptorswhichhavebothactivatingandinhibitoryactivities,withFcγIIIabeingparticularlyimportantinthisrespect.Inconclusion,alltheknownputativemechanismofactionsattributedtoinfliximabhasbeenstudied,andsimilaritytothereferenceproductwasdemonstrated.MinordifferenceswereobservedincertainassaysforADCCactivitythatwerenotdeemedtobeclinicallyrelevant.PleaseseebelowasummarydiscussionoftheADCCevaluation.
c) JustificationofExtrapolation-QualityattributesandBiologicactivityCelltrionhaspresentedtheresultsofthe2-waysimilaritystudiescomparingCT-P13withEU-approvedREMICADE®intheoriginalCDRsubmission.InsupportoftheIBDindication;CELLTRIONhasperformedadditionallargenumberandwiderangeoforthogonal,highlysensitivemethodstoprovideameaningfulfinger-print-likealgorithmtoassesssimilaritybetweenCT-P13,EUandUSapprovedREMICADE®.TheresultsarehighlightedinSection4.1aboveandfurtherdetailsareprovidedinAppendix1.ThecomprehensiveanalyseshaveshownthatCT-P13issimilartoREMICADE®inprimarystructure,higherorderstructure,aggregateandmonomericpurity,andpost-translationalmodificationsnotwithstandingminordifferencesthathavebeendemonstratedtohavenoclinicallymeaningfulimpactonsafety,purityorpotency.TheextensiverangesofinvitroandexvivobiologicalassayshavedemonstratedsimilarbiologicalactivitiesforCT-P13andREMICADE®inassaysmimickingthemechanismsofactionofinfliximabinCDandUC[30,page71].BiologicActivityManyinvitrostudiesreportedintheliterature,havefoundthatinfliximabcaninduceADCCbutallthesestudiesemployengineeredTNFα-overexpressingcelllinesastargetcells[53,58,65].NotablyinfliximabisnotobservedtoinduceADCCinasystemcomprisedofnaturallyderivedcells.Specifically,whenlipopolysaccharide(LPS)stimulatedhumanmonocytesareusedastargetcellsandPBMCasasourceofeffectorcells,noobservableADCCisseeninresponsetoinfliximab[66].ThesefindingshavebeenreplicatedvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvwithpurifiedNKcellsassourceofeffectorcells.SinceLPSstimulatedhumanmonocytesareconsideredrepresentativeofthetargetcellsencounteredinvivointheintestineswheremonocytes/macrophagesareexpectedtobestimulatedbytheLPSpresentonthesurfaceofcommensalbacteria,theseresultssuggestthatADCCisnotlikelytoplayasignificantroleinmediatingthetherapeuticeffectofanti-TNFtherapiesinCDandUC.Interestingly,applyingtheexactsameexperimentalsystembutreplacingactivatedmonocytesasthetargetwithgeneticallyengineeredJurkatcellswhichoverexpressTNFαontheirsurfacecellbyapproximately25folddoesinducemeasurableADCCactivityusinginfliximab.
FurtherevidencethatADCCmaynotplayacriticalroleinefficacyofinfliximabinCDisprovidedbyanalysisoftherapeuticeffectofinfliximabinpatientsofdifferentFcγRIIIagenotypefollowingtreatment,asthebindingaffinityofFcγRIIIaV/VisotypeforFcregionofmonoclonalantibodiesishigherthanthatofthelowaffinityF/Fisotype.ForCD,publisheddatafromseverallargestudies[67-70]shownoassociationbetweenFcγRIIIagenotypeandclinicalresponsetoinfliximabandotherTNFα-antagonists.Althoughdifferenceswerenotedinbiologicalresponse(C-reactiveproteinlevels)intheearlyphasesof
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
33CommonDrugReview November2017
treatmentinseveralCDstudies,thiseffectdidnotpersisttolaterphasesoftreatment,andnodifferencesweredetectedinclinicaloutcome[68,71].
d) JustificationofExtrapolation—PharmacokineticsSimilarityhasbeendemonstratedbetweenCT-P13andREMICADE®withrespecttoPKparametersinASpatientsandRApatients.Also,itseemsscientificallyjustifiedtoextrapolatePKprofilesforCT-P13acrossthedifferenttargetpopulationsgiventhattheCT-P13clinicalstudiesshowsimilarPKpropertiesacrossASpatientsandRApatientsaswellasbetweensingleandrepeatdosing;theappropriatenessoftheextrapolationisfurthersupportedbypublisheddataforREMICADE®showingnomajordifferencesinhalf-life,clearance,volumeofdistributionandotherPKparametersbetweenpatientsubgroupsandacrossalllicensedpopulations[30,pages72-80].Furthermore,thereal-worldexperiencewithCT-P13fromthesponsoredKoreanPMSstudyandnon-sponsoredHungarianNationwideIBDStudy[21],vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv.
e) JustificationofExtrapolation—EfficacyandSafetyTheKoreanPMSstudyhasdemonstratedthatCT-P13issafeandeffectiveinpatientswithCD,UCandFCD.InlinewithpublisheddataonREMICADE®,CT-P13hasdemonstratedefficacyintermsofclinicalandendoscopicresponseandremission,fistula-closingandmucosalhealingeffects.Therewerenonewsafetysignalsreportedinthisstudy(pleaserefertoSection4.2aboveforfurtherdetails).
f) JustificationofExtrapolation—ImmunogenicityTheimmunogenicitywithCT-P13andREMICADE®acrossCT-P13clinicalstudieswassimilarinbothRAandASpatients.IncidenceratesofADAsandneutralizingantibodylevelsandtitervaluesweresimilarincontrolledstudiesupto1year.TheratesofIRRsbetweenCT-P13andREMICADE®werealsosimilar.TheefficacywassustainedandthepatternofefficacyandsafetyamongstADA-positiveandADA-negativepatientsweresimilarbetweenCT-P13andREMICADE®.ADAdatainIBDpatientsarenotavailable,howeverlowratesofIRRswereobservedinpost-marketingIBDstudieswithCT-P13.Furthermoreinvitrocross-reactivitydatawithCT-P13andREMICADE®againstserafromADA-positiveIBDpatientsareavailable(pleaserefertoSection4.3aboveforfurtherdetails).Overall,similarandconsistentimmunogenicityprofilewithCT-P13hasbeendemonstratedagainstREMICADE®intwodistinctpatientpopulations.
g) ClinicalDevelopmenttoSupportDoseAdjustmentRecommendationsIntheREMICADE®productmonograph,thereistheoptionforadultpatientswithCDwhorespondtoinfliximabandthenlosetheirresponsetouseanescalateddoseof10mg/kg.ClinicaldatainIBDpatientstreatedwithCT-P13indosesupto10mg/kgwithintheKoreanPMSstudyvvvvvvvvvvvvvvvvvhavebeencollected.vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv.Overall,theefficacyaccordingtoresponseandsafetyofCT-P13administeredathigherdosestovvvvvIBDpatientsappearedtobesatisfactory,vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv[30,page104].
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
34CommonDrugReview November2017
ConclusionInsummary,CELLTRIONhasdemonstratedcleartherapeuticcomparabilitybetweenCT-P13andREMICADE®inRAwithsupportiveclinicaldatainASpatients.Inaddition,basedonanextensiveanalysisofthetotality-of-the-evidenceconsideringmechanismsofaction,structuralanalysis,functionalassaysandthesimilarityofpharmacokinetics,efficacy,safetyandimmunogenicity,combinedwithdatafrompost-marketingstudiesCELLTRIONconsidersthatthereissufficientscientificevidencetosupportextrapolationoftheCT-P13toCDandUCindicationsforwhichREMICADE®isregisteredinCanada.Asimilarsafetyprofilewasdemonstratedinatotalofapproximately1,000patientsexposedtotrialmedicationofwhichnearly500receivedCT-P13foruptotwoyearsorforayearfollowingtransitionfromREMICADE®.Additionallysafetydataareavailablefrom518CDandUCpatientswhohavereceivedCT-P13.ThesedatashowingeneralahighlysimilarsafetyprofiletoREMICADE®acrossallofthesepopulations.ImmunogenicityhasbeenshowntobehighlysimilarintwodifferenttherapeuticsettingsnamelyRAandAScoveringtheeffectoftwodifferentdoses(3and5mg/kg)andtheimpactofthepresenceorabsenceofMTX.Cross-reactivitystudiesandsomelimitedexperiencewithimmunogenicityevaluationinCT-P13ofREMICADE®.6.2 HealthCanada’sConclusiononExtrapolationAtthetimeoftheCDRsubmission,theIBDsNDSwasunderreviewbytheBiologicGeneticsTherapiesDirectorate.InJune2016,HealthCanadaauthorizedtheuseofCT-P13fortheIBDindicationsbasedonextrapolationfrompreviouslysubmittedclinicalstudiesinpatientswithRAandAS,comparablepharmacokinetics,andnewlysubmittedphysiochemicalandbiologicaldata.1WhentheNDSwasfiledtoHealthCanadain2012,marketauthorizationwasrequestedforalloftheindicationscurrentlyauthorizedforREMICADE®includingCDandUC.ThefollowingsectionistakenfromtheHealthCanadaSummaryBasisofDecisionforINFLECTRA®[72].“ComparabilitybetweenINFLECTRA®andthereferenceproductwasestablishedbasedoncomparativechemistryandmanufacturingstudies,andcomparativenon-clinicalstudies.Comparativepharmacokineticstudiesandclinicalstudiesinpatientswithrheumatoidarthritisorankylosingspondylitispatientsdidnotidentifyclinicallymeaningfuldifferences.Fortheremainingindicationsanduses,extrapolationwasrequired.Theindicationsforpsoriaticarthritisandplaquepsoriasisweregrantedonthebasisofsimilarityandtheabsenceofmeaningfuldifferences,betweenINFLECTRA®andthereferenceproduct,inproductquality,mechanismofaction,diseasepathophysiology,safetyprofile,anddosageregimenandonclinicalexperiencewiththereferenceproduct.However,extrapolationtoindicationsandusespertainingtoCDandUCcouldnotberecommendedduetodifferencesbetweenINFLECTRA®andthereferenceproductthatcouldhaveanimpactontheclinicalsafetyandefficacyoftheseproductsintheseindications.Thisarosefromtheobserveddifferencesinthelevelofafucosylation,FcγRIIIareceptorbinding,andsomeinvitroAntibody-DependentCell-MediatedCytotoxicity(ADCC)assays.ItwasconcludedthatdifferencesintheabilityofthetwoproductstoinduceADCCcouldnotberuledout.Therefore,sincedifferencesinADCChavebeenobservedbetweenthetwoproductsandbecauseADCCmaybeanactivemechanismofactionforinfliximabinthesettingofIBD,extrapolationfromthesettingsofrheumatoidarthritisandankylosingspondylitistoIBDcouldnotberecommendedduetotheabsenceofclinicalstudiesinIBD.”Pleaseseeabove,Section6.1,forasummaryofdatathathassincebeensubmittedaspartofasNDSfortheIBDindicationstoaddressthepotentialissuesraisedbyHealthCanada.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
35CommonDrugReview November2017
6.3 InternationalRegulatoryConclusionsonExtrapolationEuropeanMedicineAgency(EMA)TheEMAapprovedCT-P13(INFLECTRA®)fortheIBDindicationsviaextrapolationin2013.AspertheEMACommitteeforMedicinalProductsinHumanUseAssessmentReportforINFLECTRA®[73,page96]:“Inconclusion,byusingarangeofexperimentalmodelsthatareconsideredrepresentativeofthepathophysiologicalconditionsandputativemechanismsofactionofinfliximab,theApplicanthasprovidedconvincingevidencethatthedifferencedetectedintheamountofafucosylatedspecieshasnoclinicallyrelevantimpactontheefficacyandsafetyofCT-P13,inparticularinIBD.AdditionalinvitrodatafromhumanintestinalcellsarefurthersupportingextrapolationoftheclinicaldatatoIBD.”FoodandDrugAdministration(FDA)CT-P13hasbeenapprovedbytheFDAforallindications,includingCDandUCviaextrapolation[74].ThisfollowstherecommendationfromtheUSArthritisAdvisoryCommitteewhichrecommendedtheapprovalofCDandUCviaextrapolationofdata.AsperFDABriefingDocument,[75,pages70-72]:“ExtrapolationofDatatoSupportBiosimilarityinInflammatoryBowelDisease(IBD)Indications:CelltrionprovidedexperimentaldatasupportingaconclusionthatCT-P13andUS-licensedREMICADE®arehighlysimilarbasedonextensivestructuralandfunctionalanalyticalcharacterization.Further,CelltrionaddressedeachoftheknownandpotentialmechanismsofactionofUS-licensedREMICADE®.Asnoted,thereweresmalldifferencesbetweenCT-P13,US-licensedREMICADE®,andEU-approvedREMICADE®inglycosylation(a-fucosylation),FcγRIIIbinding,andsomeNK-basedADCCassays.InconsideringwhethertheapparentfractionalFcγRIIIbinding/ADCCdifferencesmaytranslateintoaclinicallymeaningfuldifferenceinIBD,theAgencyhasconsideredthefollowing:• ThebiologicalfunctionsthatthesubtleFcγRIIIbindingdifferencesmightimpact,namelyADCC,are
withinthequalityrangeofCelltrion’sdataonthereferenceproduct.• ThemechanismofactionofTNFinhibitorsintreatingIBDiscomplexand,ADCCisonlyoneofthe
severalplausiblemechanismsofaction.ItisnoteworthythatproductswithoutanyADCCcapabilityhavebeenapprovedforthetreatmentofpatientswithCD(i.e.certolizumab),whilethepossibleADCCdifferencebetweenCT-P13andUS-licensedREMICADE®issmall.CelltrionhasalsoprovideddatatodemonstrateanalyticalsimilarityinalltheotherpotentialmechanismsofactionofinfliximabinIBD.
• ThehistoricalIBDclinicaltrialdesign,includingthoseforREMICADE®,oftenutilizeddosesandtimingofprimaryendpointassessmentsthatareinthetherapeuticplateau,andthusclinicaloutcomemeasures(e.g.,clinicaleffectofsmalldifferencesinADCCandFcγRIIIbinding.
Therefore,basedontheaboveconsiderations,itisreasonabletoextrapolateconclusionsregardingsimilarefficacyandsafetyofCT-P13andUS-licensedREMICADE®toIBD.Inaggregate,theevidenceindicatesthattheextrapolationofbiosimilaritytotheindicationsforwhichCelltrionisseekinglicensure(PsA,PsO,adultandpediatricCD,andadultandpediatricUC),maybescientificallyjustified.”AustralianTherapeuticGoodsAdministration(TGA)TheTGA,afterevaluationfromtheAdvisoryCommitteeonPrescriptionMedicines(ACPM),approvedandregisteredINFLECTRA®forboththeCDandUCindicationsviaextrapolationinAugust2015.AsperaPublicSummaryDocument:
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
36CommonDrugReview November2017
“TheACPMhasstatedthereweresufficientdatatodeclareINFLECTRA®abiosimilarforREMICADE®andtoextrapolatetheconclusionofequivalentefficacyfromtherheumatoidarthritisandankylosingspondylitisindicationsforwhichevidencewasprovidedtoIBDconditions”[76,page4]6.4 CDRCommentsonExtrapolation
HealthCanadaconsidersseveralfactorswhendecidingontheappropriatenessofextrapolatingauthorizationfromoneindicationtoanother.Thesefactorsinclude:17• similaritybetweenproducts(minor,unimportantdifferencesmayhaveclinicalimpact)• similarityinmechanismofactionforeachcondition• mechanismsofthediseasestobetreated• similaritiesinclinicalexperience• typeanddesignoftheclinicaltrials,populations,andendpointsmeasured• routeofadministration,dosage,andregimen.
HealthCanadareviewsqualityinformationofthebiosimilarcomparedwiththereferenceproduct,assessesthatthemostsensitivepopulationandbestendpointswereincludedinclinicaltrials,andevaluateswhetherthebiosimilarandreferenceproducthavesimilarsafetyandimmunogenicity(>100patientsandsufficientlylongduration).17InCADTH’spreviousreviewofInflectra,18HealthCanada’sdecisionsaboutextrapolatingdatafromtheRAandASindicationstoPsOandPsAwereprovided.ThedecisiontoextrapolatetoPsOandPsAweresupportedbycommondiseasepathologies,commonmechanismofactionofanti-TNFalphadrugsinthesediseases,andsimilaritiesinproductquality,safety,andPK.Atthattime,HealthCanadadidnotsupportextrapolatingdatafromRAandAStoIBDduetodifferencesindiseasemechanisms(roleoftmTNFalphaandADCCinIBD)andsafetyprofilesofinfliximabinIBDversusrheumaticdiseases(higherriskofhepatosplenicT-celllymphomainIBD).18Thesefactorsareexplainedinmoredetailbelow,under“PointsaboutextrapolationidentifiedbyHealthCanada.”InJune2016,HealthCanadaauthorizedtheuseofCT-P13fortheIBDindicationsbasedonextrapolationfrompreviouslysubmittedclinicalstudiesinpatientswithRAandAS,comparablepharmacokinetics,andnewlysubmittedphysiochemicalandbiologicaldata.1HealthCanadaissuedanNOCforInflectrafortheindicationsofCD,FCD,andUConJune10,2016.Theapprovedindicationsareasfollows:19• Reductionofsignsandsymptoms,inductionandmaintenanceofclinicalremissionandmucosal
healing,andreductionofcorticosteroiduseinadultpatientswithmoderatelytoseverelyactiveCDwhohavehadaninadequateresponsetoacorticosteroidand/oraminosalicylate.Inflectracanbeusedaloneorincombinationwithconventionaltherapy.
• TreatmentofFCD,inadultpatientswhohavenotrespondeddespiteafullandadequatecourseoftherapywithconventionaltreatment.
• Reductionofsignsandsymptoms,inductionandmaintenanceofclinicalremissionandmucosalhealing,andreductionoreliminationofcorticosteroiduseinadultpatientswithmoderatelytoseverelyactiveUCwhohavehadaninadequateresponsetoconventionaltherapy(i.e.,anaminosalicylateand/oracorticosteroidand/oranimmunosuppressant).
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
37CommonDrugReview November2017
TheEMA,FDAandtheAustralianTherapeuticGoodsAdministrationapprovedCT-P13foruseinadultpatientswithCDandUCbasedontheextrapolationofefficacyandsafetydataforRAandAS.20-22ThesejurisdictionshavealsoextendedusetopediatricpatientswithCDorUC;asidefromtheFDAwhichhasnotapprovedCT-P13forpediatricUC.ClinicalTrialEvidenceforRAandAS:Rigorousclinicaltrials,comparingCT-P13withRemicade,havebeenconductedwithPLANET-RAforRAandPLANET-ASforAS.ThisevidencewasevaluatedindetailinthepreviousCADTHsubmissionforInflectra.18PLANET-RAwasaphaseIIIRCTinpatientswithRA(N=606).CT-P13orRemicadewereadministeredat3mg/kgalongwithMTXplusfolicacid.Thetrialdemonstratednodifferencesinefficacy,safety,immunogenicity(developmentofADA),orPK.PLANET-ASwasaphaseIRCTinpatientswithAS(N=250).CT-P13orRemicadewereadministeredat5mg/kg.SimilarPK,efficacy,safety,andimmunogenicityweredemonstrated.18PointsAboutExtrapolationIdentifiedbyHealthCanada:Inthepathologyandmechanismsofactionofanti-TNFalphadrugsforRA,ASandIBD,somedifferencesexistthatpresenteduncertaintiesinextrapolatingbetweenthesediseaseconditions.ThepredominantformofTNFinRAandASissTNFalpha;whereas,inCDandUC,tmTNFalphaplaysanadditionalandcentralrolebyinitiatingreversesignallingpathways.23Also,unlikeRAandAS,inboweldiseasesADCCisanimportantmechanismofactionandismediatedbyafucosylationandFcγIIIareceptorbinding.MinordifferenceshavebeenobservedbetweenCT-P13andthereferenceproductinFcγIIIabindingandADCCactivityusinginvitroassayswithNKcellsfrompatientswithCDandV/VorV/FFcγIIIagenotype(nodifferenceobservedwithF/Fgenotype).InotherassaysusingPBMCsfrompatientswithCDandV/ForF/FFcγIIIagenotype,nodifferenceinADCCactivitywasobserved.24TheclinicalrelevanceofdifferencesinADCCactivitymaybeminor.Etanerceptisanotheranti-TNFalphadrugthatisclinicallyeffectiveinRAbutnotinIBD,possiblybecauseitislessefficientatreversesignallingandapoptosis.23However,thestructureofetanerceptdiffersfrominfliximabandthisresultsinadistinctefficacyprofile.23CT-P13wasshowntobecomparabletothereferenceproductwithrespecttoreversesignallingandapoptosis.19Hepatosplenic-TcelllymphomahasbeenobservedtooccuratahigherincidenceinadolescentandyoungadultmaleswithCDorUCwhoaretreatedwithinfliximabincombinationwithazathioprineor6-mercaptopurine.19OtherConsiderationsAboutExtrapolatingtoIBD:TheclinicalmanagementofIBDdiffersfromRAandAS.Forexample,MTXisanimmunosuppressantthatisnotadministeredasfrequentlyforIBDasitisforRAorAS.TheuseofMTXincombinationwithinfliximabhasbeenshowntoreducethedevelopmentofimmunogenicity(i.e.,theformationofADAagainstinfliximab).23Thedevelopmentofimmunogenicityisacriticalfactorinthelossofresponsetobiologicaldrugtreatment.25TheeffectofothermedicationregimensonimmunogenicitythatareadministeredwithinfliximabinIBD,suchasazathioprine,corticosteroids,or5-ASA,isunclear.Inastudyof174patientswithCD,concomitantadministrationofMTXorazathioprinewithinfliximabwasfoundtoreducetheincidenceofATIformation(46%versus73%withinfliximabmonotherapy);however,nodifferencesinATIformationwereobservedbetweeninfliximabplusMTXandinfliximabplusazathioprine.{44}Furtherinvestigationoftheeffectofimmunosuppressantregimensonimmunogenicityisneeded.Secondly,themaximumdoseofinfliximabforIBDis10mg/kgandishigherthanthedosesusedinPLANET-RAorPLANET-AS.AlthoughinvitrostudieswiththeseraofpatientswithIBDwhodeveloped
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
38CommonDrugReview November2017
ADAafterRemicadewerefoundtobecross-reactivewithCT-P13,suggestingsimilarfeaturesofimmunogenicity(Section4.4),theimmunogenicsimilarityofthehigherdoseofCT-P13withregularorhigherdosesofRemicadeisuncertain.ThereisalsoamicrobiologicalcomponenttoIBDthatisabsentinRAorAS.PatientswithIBDareathighriskforbacteremia/sepsisandinfectionssuchasshingles,skininfections,andpneumoniaandrequireclosemonitoring,especiallyduringtreatmentwithinfliximab.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
39CommonDrugReview November2017
7. COSTCOMPARISONTheInflectra100mg/vialdrugproductwillcarrya44%lowerprice($525.0000)relativetothecurrentlylowest-listedpriceofRemicade100mg/vial,whichisat$940.0000pertheRégiedel'assurancemaladieduQuébec(RAMQ).Consequently,the44%costdifferentialequatesto$415.0000savingsper100mgvial.PleasenotethattheListPriceofREMICADE®inallotherProvincesinCanada(excludingQuebec)is$987.0000per100mgvial.ThereforethecostsavingsofINFLECTRA®versusREMICADE®inprovincesoutsideQuebec(47%or$462lessexpensivethanREMICADE®)isactuallygreaterthanwhatisshowninthefollowingtables
TABLE5:COSTCOMPARISONOFINFLECTRAANDREMICADEFORCROHN’SDISEASE(FIRSTYEAR)
Drug/Comparator Strength DosageForm Price($) RecommendedDosec
AverageDrugCost($)/Year
Inflectra 100mg/vial Lyophilizedpower $525.0000a 5mg/kg $16,800Remicade 100mg/vial Lyophilizedpower $940.0000b 5mg/kg $30,080
aPublicprice.bRAMQListofMedications,updated2016-02-08.cInflectraandRemicadeproductmonograph.
TABLE6:COSTCOMPARISONOFINFLECTRAANDREMICADEFORCROHN’SDISEASE(SUBSEQUENTYEAR)
Drug/Comparator Strength DosageForm Price($) ExpectedDosec
AverageDrugCost($)/Year
Inflectra 100mg/vial Lyophilizedpower $525.0000a 5mg/kg $14,700Remicade 100mg/vial Lyophilizedpower $940.0000b 5mg/kg $26,320
aPublicpricebRAMQlistofMedications,updated2016-02-08cInflectraandRemicadeproductmonograph
TABLE7:COSTCOMPARISONOFINFLECTRAANDREMICADEFORULCERATIVECOLITIS(FIRSTYEAR)
Drug/Comparator Strength DosageForm Price($) RecommendedDosec
AverageDrugCost($)/Year
Inflectra 100mg/vial Lyophilizedpower $525.0000a 5mg/kg $16,800Remicade 100mg/vial Lyophilizedpower $940.0000b 5mg/kg $30,080
aPublicprice.bRAMQlistofMedications,updated2016-02-08.cInflectraandRemicadeproductmonograph.
TABLE8:COSTCOMPARISONOFINFLECTRAANDREMICADEFORULCERATIVECOLITIS(MAINTENANCEATEVERY7WEEKSA),(SUBSEQUENTYEAR)
Drug/Comparator Strength DosageForm Price($) ExpectedDosec
AverageDrugCost($)/Year
Inflectra 100mg/vial Lyophilizedpower $525.0000a 5mg/kg $14,700Remicade 100mg/vial Lyophilizedpower $940.0000b 5mg/kg $26,320
aPublicprice.bRAMQlistofMedications,updated2016-02-08.cInflectraandRemicadeproductmonograph.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
40CommonDrugReview November2017
CDRReviewerCommentsRegardingCostInformationSummaryoftheManufacturer’sAnalysisSEBinfliximab(Inflectra)isavailableasa100mg/vialsolutionforintravenousinfusionatamanufacturersubmittedpriceof$525.00pervial.27ThemanufacturersubmittedacostcomparisonbetweenInflectraandreferenceinfliximab(Remicade)forthreeindications:adultpatientswithmoderatelytoseverelyactiveCD,FCD,andUC.27Themanufacturerassumedaweight-baseddoseof5mg/kgforInflectraandRemicadeforthethreereviewedindications.Undertheassumptionofsimilareffectandusageoftheinterventions,thecostsavingsofInflectracomparedwithRemicadewerereportedtobe44%ofthemanufacturer’sbasecase;usingtheRAMQ(Quebec)listpriceforRemicade($940.00per100mgvial).FortheotherCanadianjurisdictions,thedifferencewasreportedtobeupto47%ofthemanufacturer’sbasecase(Remicadeprice:$987.00per100mgvial).27CDRAssessmentoftheManufacturer’sCostComparison• UsingtheOntarioExceptionalAccessProgram(EAP)priceofRemicadeasareference,28theannual
costofInflectrais47%lowerthanthatofRemicade(refertoTable9).
TABLE9:INFLIXIMABDOSINGBASEDONTHEMANUFACTURERSCOSTCOMPARISONTreatment/Indications
TimePeriod RecommendedDosea
NumberofTreatments/Yeara
Priceper100mgVial($)b
AnnualCost($)c
Inflectra/CDandUC
Firstyear 5mg/kg 8 525.0000 16,800Subsequentyears
5mg/kg 6.5 525.0000 13,650
Remicade/CDandUC
Firstyear 5mg/kg 8 987.5600 31,601Subsequentyears
5mg/kg 6.5 987.5600 25,677
CD=Crohn’sdisease;UC=ulcerativecolitis.aInflectraandRemicadeproductmonograph.bManufacturersubmittedpriceforInflectra;27OntarioEAPpriceforRemicade.28cAssumespatientweightisbetween60kgto80kg.IssuesforConsideration• GiventhecomplexitiesofmanagingIBD,theclinicalexpertnotedthatphysiciansandpatientsmay
bereluctanttoswitchfromRemicadetoInflectrawhenapatientisadequatelymanagedonRemicade.Asaresult,InflectramaybemorelikelytobeusedinpatientswhoarenewlystartinginfliximabratherthanthoseswitchingfromRemicade.
• ThemanufacturerofRemicadesponsorsinfusioncentresfortheadministrationofRemicade,andcoverscostsofpatientfollow-upandmonitoring.ThesecostsareexpectedtobesimilarlycoveredbythemanufacturerofInflectra,therefore,thisisnotexpectedtoresultinadditionalcoststothepubliclyfundedhealthcarepayer.10
• ThedosageofInflectraisbasedonpatientweight.ConsideringthatInflectraandRemicadehavesimilarpharmacokinetics,pharmacodynamics,clinicalefficacyandharms,andsharethesamedosingstrategies,therelativecostdifferencebetweenthedrugsisthereforelikelytobemaintainedregardlessofpatientcharacteristicsorrequireddailydose.
• Basedontheproductmonograph,thedoseofinfliximabinpatientswithUCandCDcanbeincreasedtoupto10mg/kg.19DoseescalationwouldsimilarlyimpactthecostofbothInflectraandRemicade,therelativecostdifferencewouldthereforenotbeaffected.However,thiscouldaffect
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
41CommonDrugReview November2017
thecostdifferentialwithothertreatmentsfortheseindications.• Inflectra(SEBinfliximab)waspreviouslyreviewedbyCADTHforfourindications:RA,AS,PsA,and
PsO.ItwasrecommendedthatInflectrabelistedinaccordancewiththeHealthCanadaindicationandinasimilarmannertoRemicade.29
• ThelistingcriteriaforRemicadedifferacrosspubliclyfundeddrugplansinCanada;whereas,Remicadeisavailableasarestrictedbenefitwithspecificlistingcriteria(Appendix2).TheexpectedsavingsfromInflectracomparedwithRemicadearebasedontheassumptionthatthelistingcriteriaforRemicadewouldbeappliedtoInflectra.
ConclusionAtthesubmittedprice,theannualcostofInflectrais47%lessthanthereferenceproductinfliximab(Remicade)whenusingtheOntarioEAPpriceforRemicade($987.56)asareference.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
42CommonDrugReview November2017
8. DISCUSSION
BiologicaldrugsareimportanttreatmentoptionsforinducingandmaintainingremissionofCDandUC.InCanada,thethreeanti-TNFalphadrugsapprovedforIBDareinfliximab,adalimumab,andgolimumab.23Thesedrugsmaybeusedinstep-uporstep-downtreatmentapproaches.Inthestep-upapproach,5-ASAisprescribedinitially,followedbycorticosteroids(e.g.,topicalfoams,budesonide,prednisone),immunosuppressants(e.g.,azathioprine,MTX),andanti-TNFalphadrugsifsymptomsarenotcontrolled.Inthestep-downapproach,drugsatthehigherendofthetreatmentladderareinitiatedfirst,followedbydownwardtitrationtothedrug(s)thatofferthemostfavourableprofileofsymptomcontrolandminimizationofadverseeffects.30CT-P13isabiosimilarofthereferenceinfliximabproduct,Remicade,andoffersanother,potentiallycost-effective,treatmentoptionforCDandUC.Abiosimilarproductisdesignedtobesimilartoareferenceproductthatisalreadybeingusedinclinicalpractice.Themolecularcomplexityofbiologicscomparedwithotherdrugsrequiresclosescrutinyofthebiosimilar’sPK,efficacy,safety,andimmunogenicity.TheclinicalevidencefortheuseofCT-P13inIBDwasbasedonobservationaltrials.NodirectcomparisonswithRemicadeinthispatientpopulationwereavailable.Datafrominvitrostudiessuggestsimilarimmunogenicity,sTNFalphaandtmTNFalphabinding,andADCCactivityusingPMBCsamongCT-P13andRemicade,althoughdifferencesinADCCactivityusingNKcellswereobserved.SomedifferencesbetweenIBDandRAorASexist,suchasthegreaterrolesoftmTNFalphaandADCC,higherinfliximabdosingrequirements,andadministrationofdifferentimmunosuppressanttreatmentregimensinIBD.TheresultsoftheongoingRCT(CT-P133.4)areanticipatedtoprovideadditionalevidencetoassesstheefficacyandsafetyofCT-P13comparedwithRemicadeinIBD.Inaddition,theexperiencesofjurisdictionsthatarealreadyusingCT-P13forIBD,suchastheUS,Korea,andvariousEuropeancountries,canbeusedasaguidefortheongoingassessmentofitsefficacyandsafety.Nonewsafetysignalshaveemerged,althoughcontinuedlong-termmonitoringisneeded.TheCanadianAssociationofGastroenterologyhasissuedapositionstatementonSEBsforIBD.31Theysupporttheuseofbiosimilarsaspotentiallyeffectiveandcost-savingoptions,butemphasizethatevidencefromclinicaltrialsrelevanttoCanadiansshouldbeavailabletosupporttheiruseinpractice.PatientgroupsforIBDhavealsovoicedtheirconcernsabouttherapiesbeingchosenbasedsolelyonconsiderationsofcost(Appendix3).Theyhaveindicatedthatdiseaseremissioncanbedifficulttoobtainandthatchangestotherapy,includingswitchingfromaninnovatorproducttoanSEB,shouldnotbemadewithoutapatient’sconsent.Expertknowledge,open-dialogue,andpatientchoicewillbeintegraltoeffectivelyimplementingCT-P13inclinicalpractice.HealthcareprovidersandpatientsshouldbeprovidedwithinformationaboutHealthCanada’sSEBregulatoryprocess,theclinicalevidenceavailableforCT-P13,andtherationalebehindextrapolation.Post-marketingdataofCT-P13willbecriticalformonitoringexpectedandnewsafetysignalsandtoensurethatbenefitsoutweighrisksinbothtreatment-naiveandtreatment-switchpatients.Assessmentofimmunogenicityandincidenceofserioussideeffects,suchashepatosplenicT-celllymphoma,willbeneededforevaluatingCT-P13’srisk-benefitprofile.GiventheinterimnatureoftheCT-P13PMSstudy,itwillbeimportanttoassessiftheobservedresultsremainstableoverseveralyears.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
43CommonDrugReview November2017
PotentialPlaceinTherapy2Thereferenceinfliximabproduct,Remicade,iscurrentlyusedforpatientswithmoderatetosevereCDandUCaloneorincombinationwithimmunomodulatorssuchasazathioprine.Itiseffectiveintreatingperianaldiseaseaswellasluminalinflammation.OccasionallypatientsarestartedonRemicadeimmediatelyupondiagnosis,butmoreoftenbothprivateinsurersandpublicdrugplansindicatethatpatientsshouldfirsthavebeeninadequatelymanagedwith5-ASA,steroids,andimmunomodulatorssuchasazathioprine.Remicadehasasimilaractionandefficacytootheranti-TNFalphadrugs,andisadministeredundersupervisionatinfusioncentres.Forsomepatients,contactwithhealthprovidersonaregularbasisishelpful,whileforothers,self-administrationispreferred,inwhichcaseanotheranti-TNFalphadrugs,suchasadalimumab,maybeused.CT-P13isanSEBthatdoesnotaddtoavailabletherapyoptionsbutprovidesalessexpensivealternativetoanestablishedtherapy.Itisnotdesignedtobenovelbuttobesimilartothereferenceproduct(Remicade).AsignificantpercentageofpatientswithIBDdonothaveinsuranceforthecostofmedications,oftenbecausethediseaseaffectsyoungerindividualswhomaynotyethavedrugplaninsurance.32Followingdiseaseonset,insuranceisverydifficulttoobtain.Therefore,thepotentialcostsavingsofCT-P13inthispopulationwouldbeadvantageous.Bothprivateandpublicdrugplanshaveguidelinesinplacethatstipulatewhichpatientsareeligiblefortreatmentwithanti-TNFalphadrugs,andCT-P13willfitwithinthatframework.Animportantquestion,whichwillneedtobeaddressedifthedrugisintroduced,iswhetherpatientswhoarestableonRemicadewillhavethedrugsubstitutedwithCT-P13orwhetheritwillonlybeusedintreatment-naivepatients.Endoscopicevaluationofdiseaseactivitymayberequiredinpatientswhoexperienceadiseaseflareafterswitching,andtherearesignificantbarrierstothatintermsofaccesstoendoscopyprocedures.Observationalcohortstudiesfromdifferentcountriessuggestthatdiseaseactivityandadverseeffectsaresimilarbeforeandafterswitching.However,giventhelimitationsofobservationalstudies,theassessmentandpredictionofpatientresponseuponswitchingfromRemicadetoCT-P13willrequireclosemonitoring.
2ThisinformationisbasedoninformationprovidedindraftformbytheclinicalexpertconsultedbyCDRreviewersforthepurposeofthisreview.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
44CommonDrugReview November2017
9. CONCLUSION
CT-P13providescliniciansandpatientswithanotherpotentiallycost-effectivechoiceofabiologicaldrugforIBD.ThefocusofthisCDRreviewofCT-P13(Inflectra)isfortherecentlyapprovedindicationsofCD,FCD,andUCinadultpatients.TheNoticeofCompliance(NOC)fortheCD,FCD,andUCindicationswasgrantedsubsequenttoanearlierNOCforCT-P13fortheindicationsofRA,AS,PsO,andPsA.Ofnote,HealthCanadaapprovedtheindicationsofPsOandPsAbasedontheextrapolationofdatafromstudiesconductedwithpatientswithRAandAS.AllclinicalevidencecurrentlyavailableforCT-P13inpatientswithIBDisbasedonobservational,open-labelstudiesfromKoreaorEuropeinsmallnumbersofpatients.Thepivotalstudy,CT-P13PMS,isanobservational,open-labelstudyconductedinSouthKoreainpatientswithIBD,witha30-weekinterimanalysis.NaiveindirectcomparisonsofCT-P13withstudiesofRemicade(infliximab)suggestsimilarefficacyandsimilarsafetyforsomesafetyendpointsinpatientswithCDorUC.Nonetheless,intheabsenceofdatafromRCTs,theclinicalsimilarityofCT-P13andRemicadeforIBDintheCanadianpopulationremainsuncertain.GiventhattheresultsofCT-P13PMSarebasedonaninterimanalysis,theongoingmonitoringofCT-P13inpatientswithIBDwillbeimportantforevaluatinglong-termefficacyandsafety.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
45CommonDrugReview November2017
APPENDIX1:ADDITIONALDATAPleaseincludeanylargetablesorfiguresinthissectionofthetemplate.Pleaseensurethefollowingisincluded:• Allitemsinthissectionmustbewell-labelled(e.g.,Table6:AdverseEventsfromStudyX).Allitemsinthissectionmustbeclearlyreferencedinthemainbodyofthetemplate.Forexample,“pleaseseeTable6inAppendix1forcompletedetailsregardingtheadverseeventsreportedintheStudyX.”TABLE10:HIGHLEVELOVERVIEWOFTHETESTSANDCONCLUSIONSFORTHEOLIGOSACCHARIDEPROFILINGANDBIOLOGICACTIVITYCOMPARISONBETWEENCT-P13ANDREMICADE®
Typeofstudy(s) Briefoverviewoftestsandconclusions ReferencesBindingofsolubleandtransmembraneTNFαOligosaccharideprofiling • HPAEC-PADTest
• Tocharacterizetheglycanmicro-heterogeneityassociatedwiththesinglesiteofN-glycosylation(Asn300),glycanswereenzymaticallycleavedusingPNGaseFandresolvedusingchromatography.
• TheHPAEC-PADdatarevealthatthetypeandproportionoftheunchargedglycansisreasonablyconservedbetweenCT-P13,EUandUSapprovedREMICADE®.
• Minordifferencesinafucosylatedglycans:meanvaluesofMan5+G0,forEUandUSapprovedREMICADE®byHPAEC-PADwerevvvvvvvvvvvvv,respectively,comparedtovvvvvFORCT-P13.
CTDModule3.2.R.2.7
EffectofblockingsolubleTNFαinvitroIBDmodel
• InhibitionofInflammatoryCytokines(IL-8)fromCaco-2cellstest
• TheabilityofCT-P13,EUandUSapprovedREMICADE®toinhibitreleaseofinflammatorycytokines(IL-8)fromanintestinalepithelialcelllinefollowingstimulationwithcytokines(TNF-α,IL-1,LPSandIFN-γ)wasevaluated.
• Thedataindicatethatthe3productsarecomparableinrelativesuppressionofcytokineinCaCo-2cellswithmean±SDvaluesforCT-P13,EUandUSapprovedREMICADE®.
CTDModule3.2.R.2.8.1.6
tmTNFαReceptorSignalingStudies
• Suppressionofcytokinereleasebyreversesignalingtest• Thismethodwasdevelopedtomeasurereversesignaling
resultingfromsamplesbindingtotmTNFαandresultingininhibitionofLPS-inducedcytokinerelease(TNFα)fromPeripheralBloodMononuclearcells(PBMCs).
• PBMCsfromhealthysubjectswereisolatedandthenincubated,withsamplesoverarangeofconcentrations.
• TherelativeinhibitionofcytokinereleaseinducedbyreversesignalingonbindingofCT-P13issimilartothatofEUandUSapprovedREMICADE®.Themeanvaluesforeachconcentrationalsoindicatecomparableactivityofthe3productsininhibitionofcytokinereleasebyreversesignaling.
CTDModule3.2.R.2.8.1.5
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
46CommonDrugReview November2017
Typeofstudy(s) Briefoverviewoftestsandconclusions References• Inductionofapoptosisbyreversesignalingtest• Apoptoticactivity,resultingfromantibody-induced
signalingafterbindingtotransmembranewasconductedusingtherecombinantJurkatcelllinewhichstablyexpressestmTNFα.
• TheapoptosisassaywasperformedusingacommerciallyavailablekitwhichlabelscellsusingAnnexin-V/PItodeterminethenumberofapoptoticcells.
• TherelativeinductionofapoptosisthroughreversesignalingofCT-P13,EUandUSapprovedREMICADE®aresimilar.
CTDModule3.2.R.2.8.1.4
Fcf(ab’)2relatedEvaluationofRegulatoryMacrophageFunction
• EffectofInfliximabonSuppressionofTCellProliferationbyRegulatoryMacrophagesinMixedLymphocyteReaction(MLR)Assay
• TheMLRrequiresmixingofHumanLeukocyteAntigendisparatePBMCfrom2individualsthatarenonethelessmatchedforFcγRIIIagenotype.
• CT-P13,EUandUSapprovedREMICADE®inducedregulatorymacrophagesintheMLRassay.SimilaritywasobservedbetweenCT-P13andEUandUSapprovedREMICADE®atallconcentrations.
CTDModule3.2.R.2.8.2
• QuantitationofInfliximab-InducedRegulatoryMacrophagesbyFACS
• Adose-dependentinhibitionofTcellproliferationofPBMCsfromhealthydonorswasinducedbyCT-P13EUandUSapprovedREMICADE®.
• Similaractivitywasdetectedforthe3products.• EffectofWoundHealingbyRegulatoryMacrophages• Theeffectoftheinducedmacrophagesonscratchesina
colorectalcelllayer(HCT116)wasdeterminedinawoundhealingassay.
• Woundhealingmodelsusingbidirectional(V/F+V/F)MLRwithPBMCfromhealthydonorsanddemonstratedthattherewascomparableactivityforCT-P13andEUandUSapprovedREMICADE®withrespecttotheabilityofinducedregulatorymacrophagestopromotewoundhealing.
CDCStudies • Complement-dependentcytotoxicity(CDC)Activity• C1q-bindingisfollowedbyactivationofC1qenzymatic
activityandsubsequentactivationofthedownstreamcomplementcascade.Thelevelofcytotoxicactivitywasmeasuredbyviablecellcountingusingakit.
• ThemeanrelativebindingvaluesforCT-P13,EUandUSapprovedREMICADE®weresimilar.
CTDModule3.2.R.2.8.3.2
• C1qbindingaffinity(ELISA)• BindingaffinityofCT-P13EUandUSapproved
REMICADE®toC1qwasmeasuredbyELISA.• ThemeanrelativebindingvaluesCT-P13,EUandUS
approvedREMICADE®weresimilarforC1qbinding
CTDModule3.2.R.2.8.3.1
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
47CommonDrugReview November2017
Typeofstudy(s) Briefoverviewoftestsandconclusions Referencesaffinity.
FcγreceptorBindingStudies
• ComparativebindingtoFcγreceptors:FcγRIbindingaffinity(ELISA),FcγRIIa,FcγRIIbandFcRnbindingaffinity
• ThemeanrelativebindingaffinityvaluesFORCT-P13,EUandUSapprovedREMICADE®showthatthe3productshavecomparableinFcγRIIa,FcγRIIbandFcRnbindingaffinityThethreeproductshavebeendemonstratedtohavesimilarbindingaffinity.
CTDModule3.2.R.2.8.4
• ComparativebindingtoFcyreceptors:FcγRIIIa(VandFhemizygotes)andFcγRIIIbbindingaffinity(SPR)
• Usingthevvvvvvvvvinstrument,thebindingofCT-P13,EUandUSapprovedREMICADE®wasmeasuredinrealtimeat3concentrationstotheimmobilizedFcγRIIIa(Vtype)ligandbymeasuringchangesintherefractiveindex.
• TheresultsdemonstratethattheFcγRIIIa(Vtype)bindingaffinityofEUandUSapprovedREMICADE®batcheswassignificantlyhigherthanforCT-P13,confirmingthedataobtainedinthepreviousstudysubmittedintheNDSshowingFcγRIIIa(Vtypepolymorphicvariant)bindingaffinityisdependentontheafucosylationlevel(CTDModule3.2.R.5,Sequence0000).
• ThisdifferenceinbindingbetweenCT-P13andREMICADE®ismuchsmallerthanthedifferenceinbindingtoFcγRIIIaofdifferentgenotypes.Studieshavefailedtodiscernaclinicaldifferenceinresponse(Crohn’sDiseaseActivityIndex[CDAI])followinginfliximabtreatmentbetweenCDpatientsexpressingthelowaffinityF/FgenotypecomparedtothoseexpressingthehighaffinityV/Vgenotype[67].
• ThemeanrelativebindingaffinityvaluesINFLECTRA®,EUandUSapprovedREMICADE®indicatesomedifferenceinbindingaffinitytoFcγRIIIbalthoughvvvvvvvvbatchesofINFLECTRA®werewithinthemean±3SDofEUapprovedREMICADE®batchesandvvvvvvvvbatcheswerewithinthemean±3SDofUSapprovedREMICADE®batches.
• TheclinicalrelevanceofanypossibledifferencesinFcγRIIIbbindingaffinitywereinvestigatedinpreviousstudiessubmittedintheNDScomparingtheabilityofCT-P13andEUapprovedREMICADE®tobindtoNeutrophils,whichexpresspredominantlyFcγRIIIbonthecellsurface.ThesestudieswerepresentedinCTDModule3.2.R.5(Sequence0000)anddemonstratedthatthereisnodifferenceinbindingofCT-P13andEUapprovedREMICADE®toneutrophilsfromhealthyvolunteersandCDpatients.Thus,anydifferenceobservedinbindingaffinitytoFcγRIIIbbySPRappearstohavenoclinicalsignificance.
CTDModule3.2.R.2.8.4.1CTDModule3.2.R.2.8.4.2
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
48CommonDrugReview November2017
Typeofstudy(s) Briefoverviewoftestsandconclusions References• ComparativebindingtoRcyreceptors:Exvivoassay(NK
cellsfromHealthyPBMC• ToassessifthedifferencesbetweenCT-P13,EUandUS
approvedREMICADE®inFcγRIIIa(V-typeandF-typepolymorphicvariants)bindingasdeterminedbySPRtranslateintofunctionaldifferencesrelatedtobindingtotheFcγRIIIapresentonNKcells,exvivoNKcellbindingstudieswereconductedinthe3-wayabridgedstudy.NKcellsareknowntoexpressFcγRIIIaontheircellsurfaceandserveassuitableexvivomodelfortheassessmentofFcγRIIIabinding.
• ThemeanrelativebindingofCT-P13,EUandUSapprovedREMICADE®inthepresenceof1%bovineserumalbuminshowsomedifferencebetweenCT-P13andREMICADE®.Howeverinthemorephysiologicallyrepresentativeconditionsinthepresenceof50%humanserum,themeanrelativebindingofCT-P13,EUandUSapprovedREMICADE®havecomparablebindingtoFcγRIIIaonNKcells,althoughonebatchofINFLECTRA®withavalueofvvvrelativebindingtoNKcellsexvivoin50%serumwasbelowthemean-3SDofUSapprovedREMICADE®ofvvvvv.
• ThedifferenceobservedinexvivoNKcellbindingbetweenCT-P13andEUapprovedREMICADE®issmallincomparisontothedifferenceinbindingofEUapprovedREMICADE®toFcγRIIIaofdifferentgenotypes.
CTDModule3.2.R.2.8.4.8
ADCCPotencystudiesusingdifferenteffectorandtargetcells
• ADCCusingPBMCfromHealthydonors• TheADCCassayusingtransfectedtmTNFαJurkatcellsas
targetcellsandPBMCfromhealthydonorofV/FFcγRIIIagenotypeaseffectorcellswasconductedusingvvbatcheseachproduct.
• PBMCofFcγRIIIagenotypeswereusedinthisstudyADCCusingPBMCfromHealthydonors.
• ThemeanrelativeADCCactivityofCT-P13,EUandUSapprovedREMICADE®showsimilarADCCactivitybetweenINFLECTRA®andREMICADE®usingtransmembraneTNFαJurkattargetcellsandPBMCeffectorcells.AllbatchesofINFLECTRA®werewithinthemean±3SDrangeofbothEUandUSapprovedREMICADE®batchesusingthisassaysystem.
CTDModule3.2.R.2.8.5.1
• ADCCusingNKcellsfromHealthdonors• TheADCCassayusingtransfectedtmTNFαJurkatcellsas
targetcellsandNKcellisolatedfromPBMCofV/FFcγRIIIahealthydonorsaseffectorcells.
• ThemeanrelativeADCCactivityofCT-P13,EUandUSapprovedREMICADE®indicatesomeslightdifferenceinADCCactivitybetweenCT-P13andREMICADE®usingtransmembraneTNFαJurkattargetcellsandNKeffectorcells.
CTDModule3.2.R.2.8.5.1CTDModule3.2.R.2.8.5.2
• ADCCusingLipopolysaccharide(LPS)-stimulatedmonocytesastargetcells
CTDModule3.2.R.2.8.5.3
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
49CommonDrugReview November2017
Typeofstudy(s) Briefoverviewoftestsandconclusions References• TheabilityoftheLPS-stimulatedmonocytesisolated
fromhealthydonortoactastargetsinanADCCassaywasinvestigatedamongCT-P13,EUandUSapprovedREMICADE®.
• ThedatashownoADCCactivitywasdetectableforCT-P13,EUandUSapprovedREMICADE®.
• ThesefindingssuggestthatLPS-stimulatedmonocytes,supposedtoberepresentativeofinflammatoryfociinvivo,donotexpresssufficientamountsoftmTNFαtoinduceaneffectiveADCCinresponsetothepresenceofCT-P13,EUandUSapprovedREMICADE®.
• ExvivotmTNFαExpressionLevelinIBDPatients• Biopsymaterialwasobtainedfromvvpatientswithmild
tosevereUCorCDandtheleveloftmTNFexpressiononLaminaPropriaMononuclearCellsfromtheseIBDpatientshasbeeninvestigated.
• ThedataclearlyshowthatmonocytesandmacrophagesinthelaminapropriaofIBDpatientsexpresslowlevelsoftmTNF.TheexpressionoftmTNFonmonocytes/macrophageswasapproximatelyvvvvvlowerthanonmonocytes/macrophagesfromLPSstimulatedPBMCsfromhealthydonorsandtmTNFwasexpressedatonly2%(50foldlower)ofthelevelobtainedwithtmTNFαJurkatcells.
• ThesedataconfirmthatlowlevelsoftmTNFαareexpressedonmonocytes/macrophagesinlaminapropriaofIBDpatientsandtogetherwithdatafromADCCstudiessuggestthatADCCishighlyunlikelytocontributetotherapeuticeffectinIBD.
CTDModule3.2.R.2.8.5.4
REMICADE®PHARMACOKINETICLINEARITYConcentrationVersusTimeCurveofInfliximabtreatmentwithandwithoutMethotrexate(MTX):DatafortheseruminfliximablogconcentrationversustimecurveforRApatientstreatedwith3and10mg/kginfliximabsupportsadose-proportionalPKprolife,regardlessofthepresenceorabsenceofMTX[77,78].IntheCO168T14trial,assessing101RApatientstreatedwith1,3or10mg/kgorplaceboeitheraloneorincombinationwith7.5mg/kgMTX,therewasnoapparentdose-orconcentration-efficacyresponsefor3or10mg/kgdosingatevery4weeksorevery8weeks[79,80].TheplasmaconcentrationofinfliximabwasslightlyincreasedwiththeuseofMTX,withthemostprofoundeffectseenwithlowdose1mg/kg[77-80].Adramaticdecreaseinseruminfliximabconcentrationwasobservedforthe1mg/kgdosegivenwithoutMTX,andthoughttobearesultofincreasedinfliximabclearanceduetoHumanAnti-chimericAntibodyformation[77-80].RegardlessofMTXadministration,theinfliximab3and10mg/kgdoseswereassociatedwithsimilarefficacy.Thedurationofclinicalresponseinthe1mg/kgdosewithoutMTXwasmarkedlyshorterthan1mg/kgwithMTX[77].ThepivotalPhaseIIIATTRACTtrial,assessing428patientstreatedwith3or10mg/kg(withMTX)orplacebo(withMTX)at4-or8-weekintervals,showedmaximuminfliximabserumconcentrationstobedirectlyproportionaltointravenousdoseovera3mg/kgto10mg/kgrange[81].Theinfliximabmedium
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
50CommonDrugReview November2017
serumconcentrationwas3.2-3.3-foldhigherfor10mg/kgdosecomparedto3mg/kgdose,administeredevery8weeksthrough14weeksoftreatment[80].InfliximabserumAccumulation:Infliximabcouldbedetectedintheserumofmostpatientsforatleast8weeksafterasingledoseof5mg/kgforCrohn’sdiseaseandtheRAmaintenancedoseof3mg/kgevery8weeks[82].Repeatedadministrationofinfliximab(5mg/kgat0,2and6weeksinfistulisingCrohn´sdisease,3or10mg/kgevery4or8weeksinRA)resultedinaslightaccumulationofinfliximabinserumaftertheseconddose[83].Nosystemicaccumulationofinfliximabwasobservedincontinuedrepeatedtreatmentwith3mg/kgor10mg/kgat4-or8-weekintervalsinRApatientsorinsevereCrohn’sdiseasepatientsretreatedwith4infusionsof10mg/kgat8weekintervals[11,82][12].InfliximabVolumeofDistributionandClearance:Thevolumeofdistributionofinfliximabatsteadystate(4-5.6Lina70kgindividual)isnotdependentontheadministereddoseandindicatesthatinfliximabisdistributedprimarilywithinthevascularcompartment[11,84][12].Thereisaverylowsystemicclearanceofinfliximabofabout11-15mL/hourandtheeliminationhalf-lifeofinfliximabcanrange7.7-14.7days[11,77,82].Therearenospecificstudiesassessingthemetabolismorexcretionofinfliximabinhumans[77].Itisbelievedthatinfliximabiseliminatedinasimilarmannertootherproteins[11].Therearenomajordifferencesinclearanceorvolumeofdistributionofinfliximabinpatientssubgroupedbyageorweight[11,12,78].Anti-drugantibodydevelopmenthasbeenassociatedwithincreasedclearanceofinfliximabinUCpatients[12],whilehigherserumalbuminconcentrationswereassociatedwithdecreasedclearanceofinfliximabinpatientswithUC[12].HumanAnti-chimericAntibodyformationisassociatedwithincreasedclearanceofinfliximabandadecreasedexposure,basedonareaunderthecurve,whenMTXisnotco-administered[78,79,81].Thisincreaseinclearanceisdose-dependentandthehighestlevelofclearanceisobservedwiththe1mg/kgdose[78,79,81]
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
CommonDrugReview November2017 51
APPENDIX2:DRUGPLANLISTINGSTATUSFORREFERENCEPRODUCTForeachindicationthatisapprovedbyHealthCanadafortheSEB(orlikelytobeapproved,inthecaseofasubmissionfiledonapre-NOCbasis),pleaseprovidethepubliclyavailablelistingstatusandcriteriaforthereferenceproduct.
Step1:Usethefollowingabbreviationstocompletethetable.Useaseparaterowforeachindicationandaddmorerowsifnecessary.
Abbreviation DescriptionEX Exceptionitemforwhichcoverageisdeterminedonacase-by-casebasisFB FullbenefitNB NotabenefitRES Restrictedbenefitwithspecifiedcriteria(e.g.,specialauthorization,exceptiondrugstatus,limitedusebenefit)UR Underreview
ListingStatusforREMICADE®
Indication(s) CDR-ParticipatingDrugPlans
BC AB SK MB ON NB NS PE NL YK NT NIHB DND VACCrohn’sDisease RES RES RES RES RES RES RES RES RES RES RES RES RES RES
UlcerativeColitis NB RES RES RES RES NB NB NB NB RES NB NB NB NB
AB=Alberta,BC=BritishColumbia,DND=DepartmentofNationalDefence;MN=Manitoba;NIHB=Non-InsuredHealthBenefitsProgram;NL=NewfoundlandandLabrador;NS=NovaScotia;NT=NorthwestTerritories;ON=Ontario;PE=PrinceEdwardIsland;SK=Saskatchewan;VAC=VeteransAffairsCanada;YK=Yukon.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
CommonDrugReview November2017 52
Step2:Forallrestrictedbenefitentries(RES),pleasestatethecriteriausedbyeachdrugplan.Useaseparatetableforeachindicationandaddordeleterowsasnecessary.
RestrictedBenefitCriteriaforREMICADE®forthetreatmentofCrohn’sDisease
DrugPlan CriteriaforRestrictedBenefitBC TreatmentofmoderatetosevereactiveCrohn'sdiseaseorfistulisingCrohn’sdiseaseaccordingtoestablishedcriteriawhen
prescribedbyagastroenterologistActiveCrohn’sDiseaseCURRENTHARVEYBRADSHAWINDEXgreaterthan8Resistant,dependent,contraindicatedorintoleranttocorticosteroids-corticosteroidresistant:lackofasymptomaticresponsedespiteacourseoforalprednisone40-60mg/day(orequivalent)foraminimumof14days.-corticosteroiddependent:unabletowithdraworalcorticosteroidwithin3monthsofinitiationwithoutarecurrenceofsymptoms;asymptomaticrelapsewithin3monthsofstopping;ortheneedfortwoormorecoursesofcorticosteroidswithinoneyear.-corticosteroiduseiscontraindicated(specify):-intolerant/sideeffect(s)(specify):FORPATIENTSWITHFISTULIZINGCROHN’SFailurewith,intolerancetoorcontraindicationto:Ciprofloxacinatmaximallytolerateddoses(min3weektrial)Metronidazoleatmaximallytolerateddoses(min3weektrial)ForRenewalCURRENTHARVEYBRADSHAWINDEXSCOREWHILEONTREATMENTREQUIRESHBISCORE<5ORADECREASEINSCORE>4.
AB ModeratelytoSeverelyActiveCrohn'sDiseaseandFistulisingCrohn'sDisease:"SpecialauthorizationcoveragemaybeapprovedforcoverageofinfliximabforthereductioninsignsandsymptomsandinductionandmaintenanceofclinicalremissionofModeratelytoSeverelyActiveCrohn'sDiseaseand/ortreatmentof
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
CommonDrugReview November2017 53
DrugPlan CriteriaforRestrictedBenefitFistulisingCrohn'sDiseaseinpatientswhomeetthefollowingcriteria:-InfliximabmustbeprescribedbyaSpecialistinGastroenterologyoraphysicianappropriatelytrainedbytheUniversityofAlbertaortheUniversityofCalgaryandrecognizedasaprescriberbyAlbertaBlueCrossforinfliximabforcoverageforthetreatmentofModeratelytoSeverelyActiveCrohn'sDiseaseand/orFistulisingCrohn'sDiseasepatients(`Specialist').-Patientsmustbe18yearsofageoroldertobeconsideredforcoverageofinfliximab.-Patientswillbelimitedtoreceivingonedoseofinfliximabperprescriptionattheirpharmacy.-Patientsmaybeallowedtoswitchfromonebiologicagenttoanotherfollowinganadequatetrialofthefirstbiologicagentifunresponsivetotherapy(bothprimarylossofresponseandsecondarylossofresponse)orduetoseriousadverseeffectsorcontraindications.Anadequatetrialisdefinedasataminimumthecompletionofinductiondosing(e.g.initialcoverageperiod).-Patientswillnotbepermittedtoswitchbacktoapreviouslytrialedbiologicagentiftheyweredeemedunresponsivetotherapy.-Patientsarelimitedtoreceivingonebiologicagentatatimeregardlessoftheconditionforwhichitisbeingprescribed.PriortoinitiationofinfliximabtherapyforNewPatients:'NewPatients'arepatientswhohaveneverbeentreatedwithinfliximabbyanyhealthcareprovider.ModeratelytoSeverelyActiveCrohn'sDisease:Priortoinitiationofinfliximabtherapy,NewPatientsmusthaveacurrentModified(withoutthephysicalexam)HarveyBradshawIndexscoreofgreaterthanorequalto7(NewPatient'sBaselineScore),ANDbeRefractory.Refractoryisdefinedasoneormoreofthefollowing:1)Seriousadverseeffectsorreactionstothetreatmentsspecifiedbelow;OR2)Contraindications(asdefinedinproductmonographs)tothetreatmentsspecifiedbelow;OR3)Previousdocumentedlackofeffectatdosesandfordurationofalltreatmentsspecifiedbelow:a)mesalamine:minimumof3grams/dayforaminimumof6weeks;ANDrefractoryto,ordependenton,glucocorticoids:followingatleastonetaperingdosingscheduleof40mg/day,taperingby5mgeachweekto20mg,thentaperingby2.5mgeachweektozero,orsimilar;Note:PatientswhohaveusedtheabovetreatmentsincombinationwillnotberequiredtobechallengedwithindividualtreatmentsasmonotherapyAND
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
CommonDrugReview November2017 54
DrugPlan CriteriaforRestrictedBenefitb)Immunosuppressivetherapyasfollows:-Azathioprine:minimumof2mg/kg/dayforaminimumof3months;OR-6-mercaptopurine:minimumof1mg/kg/dayforaminimumof3months;OR-Methotrexate:minimumor15mg/weekforaminimumof3months.OR-Immunosuppressivetherapydiscontinuedatlessthan3monthsduetoseriousadverseeffectsorreactions.Applicationsforcoveragemustincludeinformationregardingthedosagesanddurationoftrialofeachtreatmentthepatientreceivedadescriptionofanyadverseeffects,reactions,contraindicationsand/orlackofeffect,aswellasanyotherinformationrequestedbyAlbertaBlueCross.FistulisingCrohn'sDisease:Priortoinitiationofinfliximabtherapy,NewPatientsmusthaveactivelydrainingperianalorenterocutaneousfistula(s)thathaverecurredorpersisteddespite:a)Acourseofanappropriatedoseofantibiotictherapy(e.g.ciprofloxacinormetronidazole)foraminimumof3weeks;ANDb)Immunosuppressivetherapy:-Azathioprine:minimumof2mg/kg/dayforaminimumof6weeks;OR-6-mercaptopurine:minimumof1mg/kg/dayforaminimumof6weeks;OR-Immunosuppressivetherapydiscontinuedatlessthan6weeksduetoseriousadverseeffectsorreactions.[Note:PatientswhohaveusedtheabovetreatmentsincombinationforthetreatmentofFistulisingCrohn'swillnotberequiredtobechallengedwithindividualtreatmentsasmonotherapy]Applicationsforcoveragemustincludeinformationregardingthedosagesanddurationoftrialofeachtreatmentthepatientreceivedadescriptionofanyadverseeffects,reactions,contraindicationsand/orlackofeffect,aswellasanyotherinformationrequestedbyAlbertaBlueCross.CoverageCriteriaforModeratelytoSeverelyActiveCrohn'sDiseaseAND/ORFistulisingCrohn'sDisease-NewPatientsmustmeetthecriteriaabovepriortobeingconsideredforapproval.-Allapprovalsarealsosubjecttothefollowingapplicablecriteria.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
CommonDrugReview November2017 55
DrugPlan CriteriaforRestrictedBenefitInductionDosingforNewPatients:-CoverageforInductionDosingmayonlybeapprovedforNewPatients(thosewhohaveneverbeentreatedwithinfliximabbyanyhealthcareprovider).-'InductionDosing'meansamaximumofone5mg/kgdoseofinfliximabperNewPatientateach0,2and6weeks(foramaximumtotalofthreedoses).-NewPatientsareeligibletoreceiveInductionDosingonlyonce,afterwhichtimetheMaintenanceDosingforNewPatientsandContinuedCoverageforMaintenanceDosingcriteriawillapply.MaintenanceDosing:'MaintenanceDosing'meansone5mg/kgdoseofinfliximabperpatientprovidednomoreoftenthanevery8weeksforaperiodof12monthsto:-NewPatientsfollowingthecompletionofInductionDosing;OR-ExistingPatients,whoarepatientsthatarebeingtreated,orhavepreviouslybeentreated,withinfliximab.MaintenanceDosingforNewPatientsafterCompletionofInductionDosing:-TheNewPatientmustbeassessedbyaSpecialistbetweenweeks10and14aftertheinitiationofInductionDosingtodetermineresponsebyobtainingaModifiedHarveyBradshawIndexscoreforpatientswithModeratelytoSeverelyActiveCrohn'sDiseaseand/orclosureofindividualfistulasasevidencedbynoorminimalfistuladrainagedespitegentlefingercompressionoffistulasthatweredrainingatbaselineforFistulisingCrohn's;AND-TheSpecialistmustconfirmtheModifiedHarveyBradshawIndexscoreshowsadecreasefromtheNewPatient'sBaselineScoreofgreaterthanorequalto3pointsforpatientswithModeratelytoSeverelyActiveCrohn'sand/orconfirmclosureofindividualfistulasasevidencedbynoorminimalfistuladrainagedespitegentlefingercompressionoffistulasthatweredrainingatbaselineforFistulisingCrohn's.MaintenanceDosingforExistingPatients:-ThepatientmustbeassessedbyaSpecialistatleast4to8weeksafterthedaythelastdoseofinfliximabwasadministeredtothepatientandpriortoadministrationofthenextdosetoobtain:aModifiedHarveyBradshawIndexScore(ExistingPatient'sBaselineScore)forModeratelytoSeverelyActiveCrohn'sand/orclosureofindividualfistulasasevidencedbynoorminimalfistuladrainagedespitegentlefingercompressionoffistulasthatweredrainingatbaselineforFistulisingCrohn's;AND-thesemeasuresmustbeprovidedtoAlbertaBlueCrossforassessmentforcontinuedcoverageformaintenancedosing.(ForexistingpatientswithModeratelytoSeverelyActiveCrohn'sDiseasewithanincompleteresponseorforexistingpatients
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
CommonDrugReview November2017 56
DrugPlan CriteriaforRestrictedBenefitwithFistulisingCrohn'swhorespondthenlosetheirresponse,thedosemaybeadjustedto10mg/kgbymakinganadditionalspecialauthorizationrequesttoAlbertaBlueCrossfortheincreaseddose.)ContinuedCoverageforMaintenanceDosing:Continuedcoveragemaybeconsideredforone5mg/kgdoseofinfliximabperpatientprovidednomoreoftenthanevery8weeksforaperiodof12months,ifthefollowingcriteriaaremetattheendofeach12monthperiod:-TheNewPatientortheExistingPatientmustbeassessedbyaSpecialistatleast4to6weeksafterthedaythelastdoseofinfliximabwasadministeredtothepatientandpriortotheadministrationofthenextdosetoobtainaModifiedHarveyBradshawIndexScoreforModeratelytoSeverelyActiveCrohn'sand/orclosureofindividualfistulasasevidencedbynoorminimalfistuladrainagedespitegentlefingercompressionoffistulasthatweredrainingatbaselineforFistulisingCrohn's;AND-ForNewPatients:TheSpecialistmustconfirmthatthepatienthasmaintainedagreaterthanorequalto3pointdecreasefromtheNewPatient'sBaselineScoreforModeratelytoSeverelyActiveCrohn'sand/orclosureofindividualfistulasasevidencedbynoorminimalfistuladrainagedespitegentlefingercompressionoffistulasthatweredrainingatbaselineforFistulisingCrohn's;OR-ForExistingPatients:TheSpecialistmustconfirmthatthepatienthasmaintainedtheExistingPatient'sBaselineScoreand/orclosureofindividualfistulasasevidencedbynoorminimalfistuladrainagedespitegentlefingercompressionoffistulasthatweredrainingatbaselineforFistulisingCrohn's.(FornewandexistingpatientswithModeratelytoSeverelyActiveCrohn'sDiseasewithanincompleteresponseorfornewandexistingpatientswithFistulisingCrohn'swhorespondthenlosetheirresponse,themaintenancedosemaybeadjustedto10mg/kgbymakinganadditionalspecialauthorizationrequesttoAlbertaBlueCrossfortheincreaseddose.)"Allrequests(includingrenewalrequests)forinfliximabforModeratelytoSeverelyActiveCrohn'sDiseaseandFistulisingCrohn'sDiseasemustbecompletedusingtheAdalimumabforCrohn's/InfliximabforCrohn's/FistulisingCrohn'sDiseaseSpecialAuthorizationRequestForm(ABC31200).
SK ModeratetosevereCrohn'sDisease:-Fortreatmentofpatientswhodemonstratecontinuingsymptomsdespitetheuseofoptimalconventionaltherapiessuchas5-ASAagents,glucocorticoidsandimmunosuppressivetherapy.-Fortreatmentofpatientswhoareintoleranttoconventionaltherapyincluding5-ASAagents,glucocorticoidsandimmunosuppressivetherapy.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
CommonDrugReview November2017 57
DrugPlan CriteriaforRestrictedBenefitFistulisingCrohn'sDisease:-Fortreatmentofpatientswithsymptomaticenterocutaneousorperinealfistulae,enterovaginalfistulaeorenterovesicalfistulae(i.e.anytypeoffistulisingCrohn’sDisease).Clinicalresponseshouldbeassessedaftertheinductiondose.Ongoingcoveragewillonlybeprovidedforthosewhorespondtotreatment.Patientsundergoingthistreatmentshouldbereviewedeverysixmonthsbyaspecialistinthisarea.
MB ForthetreatmentofmoderatetoseverelyactiveCrohn'sDiseaseand/orFistulisingCrohn'sDiseaseinpatientsrefractoryorwithcontraindicationstoanadequatecourseof5-aminosalicyclicacidandcorticosteroidsand/orotherimmunosuppressivetherapy.Requestforcoveragemustbemadebyaphysicianwhoisaspecialistingastroenterology.
ON TreatmentoffistulisingCrohn’sDiseaseinpatientswhohave:-Activelydrainingperianalorenterocutaneousfistula(e)thathaverecurredorpersisteddespiteacourseofantibiotictherapy(ciprofloxacinand/ormetronidazole)andimmunosuppressivetherapy(azathioprineor6-mercaptopurine).Note:Anyintolerance(s)orcontraindication(s)totreatmentwithrequiredalternative(s)mustbedescribedindetail.Renewalwillbeconsideredforpatientswithresolutionoffistulae.Theplanneddosingregimenfortherequestedbiologicshouldbeprovided.TherecommendeddoseforthetreatmentofCrohn’sDiseaseis5mg/kg/doseat0,2and6weeksfollowedby5mg/kg/doseevery8weeks.Initial:3monthsFirstrenewal:1yearSecondandsubsequentrenewals:2years
NB -FormoderatelytoseverelyactiveCrohn'sdiseaseinpatientswhoarerefractoryorhavecontraindicationstoanadequatecourseof5-aminosalicylicacidandcorticosteroidsandotherimmunosuppressivetherapy.Initialapprovalwillconsistof3dosesof5mg/kggivenatweeks0,2and6.ClinicalNote:-Infliximabwillnotbereimbursedincombinationwithotheranti-TNFagents.ClaimNotes:-Ongoingcoverageformaintenancetherapywillonlybereimbursedforrespondersandforadosenotexceeding5mg/kgevery8weeks.Coveragemustbereassessedannuallyandisdependentonevidenceofcontinuedresponse.-Mustbeprescribedby,orinconsultationwith,agastroenterologistorphysicianwithaspecialtyingastroenterology
NS FortreatmentofCrohn’sdiseaseinadults,whenprescribedbyagastroenterologistorphysicianwithaspecialtyingastroenterology:-inpatientswithmoderatetosevereactivediseaserefractoryto5-ASAproductsANDglucocorticoids(e.g.,prednisone)ANDimmunosuppressivetherapy(azathioprineor6-mercaptopurineormethotrexate)**.Initialapprovalofinfliximabwillbefora
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
CommonDrugReview November2017 58
DrugPlan CriteriaforRestrictedBenefitsingleinfusionof5mg/kg/dose.Asecondinfusionmaybewarrantedinpatientsnotrespondingtothefirstinfusionorinpatientsrespondinginitiallybutthenworseningbeforemaintenancetherapyiseffective.Requestforapprovalbeyondinductiontherapywillbeconsideredonacase-by-casebasis-inpatientswithfistulisingdiseasewhohaveactivelydrainingperianalorenterocutaneousfistula(e)thathaverecurredorpersisteddespiteacourseofappropriateantibiotictherapy(e.g.,metronidazole+/-ciprofloxacinforaminimumof3weeks)ANDimmunosuppressivetherapy(azathioprineor6-mercaptopurineormethotrexate)**.Initialapprovalisforthreeinfusionsofinfliximabof5mg/kg/doseat0,2and6weekintervals**PatientswhoareveryillandnotcandidatesforsurgerymayqualifyforinfliximabtherapywithoutatrialofAZA,6-MPorMTX,astheymayrequireamorerapidonsetofresponse
PE ForthetreatmentofmoderatetosevereCrohn=sDiseaseinpatientswho:1. HaveaHarveyBradshawIndexscoreof7ormore,AND2. Havenotrespondedto5-ASAproducts(minimumtrialof3gramsperdayfor6weeks),AND3. Havenotrespondedtoorareintoleranttoglucocorticosteroidtherapy(e.g.Prednisone)orwheresuchtherapyis
contraindicated,AND4. Havenotrespondedtoorareintoleranttoimmunosupressivetherapy(Azathioprine,MercaptopurineorMethotrexate)
orwheresuchtherapyiscontraindicated.InitialapprovalforInfliximabwillallowfor3dosesof5mg/kg/doseadministeredat0,2,and6weeks.RenewalofcoveragewillrequirereassessmentofthepatientandsubmissionofanewCrohn=sDiseaseSpecialAuthorizationform.Continuedcoveragewillbeapprovedatadosenotexceeding5mg/kgevery8weeksForthetreatmentoffistulisingCrohn’sDiseaseinpatientswho:1. HaveaHarveyBradshawIndexscoreof7ormore,AND2. Haveanactivelydrainingperianalorenercutaneiousfistula(e)thathaverecurredorpersisteddespiteacourseof
appropriateantibiotictherapy(e.g.CiprofloxacinwithorwithoutMetronidazoleforaminimumof3weeks),AND3. Havenotrespondedtoorareintoleranttoimmunosupressivetherapy(Azathioprine,MercaptopurineorMethotrexate)
orwheresuchtherapyiscontraindicated.InitialapprovalforInfliximabwillallowfor3dosesof5mg/kg/doseadministeredat0,2,and6weeks.RenewalofcoveragewillrequirereassessmentofthepatientandsubmissionofanewCrohn’sDiseaseSpecialAuthorizationform.Continuedcoveragewillbeapprovedatadosenotexceeding5mg/kgevery8weeks.
NL Forthetreatmentofpatientswithmoderateorsevereactivedisease*withcontraindicationstoornotachievingremissionwithglucocorticosteroidsANDimmunosuppressivetherapy.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
CommonDrugReview November2017 59
DrugPlan CriteriaforRestrictedBenefitInitialrequestmustincludecurrentCrohn’sDiseaseActivityIndex(CDAI)ortheHarvey-BradshawIndexAssessment(HBI)score.Initialapproval,3infusionsofinfliximab5mg/kgatweek0,2&6.Continuedcoveragedependentonevidenceofresponseusingcriteriasuchthe100pointreductioninCrohn’sDiseaseActivityIndex(CDAI)ortheHarvey-BradshawIndexAssessment(HBI)withascoreof5orlessoradecreaseinscoreof4ormore.Coveragecanbereassessedannuallydependentonevidenceofresponse(asoutlinedabove)Themaximumapproveddoseis5mg/kgevery8weeks.*Patientsveryill¬candidatesforsurgerymayqualifyforimmediateinfliximabinductiontherapy,astheymayrequireamorerapidresponse.Concurrentuseofbiologicsnotapproved.WrittenrequestbyGastroenterologistorphysicianwithaspecialtyingastroenterology
YK FormoderatetoseverelyactiveCrohn'sDiseaseonrecommendationofaspecialist.Consulttobeprovided.ForpatientswithacurrentHarveyBradshawIndex(HBI)>7,whoareintolerantorrefractoryto5-ASA(3gdailyforatleast6weeks)ANDarerefractory,intolerantordependantonglucocorticoids,ANDwhoarerefractoryorintoleranttoatleastoneofazathioprine,6-mercaptopurineormethotrexateaftera3monthtrial.
ForfistulisingCrohn'sDiseaseonrecommendationofaspecialist.Consulttobeprovided.Forpatientswithactivelydrainingfistula(s)despitea3weektrialofciprofloxacinormetronidazole,ANDatleasta6weektrialofazathioprineor6-mercaptopurine
NT FistulisingCrohn’sdiseaseaccordingtoestablishedcriteria.-ForadultpatientswithmoderatelytoseverelyactiveCrohn’sDiseasewhohavehadaninadequateresponsetoconventionaltherapy.ForthetreatmentofFISTULIZINGCROHN’SDISEASECriteriaforinitialforoneyear:-PrescribedbyagastroenterologyspecialistTheinitialcoveragewillallowfor3dosesof5mg/kg/dose,administeredat0,2and6weeks.Forcontinuedcoverage,patientmustbereassessedaftertheinitialdoses.Patientmeetsallthefollowingcriteria:-Patientisanadultwithactivelydrainingperianalorentercutaneousfistula(e)thathaverecurredorpersisteddespite:-acourseofappropriateantibiotictherapy(e.g.ciprofloxacinwithorwithoutmetronidazoleforaminimumof3weeks)PLUS-immunosuppressivetherapy:
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
CommonDrugReview November2017 60
DrugPlan CriteriaforRestrictedBenefit-azathioprine2to2.5mg/kg/dayforaminimumof6weeksortreatmentdiscontinuedbefore6weeksduetosevereadversereactions.OR-6-mercaptopurine,50-70mg/dayforaminimumof6weeksortreatmentdiscontinuedbefore6weeksduetosevereadversereactions.ORForthetreatmentforSEVEREACTIVECROHN`SDISEASECriteriaforinitialforoneyear:-PrescribedbyagastroenterologyspecialistTheinitialcoveragewillallowfor3dosesof5mg/kg/dose,administeredat0,2and6weeks.Forcontinuedcoverage,patientmustbereassessedaftertheinitialdoses.Patientmeetsthefollowingcriteria:PatientisanadultwithsevereactiveCrohn’sdiseasethathasrecurredorpersisteddespite:-Therapywith5-ASAproducts(atleast3g/dayforaminimumof6weeks).PLUS-Glucocorticoidsequivalenttoprednisone40mg/dayforaminimumof2weeks.OR-TreatmentdiscontinuedduetoseriousadversereactionsOROR-Contraindicationtoglucocorticoidtherapy.PLUS-Azathioprine2to2.5mg/kg/dayforaminimumof3months.OR-6-mercaptopurine50to70mg/dayforaminimumof3months.OR-Methotrexate15to25mg/weekforaminimumof3months.
NIHB FistulisingCrohn’sdiseaseaccordingtoestablishedcriteria.-ForadultpatientswithmoderatelytoseverelyactiveCrohn’sDiseasewhohavehadaninadequateresponsetoconventionaltherapy.ForthetreatmentofFISTULIZINGCROHN’SDISEASECriteriaforinitialforoneyear:
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
CommonDrugReview November2017 61
DrugPlan CriteriaforRestrictedBenefit-PrescribedbyagastroenterologyspecialistTheinitialcoveragewillallowfor3dosesof5mg/kg/dose,administeredat0,2and6weeks.Forcontinuedcoverage,patientmustbereassessedaftertheinitialdoses.Patientmeetsallthefollowingcriteria:-Patientisanadultwithactivelydrainingperianalorentercutaneousfistula(e)thathaverecurredorpersisteddespite:-acourseofappropriateantibiotictherapy(e.g.ciprofloxacinwithorwithoutmetronidazoleforaminimumof3weeks)PLUS-immunosuppressivetherapy:-azathioprine2to2.5mg/kg/dayforaminimumof6weeksortreatmentdiscontinuedbefore6weeksduetosevereadversereactions.OR-6-mercaptopurine,50-70mg/dayforaminimumof6weeksortreatmentdiscontinuedbefore6weeksduetosevereadversereactions.ForthetreatmentforSEVEREACTIVECROHN`SDISEASECriteriaforinitialforoneyear:-PrescribedbyagastroenterologyspecialistTheinitialcoveragewillallowfor3dosesof5mg/kg/dose,administeredat0,2and6weeks.Forcontinuedcoverage,patientmustbereassessedaftertheinitialdoses.Patientmeetsthefollowingcriteria:PatientisanadultwithsevereactiveCrohn’sdiseasethathasrecurredorpersisteddespite:-Therapywith5-ASAproducts(atleast3g/dayforaminimumof6weeks).PLUS-Glucocorticoidsequivalenttoprednisone40mg/dayforaminimumof2weeks.OR-TreatmentdiscontinuedduetoseriousadversereactionsOROR-Contraindicationtoglucocorticoidtherapy.PLUS-Azathioprine2to2.5mg/kg/dayforaminimumof3months.OR-6-mercaptopurine50to70mg/dayforaminimumof3months.OR
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
CommonDrugReview November2017 62
DrugPlan CriteriaforRestrictedBenefit-Methotrexate15to25mg/weekforaminimumof3months.
DND Crohn’sDisease:-whenprescribedbyagastroenterologistforpatientswithmoderatetosevereCrohn’sDiseasewhoarerefractoryorintolerantto:-5-ASAproductsat3g/dayfor6weeksANDprednisone40mg/dayfor2weeksANDImmunosuppressivetherapyasfollows:-azathioprine2-2.5mg/kg/dayfor3monthsOR-mercaptopurine50-75mg/dayfor3monthsOR-methotrexate15-25mg/weekfor3monthsOR-Immunosuppressivetherapydiscontinuedatlessthan3monthsduetoseriousadverseeffectsorreactionsFistulisingCrohn’s:-whenprescribedbyagastroenterologistforpatientswithactivedrainingfistulasdespite:-ciprofloxacin+metronidazolefor3weeksAND-azathioprineforaminimumof6weeksOR-6-mercaptopurinefor6weeks
VAC CriteriaNotPublicallyAvailableviaVACWebsite
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
CommonDrugReview November2017 63
RestrictedBenefitCriteriaforREMICADE®forthetreatmentofUlcerativeColitis
DrugPlan CriteriaforRestrictedBenefitBC NotaBenefit
AB SpecialauthorizationcoveragemaybeprovidedforthereductioninsignsandsymptomsandinductionandmaintenanceofclinicalremissionofUlcerativeColitisinadultpatients(18yearsofageorolder)withactivedisease(characterizedbyapartialMayoscore>4priortoinitiationofbiologictherapy)andwhoarerefractoryorintolerantto:-mesalamine:minimumof4grams/dayforaminimumof4weeksAND-corticosteroids(failuretorespondtoprednisone40mgdailyfor2weeks,or;steroiddependenti.e.failuretotaperoffsteroidswithoutrecurrenceofdiseaseordiseaserequiringaseconddoseofsteroidswithin12monthsofpreviousdose).'Refractory'isdefinedaslackofeffectattherecommendeddosesandfordurationoftreatmentsspecifiedabove.'Intolerant'isdefinedasdemonstratingseriousadverseeffectsorcontraindicationstotreatmentsasdefinedinproductmonographs.Immunosuppressivetherapyasfollowsmayalsobeinitiatedifintheclinician'sjudgmentatrialiswarranted:i)Azathioprine:minimumof2mg/kg/dayforaminimumof2months;ORii)6-mercaptopurine:minimumof1mg/kg/dayforaminimumof2monthsForcoverage,thisdrugmustbeprescribedbyaSpecialistinGastroenterologyoraphysicianappropriatelytrainedbytheUniversityofAlbertaortheUniversityofCalgaryandrecognizedasaprescriberbyAlbertaBlueCross('Specialist').Initialcoveragemaybeapprovedforthreedosesof5mg/kgofinfliximabat0,2and6weeks.-Patientswillbelimitedtoreceivingaonedoseofinfliximabperprescriptionattheirpharmacy.-Patientswillbepermittedtoswitchfromonebiologicagenttoanotherfollowinganadequatetrialofthefirstbiologicagentifunresponsivetotherapy,orduetoseriousadverseeffectsorcontraindications.Anadequatetrialisdefinedasataminimumthecompletionofinductiondosing(e.g.initialcoverageperiod).-Patientswillnotbepermittedtoswitchbacktoapreviouslytrialedbiologicagentiftheyweredeemedunresponsivetotherapy.-Patientsarelimitedtoreceivingonebiologicagentatatimeregardlessoftheconditionforwhichitisbeingprescribed.Forcontinuedcoveragebeyondthreedoses,thepatientmustmeetthefollowingcriteria:1)ThepatientmustbeassessedbyaSpecialistbetweenweeks10and14aftertheinitiationoftherapytodetermineresponse.2)TheSpecialistmustconfirminwritingthatthepatientisa'responder'thatmeetsthefollowingcriteria:-adecreaseinthepartialMayoscoreofgreaterthanorequalto2pointsFollowingthisassessment,continuedcoveragemaybeapprovedfordoseof5mg/kgevery8weeksforaperiodof12months.Ongoingcoveragemaybeconsideredonlyifthefollowingcriteriaaremetattheendofeach12-monthperiod:1)ThepatienthasbeenassessedbyaSpecialistinGastroenterologytodetermineresponse;
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
CommonDrugReview November2017 64
DrugPlan CriteriaforRestrictedBenefit2)TheSpecialistmustconfirminwritingthatthepatienthasmaintainedaresponsetotherapyasindicatedby:-adecreaseinthepartialMayoscoreofgreaterthanorequalto2pointsfromthescorepriortoinitiationofinfliximabtherapyNote:Forpatientswhoshowedaresponsetoinductiontherapythenexperiencedsecondarylossofresponsewhileonmaintenancedosingwith5mg/kg,themaintenancedosemaybeadjustedfrom5mg/kgto10mg/kgbymakinganadditionalspecialauthorizationrequesttoAlbertaBlueCrossfortheincreaseddose.Allrequests(includingrenewalrequests)forinfliximabforUlcerativeColitismustbecompletedusingtheInfliximabforUlcerativeColitisSpecialAuthorizationRequestForm(ABC60008).
SK Fortreatmentofulcerativecolitisinpatientsunresponsivetohighdoseintravenoussteroids.NOTE:Clinicalresponseshouldbeassessedafterthethree-doseinductionphasebeforeproceedingtomaintenancetherapy.Ongoingcoveragewillonlybeprovidedforthosewhorespondtotherapy.Patientsundergoingthistreatmentshouldbereviewedeverysixmonthsbyaspecialistinthisarea.3)Adequateresponsetotreatmentassessedat12weeksdefinedasatleast50%reductioninpre-treatmentbaselineBASDAIscoreorby>2unitsANDareductionof>2cminthespinalpainVAS.NOTE:Coveragewillnotbeprovidedwhenapatientswitchestoanotheranti-TNFagentifthepatientfailstorespondorifthereisalossofresponsetothefirstagent.Requestsforcoverageforthisindicationmustbemadebytherheumatologist.Asecondapplicationwouldalsoberequiredafter12weekstoassessandwouldneedtoshowanimprovementtothepatient’sconditiononeitherofthesemedications.PleaserefertotheFormularywebsitefortheapplicationform.Subsequentannualrenewalrequests(beyond15months)willbeconsideredforpatientswhoseBASDAIscoresdonotworsen(i.e.remainswithintwopointsofthesecondassessment).Foralloftheaboveindicationsthisproductshouldbeusedinconsultationwithaspecialistinthisarea.(h)Fortreatmentofulcerativecolitisinpatientsunresponsivetohighdoseintravenoussteroids.NOTE:Clinicalresponseshouldbeassessedafterthethree-doseinductionphasebeforeproceedingtomaintenancetherapy.Ongoingcoveragewillonlybeprovidedforthosewhorespondtotherapy.Patientsundergoingthistreatmentshouldbereviewedeverysixmonthsbyaspecialistinthisarea
MB Forthetreatmentofpatientswithmoderatelytoseverelyactiveulcerativecolitiswhohavehadaninadequateresponsetoconventionaltherapyincluding5-aminosalicylatecompoundscorticosteroidsandimmunomodulators.Requestforcoveragemustbemadebyaphysicianwhoisaspecialistingastroenterology
ON Induction1.Milddiseasea.Mayoscore<6ANDb.Patientswithmilddiseasewillbeconsideredonacase-by-casebasisBUTsubmissionmustincludetherationaleforcoverage
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
CommonDrugReview November2017 65
DrugPlan CriteriaforRestrictedBenefit2.Moderatediseasea.Mayoscorebetween6and10(inclusive)ANDb.*Endoscopicsubscoreof2ANDc.Failed2weeksoforalprednisone≥40mg(orIVequivalentforatleast1week)AND3monthsofAzathioprine(AZA)/6-Mercaptopurine(6MP)(orwheretheuseofimmunosuppressantsiscontraindicated)ORd.Stabilizedwith2weeksoforalprednisone≥40mg(ora1weekcourseofIVequivalent)buttheprednisonedosecannotbetapereddespite3monthsofAZA/6MP(orwheretheuseofimmunosuppressantsiscontraindicated)3.Severediseasea.Mayoscore>10ANDb.*Endoscopysubscore≥2c.Failed2weeksoforalprednisone≥40mg(or1weekIVequivalent)ORd.Stabilizedwith2weeksoforalprednisone≥40mg(or1weekofIVequivalent)buttheprednisonedosecannotbetapereddespite3monthsofAZA/6MP(orwheretheuseofimmunosuppressantsiscontraindicated)*Theendoscopyproceduremustbedonewithinthelastyearbutdoesnothavetobefullendoscopy.MaintenanceCriteria:1.After3loadingdosesofREMICADE®:a.Mayoscore<6ANDb.50%reductioninprednisonefromthestartingdoseApproval:3monthsat5mg/kg/doseevery8weeksIfpatientiscompletelyoffsteroids.Approval:12monthsat5mg/kg/doseevery8weeks2.Subsequentrenewals:a.Mayoscore<6;ANDb.Mustbeoffsteroids(Patientswhoremainonsteroidswillbeconsideredonacase-by-casebasis)Approval:12monthsat5mg/kg/doseevery8weeks
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
CommonDrugReview November2017 66
DrugPlan CriteriaforRestrictedBenefitNB NotaBenefit
NS NotaBenefitPE NotaBenefit
NL NotaBenefitYK ForUlcerativeColitisonrecommendationofaspecialist.Consulttobeprovided.ForpatientswithaMayoscore>6ANDanendoscopic
subscore≥2(withinlast12months
ANDfailed2weeksoforalprednisone≥40mg(or1weekIVequivalent)AND3monthsofazathioprineor6-mercaptopurine
ORstabilizedonprednisoneasabovebuttheprednisonedosecannotbetapereddespite3monthsofDMARDS.
Onlyonemonth'sdosetobedispensedatatime.Approvalfor12monthperiodNT NotaBenefitNIHB NotaBenefit
DND NotaBenefit
VAC NotaBenefit
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
67CommonDrugReview November2017
APPENDIX3:SUMMARYOFPATIENTINPUT
1.DescriptionofPatientGroupsSupplyingInput:Twopatientgroupsprovidedinputforthissubmission:TheGastrointestinal(GI)SocietyandCrohn’sandColitisCanada(CCC).ThemissionoftheGISocietyistoprovideevidence-basedinformationonconditionsrelatedtotheGItractandliver,improvethelivesofpeoplelivingwiththeseconditions,supportresearch,advocateforhealthcareaccess,andpromoteGIandliverhealth.TheGISocietyprovidespamphletsandonlineinformation,deliverslectures,andrespondstoinformationrequestsfrompatientsandhealthcareprofessionals.English(www.badgut.org)andFrench(www.mauxdeventre.org)websitesareavailable.Financialcontributionsarereceivedfrompharmaceuticalcompanies(Pfizer,AbbVieCorporation,Actavis,AstraZenecaCanadaInc.,InnovativeMedicinesCanada,FerringInc.,GileadSciencesCanadaInc.,GlaxoSmithKlineInc.,JanssenCanada,MerckCanadaInc.,PfizerCanadaInc.,ShireCanadaInc.,andTakedaCanadaInc.),governments,foundations,andindividuals.Noconflictofinterestwasdeclaredinpreparingthepatientinputforthissubmission.CCCisanational,volunteer-basedcharitythatworksonfindingcuresforCrohn’sdisease(CD)andulcerativecolitis(UC),improvingthelivesofpeoplelivingwiththeseconditions,providingpatientprograms,advocatingonbehalfofpatients,andincreasingawareness.Itisamongtheforemostcharityfundersofinflammatoryboweldisease(IBD)researchintheworld.Theorganizationhaschaptersin45communitiesacrossCanada.During2014-2015,11%ofCCC’srevenueswerefromcorporatedonations.Majorsupporterswere:AbbVieCorporation,JanssenInc.,TheLeonaM.andHarryB.HelmsleyCharitableTrust,M&MMeatShops,TakedaCanadaInc.,andVertexPharmaceuticals(Canada)Inc.Noconflictofinterestwasdeclaredinpreparingthepatientinputforthissubmission.2.ConditionRelatedInformation:TheCCCobtainedinformationfromCCCpublishedreports,CCCsurveys,andeducationalbrochuresavailableontheorganization’swebsite(www.crohnsandcolitis.ca).ThesourcesofinformationconsultedbytheGISocietywerenotprovided.TheGISocietyindicatedthattherearedifferencesbetweenUCandCDwithrespecttotheextentandareasofinflammationexperiencedbypatientswiththeseconditions.TheinflammationofCDaffectsmoreareasoftheintestinaltractandisdeeperinextentcomparedwithUC.InadditiontoGIsymptoms,patientswitheitherUCorCDmayexperienceextra-intestinalmanifestations,suchasfever,inflammationofeyesorjoints,ulcersofmouthorskin,tenderandinflamednodulesontheshins,anxiety,andstress.Symptomsmayhaveprofoundeffectsonthephysical,social,andemotionalaspectsofpatients’lives.Patientsalsoreportbeingconstantlyconcernedaboutdiseaseflare-ups,whichmaybeworseinseveritycomparedwithpreviousflaresandoccurunpredictably.Thiscausesgreatdisruptiontopatients’lives.Sustainedremissionortreatmentresponse,therefore,isdesiredbypatients.TheCCCreportedthatthemostunbearablesymptomsexperiencedbypatientsarelackofcontroloverbowelmovementsandurgentandfrequentneedtousethebathroom.ACCC2011surveyfoundthat73%ofpatientsexperienced5to20ormorebowelmovementsperday.Althoughpatientsindicatedbloodinthestoolandabdominalpainasimportantsymptoms,thedominatingconcernwasaccesstoawashroom.Somepatientswerealsoconcernedabouttheincreasedriskofcoloncancer.Limitationsin
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
68CommonDrugReview November2017
leisureactivities(e.g.,goingoutfordinners,movies,andconcerts),physicalactivities,useofpublictransportation,andworkwerereported.Accordingtoonerespondent,“Yousimplycan’tleadanormallifeofworkingandgoingtotheoffice.”Thirty-fourpercentfrequentlymissedplayingsports,22%missedschooltrips,20%skippedfamilyvacations,40%avoidedparties,and22%didnotattendspecialeventssuchasgraduationsorfamilyweddings.Inaddition,patientsreportedexperiencinggreaterscrutinyfrombossesduetofrequentwashroombreaksorsickdays.IBDsareattachedwithstigma,whichmakesitdifficultforpatientstoopenlytalkabouttheircondition.Caregiversarealsoaffectedbythecondition,oftenactingasadvocatesfortheirlovedoneanddevotingtimeandresourcestohelpmanagethepotentiallimitationsincarryingoutday-to-dayactivities.Theprocessofcaring,however,mayaffectthecaregiver’smentalandphysicalhealth,andoftenexertsfinancialburdenincludingout-of-pocketexpensesassociatedwithdiseasemanagement.3.CurrentTherapy-RelatedInformation:TheCCCobtainedinformationfrompatientreportsofinnovatordrugs,whichwereincludedinpreviousdrugsubmissionstoCADTH.ThesourcesofinformationconsultedbytheGISocietywerenotprovided.AsurveywasconductedbytheGISocietyin2015ontheirEnglishandFrenchwebsitestounderstandtheperspectivesofpatientswithIBDorcaregiversofapersonwithIBDregardingsubsequententrybiologics(SEBs).Atotalof423respondentsparticipated,fromallprovincesandterritories.Thegoalsoftherapyareinductionofremissionandmaintenanceofremission.Thisisachievedbyusingtreatmentsthatcontrolinflammationintheintestinaltract.Oldertreatmentsinclude5-aminosalicylicacid(5-ASA),corticosteroids,andimmunosuppressivedrugs.AccordingtotheGISociety,theintroductionofbiologicdrugswaslife-changingand“revolutionary”whenoldertreatmentsfailedtoachievethegoalsoftherapy.However,biologicsdohavesideeffectsandrisksand,therefore,areprescribedonlyiftheyarethebestoptionforcontrollinginflammation.ThecourseofIBDisoftenunpredictableanduniqueamongpatientsand,thus,treatmentmustbeindividualized;atreatmentregimenthatworksforonepatientmaynotbesuitableforanother.Availabilityandchoiceofdifferenttreatmentsoptionsareamust.SincethereisnocureforIBD,isitimportanttomaintainongoingmedicalcare,propernutrition,andmedication.PatientswhoreportedtotheCCCindicatedthattheyrespondedwelltotheinnovatorbiologic.Afterfailureoffirst-linetreatments,innovatorbiologicdrugshaveallowedpatientstoachieveremissionandexperienceareductioninthenumberofbowelmovements,decreasedfatigue,lesspain,andlesspsychologicalstressassociatedwithneedforwashroomaccess.Accordingtoonerespondent,“withsteroidsIwasat60%butwith[innovatorbiologics]I’mat95%.”Patientsreportedthatinnovatorbiologicshelpedthemachieveasclosetoanormallifeaspossible.Biologicdrugsofferanalternativetosurgerywhenothertreatmentshavefailed.Thispreventsthecomplicationsofsurgery,suchascontinence/soiling,poorpouchfunction,pouchitis,sexualdysfunction,andlossoffertilityinfemales.4.ExpectationsfortheDrugBeingReviewed:TheinformationforthissectionwasobtainedfromthesurveyconductedbytheGIsociety.Patientsexpectthattreatmentwillimprovetheirqualityoflife,whichmeansreliefofsymptoms,alleviationofanxietyandstress,abilitytoleadanormallifewithfamily,career/education,andwithoutinterruptionsduetoflare-ups.TheyexpectthatanapprovedSEBhasbeenproventobesafeandeffective,specificallyinIBD.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
69CommonDrugReview November2017
PatientsexpressedconcernsaboutthesafetyandefficacyofSEBs,theregulatoryprocessofSEBsinCanada,andswitchingbetweeninnovatorandSEBtreatments,especiallywithouttheirconsent.Theydonotwantcosttobetheonlyconsiderationwhendecidingwhichbiologictouse.Inaddition,itwasimportantforpatientsthatthephysicianchoosesinconsultationwiththemthebestdrugfortheircondition(andthatthechoiceisnotjustmadebyagovernmentordrugplan).PatientsexpectthatSEBregulationsconsider,inorderofpriority:safety,areviewandapprovalprocessthatisasrigorousasfortheinnovator,thattheSEBistestedforallindications/diseases,theimportanceofmoretreatmentoptions,andthattheSEBisclinicallytestedinCanadians.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
70CommonDrugReview November2017
REFERENCES
ManufacturerReferences(IdentifiedBySquareBracketswithintheReport)1. Park,S.H.,etal.,Post-marketingstudyofbiosimilarinfliximab(CT-P13)toevaluateitssafetyand
efficacyinKorea.ExpertRevGastroenterolHepatol,2015.9Suppl1:p.35-44.2. KoreanLabelforInflectra,ApprovedIndicationsforInflectrainKorea.2013,CellTrionInc:Seoul,
SouthKorea.3. Sands,B.E.,etal.,Long-termtreatmentofrectovaginalfistulasinCrohn'sdisease:responseto
infliximabintheACCENTIIStudy.ClinGastroenterolHepatol,2004.2(10):p.912-20.4. Rutgeerts,P.,etal.,Comparisonofscheduledandepisodictreatmentstrategiesofinfliximabin
Crohn'sdisease.Gastroenterology,2004.126(2):p.402-13.5. Sandborn,W.J.,etal.,One-yearmaintenanceoutcomesamongpatientswithmoderately-to-
severelyactiveulcerativecolitiswhorespondedtoinductiontherapywithadalimumab:subgroupanalysesfromULTRA2.AlimentPharmacolTher,2013.37(2):p.204-13.
6. Reinisch,W.,etal.,Adalimumabforinductionofclinicalremissioninmoderatelytoseverelyactiveulcerativecolitis:resultsofarandomisedcontrolledtrial.Gut,2011.60(6):p.780-7.
7. Fischer,M.,NeedforrescuetherapyinIBDpatientsoninfliximabmaintenancetherapyafterdiscontinuationofimmunomodulator.InflammatoryBoweldiseases,2009.15(Supplement2):p.S1-S2.
8. Lynch,R.W.,etal.,Outcomesofrescuetherapyinacutesevereulcerativecolitis:datafromtheUnitedKingdominflammatoryboweldiseaseaudit.AlimentPharmacolTher,2013.38(8):p.935-45.
9. vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv
10. KoreanPMSTables,TabularDataforCT-P13PMSStudyinKoreanpatients.2015,CelltrionInc:Seoul,SouthKorea.
11. RemicadeProductMonograph,ProductMonographforREMICADE(infliximab)100mgpervial.2014,HealthCanada:Ottawa,Ontario.
12. RemicadeSummaryofProductCharacteristics,RemicadeSummaryofProductCharacteristics.2011,EuropeanMedicinesAgency.
13. RemicadeSystematicReview,SafetyofinfliximabinthetreatmentofpatientswithCrohn’sDiseaseandUlcerativeColitis:asystematicreviewofrandomized,controlledtrialsconductedwithRemicade®.2015,CelltrionInc.
14. RemicadeSystematicReviewforObservationStudies,EfficacyandsafetyofinfliximabinthetreatmentofpatientswithCrohn’sdiseaseandulcerativecolitis:asystematicreviewofRemicade®observationalstudies.2015,CellTrionInc:Seoul,SouthKorea.
15. vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv
16. vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv
17. vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
71CommonDrugReview November2017
18. vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv
19. vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv
20. CT-P13PKModellingReport,DoseProportionalityofCT-P13ExtrapolatedfromPopulationPharmacokineticAnalysis.2014,St.Mary’sHospital:Seoul,SouthKorea.
21. LakatosP,Biosimilarinfliximabininflammatoryboweldiseases:whatisthereallifeevidence?2015,Semmelweisniversity:Budapest,Hungary.
22. vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv.
23. Miheller,P.,etal.,EfficacyandsafetyofinfliximabinductiontherapyinCrohn'sDiseaseinCentralEurope--aHungariannationwideobservationalstudy.BMCGastroenterol,2009.9:p.66.
24. JahnsenJ,Post-marketingreal-worldclinicalexperiencewithREMSIMA™100mg(infliximab)(monoclonalantibody,recombinant)inpatientswithinflammatoryboweldiseaseatAkershusUniversityHospital,Norway.2015,AkershusUniversityHospital:OsloNorway.
25. vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv.
26. vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv.
27. Ben-Horin,S.,Remicade®cross-immunoreactivitytowardsREMSIMA™inIBD.2014,ShebaMedicalCenterTelAvivUniversity:Israel.
28. Ben-Horin,S.,etal.,Cross-immunogenicity:antibodiestoinfliximabinRemicade-treatedpatientswithIBDsimilarlyrecognisethebiosimilarRemsima.Gut,2015.
29. GecseK.Biosimilarinfliximabininflammatoryboweldiseases:firstinterimresultsfromaprospectivenationwideobservationalcohort.2015[cited2016April6];Availablefrom:https://www.ecco-ibd.eu/index.php/publications/congress-abstract-s/abstracts-2015/item/p314-biosimilar-infliximab-in-inflammatory-bowel-diseases-first-interim-results-from-a-prospective-nationwide-observational-cohort.html.
30. vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv
31. O'Shea,J.J.,A.Ma,andP.Lipsky,Cytokinesandautoimmunity.NatRevImmunol,2002.2(1):p.37-45.
32. Reinecker,H.C.,etal.,Enhancedsecretionoftumournecrosisfactor-alpha,IL-6,andIL-1betabyisolatedlaminapropriamononuclearcellsfrompatientswithulcerativecolitisandCrohn'sdisease.ClinExpImmunol,1993.94(1):p.174-81.
33. Lee,T.W.andR.N.Fedorak,Tumornecrosisfactor-alphamonoclonalantibodiesinthetreatmentofinflammatoryboweldisease:clinicalpracticepharmacology.GastroenterolClinNorthAm,2010.39(3):p.543-57.
34. DiSabatino,A.,etal.,FunctionalmodulationofCrohn'sdiseasemyofibroblastsbyanti-tumornecrosisfactorantibodies.Gastroenterology,2007.133(1):p.137-49.
35. Yoo,J.,etal.,ProteinkinaseD1mediatessynergisticMMP-3expressioninducedbyTNF-alphaandbradykinininhumancolonicmyofibroblasts.BiochemBiophysResCommun,2011.413(1):p.30-5.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
72CommonDrugReview November2017
36. Hamilton,K.E.,etal.,Cytokineinductionoftumornecrosisfactorreceptor2ismediatedbySTAT3incoloncancercells.MolCancerRes,2011.9(12):p.1718-31.
37. Zeissig,S.,etal.,DownregulationofepithelialapoptosisandbarrierrepairinactiveCrohn'sdiseasebytumournecrosisfactoralphaantibodytreatment.Gut,2004.53(9):p.1295-302.
38. Mankertz,J.andJ.D.Schulzke,Alteredpermeabilityininflammatoryboweldisease:pathophysiologyandclinicalimplications.CurrOpinGastroenterol,2007.23(4):p.379-83.
39. Bu,P.,etal.,Apoptosis:oneofthemechanismsthatmaintainsunresponsivenessoftheintestinalmucosalimmunesystem.JImmunol,2001.166(10):p.6399-403.
40. Ho,G.-T.,C.Lees,andJ.Satsangi,Ulcerativecolitis.Medicine,2011.39(4):p.224-228.41. Baughman,R.P.andM.Iannuzzi,Tumournecrosisfactorinsarcoidosisanditspotentialfor
targetedtherapy.BioDrugs,2003.17(6):p.425-31.42. vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv
vvvvvvvvvvvvvvvvvvvvv43. Scallon,B.,etal.,Bindingandfunctionalcomparisonsoftwotypesoftumornecrosisfactor
antagonists.JPharmacolExpTher,2002.301(2):p.418-26.44. Tracey,D.,etal.,Tumornecrosisfactorantagonistmechanismsofaction:acomprehensive
review.PharmacolTher,2008.117(2):p.244-79.45. Feldmann,M.,Developmentofanti-TNFtherapyforrheumatoidarthritis.NatRevImmunol,
2002.2(5):p.364-71.46. Bosani,M.,S.Ardizzone,andG.B.Porro,Biologictargetinginthetreatmentofinflammatory
boweldiseases.Biologics,2009.3:p.77-97.47. VanDeventer,S.J.,TumournecrosisfactorandCrohn'sdisease.Gut,1997.40(4):p.443-8.48. Kankaanranta,H.,etal.,Tumournecrosisfactor-alpharegulateshumaneosinophilapoptosisvia
ligationofTNF-receptor1andbalancebetweenNF-kappaBandAP-1.PLoSOne,2014.9(2):p.e90298.
49. Onnheim,K.,etal.,Tumournecrosisfactor(TNF)-alphaprimesmurineneutrophilswhentriggeredviaformylpeptidereceptor-relatedsequence2,themurineorthologueofhumanformylpeptidereceptor-like1,throughaprocessinvolvingthetypeITNFreceptorandsubcellulargranulemobilization.Immunology,2008.125(4):p.591-600.
50. Zeck-Kapp,G.,W.Czech,andA.Kapp,TNFalpha-inducedactivationofeosinophiloxidativemetabolismandmorphology--comparisonwithIL-5.ExpDermatol,1994.3(4):p.176-88.
51. Koshy,P.J.,etal.,Interleukin17inducescartilagecollagenbreakdown:novelsynergisticeffectsincombinationwithproinflammatorycytokines.AnnRheumDis,2002.61(8):p.704-13.
52. Goretsky,T.,etal.,p53mediatesTNF-inducedepithelialcellapoptosisinIBD.AmJPathol,2012.181(4):p.1306-15.
53. Nesbitt,A.,etal.,Mechanismofactionofcertolizumabpegol(CDP870):invitrocomparisonwithotheranti-tumornecrosisfactoralphaagents.InflammBowelDis,2007.13(11):p.1323-32.
54. Shen,C.,etal.,Adalimumabinducesapoptosisofhumanmonocytes:acomparativestudywithinfliximabandetanercept.AlimentPharmacolTher,2005.21(3):p.251-8.
55. Vos,A.C.,etal.,Regulatorymacrophagesinducedbyinfliximabareinvolvedinhealinginvivoandinvitro.InflammBowelDis,2012.18(3):p.401-8.
56. Vos,A.C.,etal.,Anti-tumornecrosisfactor-alphaantibodiesinduceregulatorymacrophagesinanFcregion-dependentmanner.Gastroenterology,2011.140(1):p.221-30.
57. Eissner,G.,etal.,ReversesignalingthroughtransmembraneTNFconfersresistancetolipopolysaccharideinhumanmonocytesandmacrophages.JImmunol,2000.164(12):p.6193-8.
58. Mitoma,H.,etal.,Mechanismsforcytotoxiceffectsofanti-tumornecrosisfactoragentsontransmembranetumornecrosisfactoralpha-expressingcells:comparisonamonginfliximab,etanercept,andadalimumab.ArthritisRheum,2008.58(5):p.1248-57.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
73CommonDrugReview November2017
59. Sindrilaru,A.andK.Scharffetter-Kochanek,DisclosureoftheCulprits:Macrophages-VersatileRegulatorsofWoundHealing.AdvWoundCare(NewRochelle),2013.2(7):p.357-368.
60. Zareie,M.,etal.,Monocyte/macrophageactivationbynormalbacteriaandbacterialproducts:implicationsforalteredepithelialfunctioninCrohn'sdisease.AmJPathol,2001.158(3):p.1101-9.
61. Zhu,W.,etal.,DisequilibriumofM1andM2macrophagescorrelateswiththedevelopmentofexperimentalinflammatoryboweldiseases.ImmunolInvest,2014.43(7):p.638-52.
62. Hunter,M.M.,etal.,Invitro-derivedalternativelyactivatedmacrophagesreducecolonicinflammationinmice.Gastroenterology,2010.138(4):p.1395-405.
63. Novak,M.L.andT.J.Koh,Macrophagephenotypesduringtissuerepair.JLeukocBiol,2013.93(6):p.875-81.
64. Benucci,M.,etal.,Tumornecrosisfactorsblockingagents:analogiesanddifferences.ActaBiomed,2012.83(1):p.72-80.
65. Arora,T.,etal.,DifferencesinbindingandeffectorfunctionsbetweenclassesofTNFantagonists.Cytokine,2009.45(2):p.124-31.
66. Shealy,D.J.,etal.,Characterizationofgolimumab,ahumanmonoclonalantibodyspecificforhumantumornecrosisfactoralpha.MAbs,2010.2(4):p.428-39.
67. Louis,E.J.,etal.,PolymorphisminIgGFcreceptorgeneFCGR3AandresponsetoinfliximabinCrohn'sdisease:asubanalysisoftheACCENTIstudy.PharmacogenetGenomics,2006.16(12):p.911-4.
68. Moroi,R.,etal.,FCGR3A-158polymorphisminfluencesthebiologicalresponsetoinfliximabinCrohn'sdiseasethroughaffectingtheADCCactivity.Immunogenetics,2013.65(4):p.265-71.
69. Papamichael,K.,etal.,AssociationofandgenepolymorphismswithdifferentialresponsetoinfliximabinaGreekcohortofCrohn'sdiseasepatients.AnnGastroenterol,2011.24(1):p.35-40.
70. Tomita,K.,etal.,Associationbetweentumornecrosisfactor-alphaandFc-gammareceptorpolymorphismswithinfliximabinCrohn'sdisease.Hepatogastroenterology,2010.57(99-100):p.535-9.
71. Louis,E.,etal.,AssociationbetweenpolymorphisminIgGFcreceptorIIIacodinggeneandbiologicalresponsetoinfliximabinCrohn'sdisease.AlimentPharmacolTher,2004.19(5):p.511-9.
72. HealthCanada.SummaryBasisofDecisionforInflectra.2014[cited2016March25];Availablefrom:http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2014_inflectra_159493-eng.php.
73. CHMPAssessmentReport,AssessmentReportforInflectra.2013,EuropeanMedicinesAgency:London,UnitedKingdom.
74. FDA.FDAapprovesInflectra,abiosimilartoRemiacde.2016[cited2016April6];Availablefrom:http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494227.htm.
75. FDAAdvisoryCommittee.FDABriefingDocumentforCT-P13abiosimilartoRemicade.2016[cited2016March28];Availablefrom:http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM484859.pdf?&.
76. PharmaceuticalBenefitsScheme.InflectraPublicSummaryDocument.2015[cited2016March28];Availablefrom:http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2015-07/infliximab-psd-july-2015.
77. EPARRemicadeScientificDiscussion,EuropeanPublicAssessmentReportforRemicade.2005,EuropeanMedicineAgency.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
74CommonDrugReview November2017
78. FDAClinicalPharmacologyReviewofRemicade,FDAClinicalPharmacologyReviewofBLA99-0128.Remicade.1999,FoodandDrugAdministration(FDA).
79. StClair,E.W.,etal.,Therelationshipofseruminfliximabconcentrationstoclinicalimprovementinrheumatoidarthritis:resultsfromATTRACT,amulticenter,randomized,double-blind,placebo-controlledtrial.ArthritisRheum,2002.46(6):p.1451-9.
80. Yoo,D.H.,etal.,Arandomised,double-blind,parallel-groupstudytodemonstrateequivalenceinefficacyandsafetyofCT-P13comparedwithinnovatorinfliximabwhencoadministeredwithmethotrexateinpatientswithactiverheumatoidarthritis:thePLANETRAstudy.AnnRheumDis,2013.72(10):p.1613-20.
81. Maini,R.N.,etal.,Therapeuticefficacyofmultipleintravenousinfusionsofanti-tumornecrosisfactoralphamonoclonalantibodycombinedwithlow-doseweeklymethotrexateinrheumatoidarthritis.ArthritisRheum,1998.41(9):p.1552-63.
82. Klotz,U.,A.Teml,andM.Schwab,Clinicalpharmacokineticsanduseofinfliximab.ClinPharmacokinet,2007.46(8):p.645-60.
83. Kim,J.,etal.,KineticsofFcRn-mediatedrecyclingofIgGandalbumininhuman:pathophysiologyandtherapeuticimplicationsusingasimplifiedmechanism-basedmodel.ClinImmunol,2007.122(2):p.146-55.
84. Fasanmade,A.A.,etal.,Populationpharmacokineticanalysisofinfliximabinpatientswithulcerativecolitis.EurJClinPharmacol,2009.65(12):p.1211-28.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
75CommonDrugReview November2017
CDRReferences(IdentifiedBySuperscriptswithintheReport)
1. HealthCanadareviewer'sreport:Inflectra(infliximab)[CONFIDENTIALinternalreport].Ottawa:TherapeuticsProductsDirectorate,HealthCanada;2015Aug7.
2. vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv
3. ParkSH,KimYH,LeeJH,KwonHJ,LeeSH,ParkDI,etal.Post-marketingstudyofbiosimilarinfliximab(CT-P13)toevaluateitssafetyandefficacyinKorea.ExpertRevGastroenterolHepatol.2015;9Suppl1:35-44.
4. JahnsenJ,DetlieTE,VatnS,RicanekP.Biosimilarinfliximab(CT-P13)inthetreatmentofinflammatoryboweldisease:ANorwegianobservationalstudy.ExpertRevGastroenterolHepatol.2015;9Suppl1:45-52.
5. GecseKB,LovaszBD,FarkasK,BanaiJ,BeneL,GasztonyiB,etal.EfficacyandsafetyofthebiosimilarinfliximabCT-P13treatmentininflammatoryboweldiseases:Aprospective,multicentre,nationwidecohort.JCrohnsColitis.2016Feb;10(2):133-40.
6. MolnarT,FarkasK,RutkaM,BalintA,NagyF,BorR,etal.EfficacyofthenewinfliximabbiomarkerCT-P13inductiontherapyonmucosalhealinginulcerativecolitispatients.Posterpresentedat:10thCongressoftheEuropeanCrohn'sandColitisOrganisation;2015Feb18-21;Barcelona,Spain.
7. Interimreport:post-marketingreal-worldclinicalexperiencewithREMISMa™100mg(infliximab)(monoclonalantibody,recombinant)inpatientswithinflammatoryboweldiseaseatIBDClinicalandResearchCentre,ISCARELighthouseandCharlesUniversity,Prague,CzechRepublic.Prague,CzechRepublic:CharlesUniversity;2015May4.
8. KangYS,MoonHH,LeeSE,LimYJ,KangHW.ClinicalexperienceoftheuseofCT-P13,abiosimilartoinfliximabinpatientswithinflammatoryboweldisease:Acaseseries.DigDisSci.2015Apr;60(4):951-6.
9. JungYS,ParkDI,KimYH,LeeJH,SeoPJ,CheonJH,etal.EfficacyandsafetyofCT-P13,abiosimilarofinfliximab,inpatientswithinflammatoryboweldisease:Aretrospectivemulticenterstudy.JGastroenterolHepatol.2015Dec;30(12):1705-12.
10. CDRsubmission:Inflectra(infliximab),1mg/vialsterile,lyophilizedpowderforsolution.Company:HospiraHealthCareCorporation,aPfizerCompany[CONFIDENTIALmanufacturer'ssubmission].Incheon(KR):HospiraHealthCareCorporation,aPfizerCompany;2016Apr.
11. vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvv.
12. CelltrionresponsetoHealthCanadaclarifaxinformationrequestforInflectraIBDdatedMay62016[CONFIDENTIALinternalreport].Incheon(KR):CelltrionHealthcareCo.Ltd;2016.
13. ManufacturercommentsonCDRclinicalandpharmacoeconomicreviewers'reportsoninfliximab(Inflectra)[CONFIDENTIALmanufacturer'sreport].Incheon(KR):HospiraHealthCareCorporation,aPfizerCompany;2016Aug.
14. YoshidaEM.TheCrohn'sDiseaseActivityIndex,itsderivativesandtheInflammatoryBowelDiseaseQuestionnaire:areviewofinstrumentstoassessCrohn'sdisease.CanJGastroenterol.1999Jan;13(1):65-73.
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
76CommonDrugReview November2017
15. ZelinkovaZ,vanderWoudeCJ.Genderandinflammatoryboweldisease.JClinCellImmunol.2014;5:4.
16. FeaginsLA,KaneSV.Caringforwomenwithinflammatoryboweldisease.GastroenterolClinNorthAm.2016Jun;45(2):303-15.
17. Biologicandbiosimilartherapies:presentations[Internet].Edmonton:InstituteofHealthEconomics;2014.[cited2016Jun20].Availablefrom:http://www.ihe.ca/research-programs/knowledge-transfer-dissemination/conferences/biologics/bios-pres
18. CommonDrugReview.Inflectra(infliximab)[Internet].Ottawa:CADTH;2015.[cited2016Jun13].(Subsequententrybiologicreviewreport).Availablefrom:https://www.cadth.ca/sites/default/files/cdr/seb/SE0384_Inflectra_SEB_Report.pdf
19. Inflectra(infliximab):powderforsolution,sterile,lyophilized,100mg/vial[productmonograph].Incheon,KR:CelltrionHealthcareCo.Ltd;2016Jun10.
20. Inflectra(infliximab)[Internet].London:EuropeanMedicinesAgency;2016.[cited2016Jun20].Availablefrom:http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002778/human_med_001677.jsp&mid=WC0b01ac058001d124
21. Highlightsofprescribinginformation:inflectra(infliximab-dyyb)forinjection,forintravenoususe[Internet].Incheon(KR):Celltrion,Inc.;2016.[cited2016Jun20].Availablefrom:http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125544s000lbl.pdf
22. Inflectra™:productinformation[Internet].Canberra:GovernmentofAustralia,DepartmentofHealth;2016.[cited2016Jun20].Availablefrom:https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2015-PI-02425-1&d=2016061616114622483
23. OlesenCM,CoskunM,Peyrin-BirouletL,NielsenOH.Mechanismsbehindefficacyoftumornecrosisfactorinhibitorsininflammatoryboweldiseases.PharmacolTher.2016Mar;159:110-9.
24. FeaganBG,ChoquetteD,GhoshS,GladmanDD,HoV,MeibohmB,etal.Thechallengeofindicationextrapolationforinfliximabbiosimilars.Biologicals.2014Jul;42(4):177-83.
25. KopylovU,Ben-HorinS,SeidmanE.Therapeuticdrugmonitoringininflammatoryboweldisease.AnnGastroenterol[Internet].2014[cited2016May27];27(4):304-12.Availablefrom:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4188926
26. VermeireS,NomanM,VanAssche,BaertF,D'HaensG,RutgeertsP.EffectivenessofconcomitantimmunosuppressivetherapyinsuppressingtheformationofantibodiestoinfliximabinCrohn'sdisease.Gut[Internet].2007Sep[cited2016Aug5];56(9):1226-31.Availablefrom:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1954977
27. Pharmacoeconomicevaluation.In:CDRsubmission:Inflectra(infliximab),1mg/vialsterile,lyophilizedpowderforsolution.Company:HospiraHealthCareCorporation,aPfizerCompany[CONFIDENTIALmanufacturer'ssubmission].Montreal:HospiraHealthCareCorporation,aPfizerCompany;2016Apr.
28. ExceptionalAccessProgram(EAP)[Internet].Toronto:OntarioMinistryofHealthandLong-TermCare;2009;updated2016.[cited2016Jun30].Availablefrom:http://www.health.gov.on.ca/en/pro/programs/drugs/odbf/odbf_except_access.aspx
29. CADTHCanadianDrugExpertCommittee(CDEC)finalrecommendation:infliximab(Inflectra-HospiraHealthcareCorporation)[Internet].Ottawa:CADTH;2014Dec19.[cited2016Jun30].Availablefrom:https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_SE0384_Inflectra_Dec-23-14.pdf
CDRSUBSEQUENTENTRYBIOLOGICREVIEWREPORTFORINFLECTRA
77CommonDrugReview November2017
30. SohrabpourAA,MalekzadehR,KeshavarzianA.Currenttherapeuticapproachesininflammatoryboweldisease.CurrPharmDes.2010;16(33):3668-83.
31. DevlinSM,BresslerB,BernsteinCN,FedorakRN,BittonA,SinghH,etal.OverviewofsubsequententrybiologicsforthemanagementofinflammatoryboweldiseaseandCanadianAssociationofGastroenterologypositionstatementonsubsequententrybiologics.CanJGastroenterol[Internet].2013Oct[cited2016Jun13];27(10):567-71.Availablefrom:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805336
32. JonesJ,PanaccioneR,RussellML,HilsdenR.MedicalmanagementofinflammatoryboweldiseaseamongCanadiangastroenterologists.CanJGastroenterol.2011Oct;25(10):565-9.Availablefrom:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206553